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Abstract
This thesis involves two distinct topics related to carbohydrate and organometallic
chemistry.
The first chapter includes chemical synthesis of oligosaccharides present in human
milk. Human milk oligosaccharides are a family of structurally diverse glycans, which
are highly unique for human milk. These oligosaccharides participate in multiple mech-
anisms by which breast-fed infants become protected against infections and they are
believed to serve as nutrients for the early brain development.
The synthesized oligosaccharides are based on the motif Galβ1–3/4GlcNAcβ1–
3Galβ1–4Glc, which is the core of many human milk oligosaccharides. Three distinct
human milk oligosaccharides were synthezised; Lacto-N -tetraose, Lacto-N -fucopentaose
I and Lacto-N -neofucopentaose I. A one-pot strategy was developed for the synthesis
of the tetrasaccharide backbone core based on the different reactivity of thioglycoside
donors and acceptors. The tetrasaccharides were formed both by sequential and the
developed one-pot method. Deprotection of the protecting group at the C-2-position
on the galactose moiety liberated an acceptor for the fucosylation eventually creating
the two linear pentasaccharides Lacto-N -fucopentaose I and Lacto-N -neofucopentaose
I.
The scope of the developed one-pot method was further enhanced by performing
selective 1-4 glucosylations utilizing a glucosamine building block containing two free
hydroxy groups. Furthermore, this work was executed in the hope to synthesize the
branched oligosaccharide Lacto-N -fucopentaose III where the fucose is also attached in
the same pot.
In addition, pNP-neuraminic acid was synthesized for the purpose to perform activ-
ity studies on enzymes. The enzymes were designed to perform sialyl transfer reactions
in the synthesis human milk oligosaccharides containing neuraminic acid.
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The second chapter describes the regioselective ring opening of enantiopure oxabicy-
cles primarily by the use of rhodium catalysts and phosphine ligands. The ring opened
iii
products were similar to compounds, which had shown to be potential protein Bcl-XL
antagonists, a target for future drugs in cancer treatment.
The aim was to create a general asymmetric ring opening method of several enan-
tiopure oxabicycles having different functional moieties attached to the ring. By em-
ploying a [Rh(COD)Cl]2 catalyst with a Josiphos ligand, it was possible to perform the
ring opening of oxabicycles with ester moieties in good yield end excellent regioselec-
tivity.
Other functional groups showed to be more challenging, therefore several alterations
of the functional groups were performed to form oxabicycles, which could be ring opened
regioselectively by the [Rh(COD)Cl]2 catalyst and Josiphos ligand.
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Resumé
Denne afhandling omfatter to adskilte emner, et vedrørende kulhydrat kemi og et
omhandlende organometallisk kemi.
Det første kapitel omhandler kemisk syntese af oligosakkarider til stede i modermælk.
Human mælk oligosakkarider er en familie af strukturelt forskellige glycaner, som er
meget unikke for modermælk. Disse oligosakkarider tager del i adskillige mekanismer,
der beskytter ammede børn mod infektioner, og desuden menes de at fungere som
næringsstoffer for den tidlige udvikling af hjernen.
De syntetiserede forbindelser indeholder Galβ1–3/4GlcNAcβ1–3Galβ1–4Glc, som
er en gennemgående central del i mange human mælk oligosakkarider. Tre forskel-
lige human mælk olligosakkarider er blevet syntetiseret; Lacto-N -tetraose, Lacto-N -
fucopentaose I og Lacto-N -neofucopentaose I. En "one-pot" syntese strategi blev ud-
viklet, baseret på forskellen i reaktivitet mellem thioglycosid donor og acceptor, og
anvendt til dannelse af tetrasakkarid kernen. Tetrasakkariderne blev syntetiseret ved
brug af den udviklede "one-pot" mekanisme, samt ved sekventiel syntese. Ved af-
beskyttelse af beskyttelsesgruppen i C-2 stillingen på galactose delen blev en ny accep-
tor dannet som ved efterfølgende fucosylering dannede de to linære pentasakkarider
Lacto-N -fucopentaose I og Lacto-N -neofucopentaose I.
For at udvide anvendelses mulighederne for "one-pot" motoden, blev der udført
selektive 1-4 glycosyleringer ved anvendelse af en glucosamin byggeblok med to frie
hydroxygrupper. Endvidere blev dette arbejde udført i håb om at syntetisere den
forgrenede oligosakkarid Lacto-N -fucopentaose III, hvor alle byggeblokke blev samlet
i samme kolbe.
Derudover blev pNP-neuraminsyre syntetiseret for at foretage enzymaktivitets målin-
ger. Enzymerne som skulle undersøges havde til formål at overføre dislyl grupper i
enzymatisk syntese af human mælk oligosakkarider, som indeholder neuraminsyre.
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Det andet kapitel beskriver den regioselektive ringåbning af enantiorene oxabicykler,
primært ved anvendelse af rhodium-katalysatorer og phosphinligander. De ringåbnede
produkter var analoger til forbindelser, der har vist sig at være potentielle protein
v
Bcl-xL antagonister, et protein der er fokus på til udvikling af fremtidige lægemidler i
kræftbehandlingen.
Der ønskedes at udvikle en generel metode for asymmetrisk ring åbning af enan-
tiorene oxabicykler med varierende funktionelle grupper på ringen. Ved anvendelse af
katalysatoren [Rh(COD)Cl]2 og en josiphos ligand var det muligt at foretage regiose-
lektive ringåbninger af oxabicykler i højt udbytte og god regioselektivitet, når en af de
funktionelle grupper var en ester gruppe.
Det viste sig at være mere udfordrende at foretage ringåbninger, ved tilstedeværelse
af andre funktionelle grupper end ester grupper. Derfor blev der foretaget flere æn-
dringer af de funktionelle grupper, med det mål at disse kunne blive ringåbnet regiose-
lektivt ved anvendelse af katalysatoren [Rh(COD)Cl]2 og en josiphos ligand.
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Human Milk Oligosaccharides
This chapter will cover the synthesis of tetra- and pentasaccharides present in human
milk along with the synthesis of pNP-Neu5Ac used for measuring the activity of en-
zymes for the synthesis of human milk oligosaccharides.
1.1 Human Milk Oligosaccharides
Human milk oligosaccharides (HMOs) are a family of structurally diverse glycans that
are highly abundant in and unique to human milk. The discovery of HMOs was driven
by both scientists and physicians. Physicians and microbiologists were trying to un-
derstand the observed health benefits associated with breast-feeding, whereas chemists
were trying to characterize the highly abundant carbohydrates. At the end of the 19th
century it was observed that breast-fed infants had lower incidences of diarrhea and
other diseases than bottle-fed infants, hence had a greater chance of survival.1
In 1900 Tissier and Moro reported that there was a difference in the bacterial compo-
sition in the feces of breast-fed compared with formula-fed infants.2,3 Around the same
time it was observed, that human milk contained additional unknown carbohydrate
fractions than bovine milk. Through the 1930th small progress in structural charac-
terisation was made but at the end of the 1950th several HMOs were characterized in
detail.4–9 Around this time it was also confirmed, that the growth-promoting factor for
Bifidobacterium bifidus consisted of oligosaccharides.10–14 Some of the oligosaccharides
showed activities of blood group determinants, which contributed to the structural char-
acterization of H and Lewis blood group determinants. As the interest in blood group
glycans increased, new methods and tools were developed leading to characterization
of additional HMOs.15–17 In the time following, even more HMOs were discovered and
today more than 200 distinct complex oligosaccharides have been identified in human
milk.18
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Chapter 1. Human Milk Oligosaccharides
Human milk containes a broad range of biomolecules including lipids (vitamins),
enzymes, proteins and oligosaccharides. The third most abundant component in human
milk is the oligosaccharides (5–15 g/L).19 HMOs are composed of the five monosac-
charide building blocks galactose (Gal), glucose (Glc), N -acetylglucosamine (GlcNAc),
fucose (Fuc) and N -acetylneuraminic acid (Neu5Ac). With a few exceptions they are
all composed of a lactose (Galβ1–4Glc) unit at the reducing end and can be elongated
with up to 15 repeating units of the disaccharides (Galβ1–3/4GlcNAc). Lactose or
the resulting linear core structure can be sialylated with α2–3 and/or α2–6 linkages
and/or fucosylated with α1–2, α1–3, and/or α1–4 linkages. The different linkages that
are observed in HMOs are shown in Figure 1.1.20
[Galß1-3/4GlcNAc]ß1-3/6[Galß1-3/4GlcNAc]ß1-3/6[Galß1-4Glc]
2             3/4                  2            3
Fuc
Neu5Ac
3/6             6                    3/6
α1 Fucα1 Fucα1 Fucα1
α2 Neu5Acα2 Neu5Acα2Neu5Acα2 Neu5Acα2
3/6            6
2             3/4
Fucα1 Fucα1
Figure 1.1: Core structure of HMOs with possible linkages of N -acetylneuraminic acid
and fucose.
The oligosaccharide amount and composition vary between women, and the compo-
sition is very different compared with bovine milk. The oligosaccharides in bovine milk
are less abundant and structurally less complex than oligosaccharides in human milk,
and therefore formula-fed infants are not provided with the same amount of HMOs as
breast-fed infants.1 In Tabel 1.1 is shown the difference in oligosaccharide composition
of human milk and bovine milk.
As can be seen the fucosylated oligosaccharides are the most abundant in human
milk, but bovine milk only containes traces of fucosylated oligosaccharides. While
sialylated oligosaccharides are common in both human and bovine milk, the latter also
contains sialyloligosaccharides containing N -glycolylneuraminic acid (Neu5Gc), which
is not present in human milk.22 The postulated beneficial effects of some of the most
abundant HMOs will be discussed in the following section.
1.1.1 Postulated beneficial effects of human milk oligosaccharides
HMOs were mainly known for their prebiotic effects, as the first discovery was the
growth-promoting factor of HMOs for Bifidobacterium bifidus. However, since the early
1990s research have provided more and more evidence suggesting that HMOs are more
than a substrate to promote the growth of desired bacteria in the infant’s intestine.
2 Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
Postulated beneficial effects of human milk oligosaccharides
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Prebiotic effect
The effect is defined as ’A prebiotic is a selectively fermented ingredient that allows
specific changes, both in the composition and/or activity in the gastrointestinal mi-
croflora that confers benefits upon host well being and health’.23 Three criteria need
to be met for HMOs to be defined as prebiotics, firstly, they have to resist gastric acid-
ity, hydrolysis by mammalian enzymes and gastrointestinal absorption, secondly, they
need to be fermented by the intestinal microflora, and thirdly, they should selectively
stimulate the growth and/or activity of intestinal bacteria associated with health and
well being. HMOs meet all three criteria.
HMOs serve as prebiotics by increasing the number of beneficial bifidobacteria and
Lactobacillius species. As a consequence, the competition between the beneficial bac-
teria and undesired pathogenic bacteria for binding sites on the intestinal epithelium
and for nutrients is increased, thus inhibiting survival of the pathogenic strains (Fig-
ure 1.2). The fermentation of prebiotics by Bifidobacterium species produce short
chain fatty acids, which acts as nutrients for the epithelial cells. Also the short chain
fatty acids creates an acidic environment in the colon inhibiting the growth of some
pathogenic strains of bacteria such as colibacteria.24
As about 90% of all HMOs are found intact and not metabolized in the infant’s feces
the HMOs are postulated to have additional effects to establish a certain microbiota
composition.
Anti-adhesive antimicrobial effect
HMOs directly reduce microbial infections by serving as anti-adhesive antimicrobials.
It is essential for many pathogens (e.g. Campylobacter jejuni, Escherichia coli (E.
Coli), Vibrio cholera, and Salmonella species) to adhere to the mucosal surfaces for
the spreading of these bacteria.21 Bacterial adhesion is often initiated by lectin-glycan
interactions, where lectins bind to oligosaccharides on the epithelial cell surface. Some
HMOs resemble mucosal cell surface glycans and hereby are able to serve as soluble
ligand analogs and block pathogen adhesion, thus protecting the infants against infec-
tions.18 A good example of this, is Campylobacter jejuni that adhere to intestinal 2’-
and impact the composition of the infant’s intestinal
microbiota. Already in 1954, György et al.1 repor ed
prebiotic effects of HMOs, showing that a mixture of
HMOs promotes the growth of Bifidobacterium bifidum
(Figure 2). LoCascio et al.2 reported recently that Bifido-
bacterium longum biovar infantis, an isolate from the
infant gut, prefers certain short-chain HMOs over more
complex, high-molecular-weight HMOs, correlating with
the expression of bacterial enzymes capable of cleaving
oligosaccharides. These results suggest that the prebiotic,
bifidogenic effects of HMOs are structure-specific and
may vary depending on the HMO composition in the
milk of different individuals or change over the course of
lactation.
The prebiotic effects of HMOs are probably best
known and most referenced. However, about 90% of all
HMOs are found intact and not metabolized in the
infant’s feces. This suggests that HMOs have additional
effects other than just serving as prebiotic “fuel” to estab-
lish and maintain a certain desired mircobiota composi-
tion. The following sections describe some of these
postulated effects.
ANTI-ADHESIVE EFFECTS
The virulence of most pathogenic microorganisms, e.g.,
Campylobacter jejuni, Escherichia coli,Vibrio cholera, and
Shigella and Salmonella strains, often depends on their
ability to adhere to the host’s epithelial surface.Adhesion-
related virulence factors are often lectins, glycan-binding
proteins, which bind to oligosaccharides on the epithelial
cell surface3 (Figure 3A). Some of these glycan-binding
determinants are also part of HMOs, suggesting that
HMOs serve as soluble ligand analogs, block pathogen
adhesion, and protect the breastfed infant against infec-
tions and diarrhea4 (Figure 3B). For example, Campylo-
bacter jejuni, one of the major causes of diarrhea
worldwide,5 adheres to intestinal 2′- fucosyllactosamine,6
Figure 1 Structural composition of milk oligosaccharides. Milk oligosaccharides can be short-chain trisaccharides, e.g.,
sialyllactos or fucosyllactose, or complex high-molecular-weight glycans.
Figure 2 Prebiotic effects of HMOs. This highly simplified scheme shows that desired (light) and undesired (dark) bacteria
have different capabilities of metabolizing HMOs. In the presence of HMOs (right), the desired bacteria metabolize HMOs and
thrive while undesired bacteria cannot metabolize HMOs. Metabolites from bacterial HMO degradation, e.g., short-chain fatty
acids, create an environment that also benefits the growth of desired bacteria. In the absence of HMOs (left), both desired and
undesired bacteria can grow.
Nutrition Reviews® Vol. 67(Suppl. 2):S183–S191S184
Figure 1.2: Simplified figure showing the intestine without HMOs (left) and with HMOs
(right). In the absence of HMOs the undesired pat ogenic b cteria (purple) and the
desired bacteria (green) compete for the binding sites. When H Os (blue) are present,
beneficial bacteria (green) metabolize HMOs and thrive, while undesired bacteria (pur-
ple) can not metabolize HMOs. Hereby fewer undesired bacteria will bind to the in-
testinal epithelium.18
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fucosyllactosamine (Fucα1–2Galβ1–3GlcNAc). The incidences of Campylobacter diar-
rhea in breast-fed infants were less for breast-fed infants receiving milk with high con-
centration of 2’-fucosyllactose than those with low concentration of 2’-fucosyllactose.25
Also influenza A, B and C viruses have a specificity for Neu5Acα2–3Galβ1–4Glc and
Neu5Acα2–6Galβ1–4Glc, which both are of high concentration in human milk.21
Scientific studies have shown that HMOs might protect infants against postnatal hu-
man immunodeficiency virus (HIV) transmission. HIV entry across the infant’s mucosal
barrier is partially mediated through binding of the viral envelope glycoprotein gp120
to DC-SIGN (dentritic cell-specific ICAM3-grabbing non-integrin) on human dendritic
cells. This initial gp120/DC-SIGN interaction is important for HIV transmission from
mother to child via breast-feeding. DC-SIGN recognizes mannose containing glyco-
conjugates, such as HIV-gp120, but has even higher binding affinities for Lewis blood
group antigens.26 The Lewis antigens contain fucosylated Galβ1–3/4GlcNAc residues.
As HMOs contain these Lewis antigens they can compete with gp120 for binding to
DC-SIGN in vitro. This may explain the low HIV transmission through breast-feeding
as 80–90% of infants are not infected, despite continuous exposure to the virus in milk
over many months.1
It has also been suggested that HMOs reduce upper respirartory and urinary tract
infections.
In summary, the antiadhesive antimicrobial effects of HMOs may contribute to
a lowering of intestinal, upper respiratory and urinary tract infections in breast-fed
compared with formula-fed infants.
Other postulated benefits
Many other benefits of HMOs have been postulated, among these is their ability to
modulate the expression of intestinal epithelial cell surface glycans. When cultured hu-
man intestinal epithelial cell lines are incubated with 3’-sialyllactose the gene expression
levels of sialyltransferases is reduced, thus diminishing α2-3- and α2-6-sialylation on
cell surface glycans. Consequently, binding of enteropathogenic E. coli is reduced as it
uses sialylated cell surface glycans to attach to the host’s intestinal epithelial cell.27
It is also postulated that certain sialylated HMOs may contribute to prevent allergy
and autoimmune diseases.29 Breast-feeding promotes an anti-inflammatory cytokine
milieu, which is maintained throughout infancy. Higher serum concentrations of the
potentially pro-inflammatory cytokines were found in formula-fed infants than in those
who were breast-fed.30
Necrotizing enterocolitis (NEC) is a disorder primarily seen in premature infants,
and is often fatal. Breast-fed infants have a 6–10 fold lower risk of developing NEC
than formula-fed infants.28 Studies on rats have shown that some HMOs protect againts
NEC.31 Neu5Acα2–3Galβ1–3(Neu5Acα2–6)GlcNAcβ1–3Galβ1–4Glc (DSLNT) was found
to protect rats against NEC disorder, and for that reason it could be interesting to in-
vestigate whether these effects translate to infants.
They are believed to serve as nutrients for the early brain development. Many
other beneficial effects of HMOs have been suggested, and they are currently being
investigated.
Unfortunately, large quantities of these oligosaccharides are not easily available.
This calls for other ways to provide the quantity needed, if formula-fed infants are to
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be provided with some of the same benefits as breast-fed infants. As a consequense
enzymatic, chemoenzymatic and chemical syntheses of HMOs have become the aim for
many research groups. In the present project focus was devoted to chemical synthesis
some of the more abundant HMOs in human milk.
1.2 Chemical synthesis of human milk oligosaccharides
The oligosaccharide moieties of glycoconjugates are involved in a number of biological
interactions within the human body. This have led to a growing interest in obtain-
ing large amounts of natural and modified oligosaccharides for biological and phar-
macological investigations. As a consequence much research have been performed in
finding new methods and strategies for assembling these oligosaccharides. Such as
enzymatic, chemoenzymatic or chemical syntheses. The first glycoside synthesis was
reported in 187932 and since then the field of chemical synthesis of glycosides has been
widely explored and expanded.33–37 In this thesis, however, a comprehensive overview
of oligosaccharide synthesis will not be provided. Instead the strategies employed in
this work will be discussed together with an overview of the reported chemical synthesis
of HMOs.
1.2.1 The glycosylation reaction
In a glycosylation reaction a glycosidic linkage between a glycosyl donor and a glycosyl
acceptor is being formed. It is most common to form O-glycosides, but N-, S-, and
C -glycosides are also possible to form, but is not relevant for HMO synthesis. The chal-
lenge with forming glycosidic linkages is to generate them stereo- and regioselectively.
To achieve high stereo- and regioselectivity protecting group manipulation is applied.
The most common way is to use a fully protected glycosyl donor, which bears a leaving
group at its anomeric center, together with a suitably protected glycosyl acceptor that
often contains only one free hydroxy group (this specifies the regioselectivity) (Scheme
1.1).33
It is believed that a typical glycosylation follows a unimolecular mechanism (SN1).
The mechanism of a given glycosylation reaction possesses partial or complete SN1
type character, but it has not yet been possible to achieve a clean SN2 type character.
The rate limiting step often involves the development of positively charged oxocarbe-
nium ion. Consequently, the electronic effects of the substituents of the glycosyl donor
can affect the reactivity remarkably. Thus, the rate limiting transition state will be
stabilized by electron donating substituents.35
As a result of the SN1 type character of the glycosylation reaction, controling
the stereochemistry is the most challenging aspect of oligosaccharide synthesis. When
considering only the D-sugars (in pyranose form), the nature of the protecting group at
C-2 of the glycosyl donor determines the selectivity. When a participating neighboring
O
LG O
Glycosyl donor oxocarbenium ion
O
OR
HOR
glycoside
PGO PGO PGO
Scheme 1.1: Genereal glycosylation mechanism.
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O O
O O
R
O
O O
R
HO O
O
R
O
O O
a)
b)
O
RO
OO
1,2-trans
O
RO
O O
O
RO O O
1,2-trans
1,2-cis
Scheme 1.2: Glycoside synthesis with a) neighboring group participation b) no neigh-
boring group participation.
group is employed, the glycosidic linkage will be a 1,2-trans glycosidic linkage (β) and
the reaction is stereospecific. Whilst glucosylation with a non-participating group at
C-2 will lead to a mixture of the 1,2-trans and the 1,2-cis product. In this case the
reaction conditions will determine the stereoselectivity (Scheme 1.2).38
A wide range of glycosyl donors are used in glycoside synthesis and the number is
still increasing. By selecting the appropriate reaction conditions, high yields and good
α:β ratios can be obtained. As Hans Paulsen so beautifully put it "...each oligosaccha-
ride synthesis remains an independent problem, whose resolution requires considerable
systematic research and a good deal of know-how. There are no universal reaction
conditions for oligosaccharide synthesis".39
1.2.2 Glycosyl donors
Today the selection of glycosyl donors is huge, they all have advantages and disad-
vantages. When performing an unknown glycosidic linkage it can be an advantage to
consider some of them. A selection of the wide array of glycosyl donors to choose from
spands from anomeric halides,40–42 glycals,43 selenoglycosides,44 thioglycosides,45 sul-
foxides,46 vinyl glycosides,47 xanthates,48 through pentenyl glycosides,49,50 phosphorus
containing compounds,51,52 orthoesters,53 imidates,54,55 and even more (Figure 1.3).
Each of these glycosyl donors have a certain set of promotors which establishes the
reaction conditions. The methods employed in the present work uses glycosyl halides,
pentenyl glycosides, N -phenyl trifluoroacetimidates, trichloroacetimidates and thiogly-
cosides, hence a more thorough discussion of these will be given.
Glycosyl bromides and chlorides
One of the oldest methods, and traditionally the most widely used method for the syn-
thesis of complex glycosides, is the Koenigs-Knorr method.40,56 The classical glycosyl
donors are glycosyl bromides and chlorides and the promoters used are heavy metal
salts. Over the years a wide variety of promotors have been employed but the most
widely used till date are silver salts such as Ag2CO3,40,56 Ag2O,56 silver perchlorate
(AgClO4)57 and silver triflate (AgOTf).58 This method aquire at least stoichiomet-
ric amounts of the promoters. Water is beeing formed during this reaction with the
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O
X
halids
O O
SeAr
O
S
O
SR
O
S
X = F, Cl, Br, I
glycals selenoglycosides thioglycosides
O
O
pentenylglycosides
Ar
O
sulfoxides
SEt
S
xanthates
O O CCl3
NH
trichloroacetimidate
O O CF3
NPh
N-phenyl trifluoroacetimidate
O O R O O
P
O
R
R
vinyl glycoside
O
O O
R OR
phosphates/phosphites orthoesters
Figure 1.3: Glycosyl donors.
first two salts, and as a consequence of this they are often low yielding if a no drying
agent is used. The silver carbonate and oxide also act as acid scavengers for the acid
released, but organic bases, such as collidine, lutidine, tetramethylurea (TMU) and
2,4,6-tri-tbutylpyrimidine (TTBP) may also be used for the same purpose.37
The disadvantage of the Koenigs-Knorr method is the thermal instability of the
glycosyl bromides and chlorides, especially when they bear electron-donating protecting
groups. Often the halide is introduced immediately before the glycosylation step, and
purification of the halides are often problematic.
Glycosyl trichloroacetimidates and N -phenyl trifluoroacetimidates
The first attempts to find alternatives to the glycosyl halide methodologies were the em-
ployment of imidate and orthoester procedures. Trichloroacetimidates were introduced
by Schmidt and co-workers.54 They can be prepared by base catalyzed addition of
trichloroacetonitrile to the free hydroxyl of lactols. The strength of the base employed
determines the relative stereochemistry.59 They are sufficiently stable for purification,
and can be stored at low temperatures for months. Trichloroacetimidates are activated
by catalytic amounts of Brønsted or Lewis acid, with the currently most used Lewis
acid being trimethylsilyl triflate (TMSOTf).60 The stereoselectivity of the glycosyla-
tion is determined by the nature of the donor (α or β), the promotor and the solvent.
Both 1,2-cis and 1,2-trans products can be favored. In many ways trichloroacetimidates
are prefered over glycosyl halides, as they are more stable, only catalytic amounts of
promotor is needed, and there are various possibilities for stereocontrol. The high re-
activity of trichloroacetimidates can lead to side reactions or even decomposition of the
donor. Also when the acceptor is unreactive, rearrangement of the trichloroacetimi-
date donor into the corresponding glycosyl trichloroacetamide has been observed under
Lewis catalysis (Scheme 1.3). The glycosyl acetamide is not reactive towards glycosyla-
O O CCl3
NH
Lewis acid O
H
N CCl3
O
glycosyl acetimidate glycosyl acetamide
Scheme 1.3: Rearrangment of trichloroacetimidate into the corresponding trichloroac-
etamide under Lewis acid catalysis.
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Glycosyl donors
tion.61 To circomvent this problem N -phenyl trifluoroacetimidates can be employed, as
these are less reactive and the rearrangment is not possible. They are synthesized from
N -substituted trifluoroacetimidoyl halides and are also activated by Lewis acids.55
n-Pentenyl glycosides
Another group of stable glycosyl donors are the n-pentenyl glycosides, which was intro-
duced by Fraser-Reid.49 They can be stored at room temperature for several months
some even years. n-Pentenyl glycosides are activated by halogenation of the dou-
ble bond, leading to the formation of a cyclic halonium ion intermediate, followed
by subsequent rearrangement into a cyclic intermediate containing the leaving group.
Elimination of the leaving group provides the active glycosylation species (Scheme 1.4).
O
O
O
O
X
O
O
X
X
O
X
O ROH O
OR
halonium ion intermediate cyclic intermediate
Scheme 1.4: Mechanism for the activation of n-Pentenyl glycosides.
The promotors employed areN -bromosuccinimide (NBS),N -iodosuccinimide (NIS),
iodonium di-sym-collidine perchlorate (IDCP) or iodonium dicollidine triflate (IDCT).
Equimolar amounts of the promoter are required. When NBS or NIS is used with
a protic acid such as triflic acid (TfOH) or a Lewis acid such as triethylsilyl trifluo-
romethanesulfonate (TESOTf) a more active catalyst is formed.62 It is possible to form
the 1,2-trans glycosides with participating neighboring groups, but without it leads to
a mixture of α and β in favor of the α-glycoside. As the reactivity of n-pentenyl gly-
cosides vary with the protecting groups employed, they can be used together in the
armed-disarmed concept, which will be discussed more thoroughly in Section 1.2.3.
Thioglycosides
Thioglycosides are among the most widely used choices of glycosyl donors and were
introduced by Ferrier and co-workers.63 This popularity is partly due to their ready
synthesis and partly to their easy conversion into sulfoxides and other glycosyl donors,
offering an alternative glycosyl donor source. Thioglycosides can easily be prepared
from acetylated sugars (often 1,2-trans acetates) with thiols in the presence of a Lewis
acid such as TESOTf, SnCl4 and BF3·OEt2. But they can also be obtained from other
common glycosyl donors like glycosyl halides. The advantage of thioglycosides are their
remarkable stability. They have long shelf lives, but more importantly, they posses an
increased stability against protecting group manipulation and other chemical transfor-
mations. Activation of thioglycosides can be achieved by a wide variety of electrophilic
promotors. The most commonly employed activators are NIS/TfOH, IDCP, methyl tri-
fluoromethanesulfonate (MeOTf), phenylselenyl trifluoromethanesulfonate (PhSeOTf),
dimethylthiomethylsulfonium trifluoromethanesulfonate (DMTST), 1-benzenesulfinyl
piperidine-triflic anhydride (BSP-Tf2O), and diphenyl sulfoxide-Tf2O (Ph2SO-Tf2O)
(Figure 1.5).45 All promotors are required in at least stoichiometric amounts.
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N
O
O
I N
O
O
H+ TfOH + +I TfO
N
I N
ClO4
(IDCP)
PhSeCl + AgOTf OTfPhSe + AgCl
SMeMeS + MeOTf SMeS
OTf
Me
Me (DMTST)
S N
OTf
TfO
S
OTf
TfO
(BSP-Tf2O) (Ph2SO-Tf2O)
Scheme 1.5: The most commonly employed activators for thioglycosides
The configuration of the glycosidic linkage follows the same pattern as for other gly-
cosyl donors bearing a participating neighboring group leading to the 1,2-trans product.
Wheras the use of non participating neighboring group lead to a mixture of α and β.
The use of diethylether will favor the α-glycoside, while the use of acetonitrile will favor
the β-glycoside.64 Thioglycosides can be applied in the armed-disarmed concept, both
with other thioglycosides and/or other glycoside donors and acceptors such as pentenyl
glycosides.
1.2.3 Synthetic strategies for oligosaccharide formation
In the synthesis of natural products, one aim is to apply as few steps as possible,
especially as few linear steps as possible. This is also a goal in oligosaccharide synthesis.
Multiple ways of acheiving this have been employed. A short overview of some of the
different strategies will be given hereafter.
Two major strategies can be considered for oligosaccharide synthesis, one is the lin-
ear approach using stepwise synthesis and the other is block synthesis. In the stepwise
(linear) synthesis a donor and an acceptor is first coupled to form a disaccharide inter-
mediate (Scheme 1.6). The disaccharide can either be deprotected to form a glycosyl
acceptor, or the R-group at the anomeric center of the reducing end can be converted
into a leaving group (LG), hence become a glycosyl donor. The formed disaccharide
acceptor can be reacted with a monosaccharide donor to furnish a trisaccharide. The
disaccharide doner would by reaction with an acceptor create the same (or a similar)
trisaccharide. The trisaccharide can be further elongated by deprotection/introduction
of a leaving group followed by another glycosylation.
In the block synthesis, a disaccharide building block is first assembled and then
transformed into a glycosyl donor and a glycosyl acceptor. The two disaccharides
are then coupled yielding a tetrasaccharide. The tetrasaccharide can be further elon-
gated by deprotection/introduction of a leaving group followed by another glycosylation
(Scheme 1.7).36
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O
LG
Glycosyl donor
O
R
Glycosyl acceptor
PGO
PG = Protecting group
LG = Leaving group
HO+
O
R
O
OPGO
Deprotection Introduction of LG
O
R
O
OHO
O
LG
O
OPGO
O
R
Glycosyl acceptor
HO
Glycosyl donorGlycosyl acceptor
O
LGPGO
Glycosyl donor
O
R
O
OO
O
PGO
Disaccharide intermediate
Triaccharide intermediate
Scheme 1.6: Stepwise (linear) synthesis
When higher oligosaccharides are wanted, the block strategy is to be prefered es-
pecially when two or more sequential rrepeating units are employed. Block synthesis
also have the advantage that critical steps can be performed at an early stage on
smaller compounds, hence facilitating chromatographic separation and hopefully avoid
complicated separation steps of diastereoisomers.
As the selection of glycosyl donors and promoter systems have multiplied over the
years, the methods for assembling oligosaccharides have been similarly expanded. In
the following, a short overview of selected concepts in glycoside formation will be
summarized.
Selective activation involves a glycosyl donor, bearing a reactive leaving group
(LGa), which is coupled with a glycosyl acceptor, bearing a relative stable leaving
group (LGb) at the anomeric center. The requirements for the promoter is to selectively
activate LGa over LGb, and LGb should not be altered under the applied conditions.
One of the first reported examples involved a bromide as LGa and a thioethyl as LGb.65
Demchenko and co-workers have developed many glycosylations by this strategy.66,67
O
LG
Glycosyl donor
O
R
Glycosyl acceptor
PGO
PG = Protecting group
LG = Leaving group
HO+
O
R
O
OPGO
DeprotectionIntroduction of LG
O
R
O
OHO
O
LG
O
OPGO
Glycosyl donor Glycosyl acceptor
O
R
O
OO
O
O
Disaccharide intermediate
Tetrasaccharide intermediate
O
PGO
Scheme 1.7: Convergent block synthesis
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The armed-disarmed concept was developed by Fraser-Reid and co-workers.68
The concept rely on the observation, that electron donating substituents such as ethers
tend to stabilize the rate limiting transition state of the glycosylation reaction. Thus
the reactivity is increased and these donors are termed ’armed’. On the contrary,
electron withdrawing groups such as esters lowers the glycosylating capability and
these glycosides are termed ’disarmed’. The armed saccharide will be chemoselectively
activated over the disarmed, hence acting as the donor by the use of a mild promoter.
The newly formed dissacharide can be coupled with other saccharides using a more
powerful promoter.
As the chemoselective activation principles have expanded since, a database of rel-
ative reactivity values (RRVs) has been established.71 Several observations were done
and some are listed below.
1. the trend of reactivity of aminosugars is as follows for the N -protecting groups
NHCbz > NHTroc > NPhth > N3 > NHAc. Hence an aminosugar with a NHCbz
group is more reactive than one with a NHAc group.72
2. the general trend for reactivity enhancement of glycosides by protective groups
is (H) > OSilyl > OH » OBn > NHTroc > OAc > OBz > OClAc.72
3. pyranosides show reactivities, which differ as a function of sugar. The reactivity
decreases in the order fucose > galactose > mannose > glucose > neuraminic
acid. It should be noted that the differences in reactivity are not significant.72
4. the position that affects pyranoside reactivity most is not the same for each
sugar.72
5. the anomeric deactivation can also be achieved by the torsional effect of cyclic
acetals, bulky protecting groups and/or dispiroketal protecting groups.69,70,73
6. bulky leaving groups reduce the reactivity.74
7. axial substituents increase reactivity.75
The armed disarmed concept has been expanded by additional concepts such as the
active-latent strategy,76 orthogonal strategies77 and one-pot multistep strategies.45
The aim of this PhD project was to develop a general one-pot method, which could
be applied for the synthesis of several HMOs. The one-pot multicomponent strategy
is, as the name implies, the synthesis of oligosaccharides by a controlled cascade of
glycosylations in the same reaction flask. The one-pot reactions are controlled by tuning
the reactivity of the glycosides. The advantage of one-pot glycosylations compared to
the sequential glycosylations is that tedious purification steps are avoided. Also the
yield of one-pot reactions tend to be higher due to the fewer purification steps.
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1.2.4 Reported synthesis of human milk tetrasaccharides and
higher oligosaccharides
Chemical synthesis of more than 15 different structures ranging from tetrasaccharides
to octasaccharides has been prepared so far. The main part of these were presented as
the parent oligosaccharides, but some were synthesized with a chemical deviant group
at the reducing end. This includes alkyl azides90,97 or potential donor aglycons such as
pent-4-enyls.91,92 Much focus has been on the synthesis of the backbone core [Galβ1–
3/4GlcNAcβ1–3/6]nGalβ1–4Glc, and various approaches have been employed for the
assambly of this, including solid phase methods. Numerous groups have synthesized
Lewis antigens, which consists of Galβ1–3[Fucα1–4]GlcNAc—R (Lea), Galβ1–4[Fucα1–
3]GlcNAc—R (Lex), Fucα1–2Galβ1–3[Fucα1–4]GlcNAc—R (Leb) and Fucα1–2Galβ1–
4[Fucα1–3]GlcNAc—R (Leb). When the R-group is lactose, all of these compounds are
present in human milk. For further information of Lewis antigens synthesis see ref.78–80
An overview of the reported synthesis of HMOs is summerized in Table 1.2. A
selection of these will be reviewed more thoroughly.
The first chemical synthesis of the backbone core lacto-N -tetraose (LNT) was re-
poted by Noro and co-workers81 in 1979 and one year later by another group who
utilized the exact same experimental procedure.82 They reacted donor 1 with acceptor
2 in a toluene-nitromethane mixture with p-toluenesulfonic acid as catalyst for 48 h at
60 ◦C. This yields the protected LNT 3 in 77-79% that upon deprotection provides the
desired product 4 (Scheme 1.8). In 1981 lacto-N -neotetraose (LNnT) was prepared by
a similar strategy.83
The pioneer within synthesis of HMOs is Richard R. Schmidt.84,86,87,99,101,105 Quite
a few research groups have focused on the synthesis of HMO analogs containing lac-
tose at the reducing end, and with a group attached (e.g. glycosyl ceramides) to
the anomeric center of glucose.94,107–109 Schmidt and co-workers84 have synthesized
both of the backbone cores LNT and LNnT. A TMSOTf promoted coupling of the
trichloroacetimidate donor 5 and glucosamine acceptor 6 yielded 7 in 89%.110 The tert-
butyldimethylsilyl (TBDMS) group was removed and the newly formed disaccharide
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Scheme 1.8: The first reported synthesis of LNT.81,82
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Scheme 1.9: Synthesis of LNT by Schmidt and co-workers.84,110
was converted into the trichloroacetimidate donor 8. TMSOTf promoted glycosylation
of trichloroacetimidate donor 8 and lactose acceptor 9 to created the fully protected
tetrasaccharide 10 in 76% yield, which upon deprotection and N -acetylation yielded
LNT (4) (Scheme 1.9).
LNnT was prepared using the same reaction conditions as for the synthesis of LNT,
employing glucosamine acceptor 11 to get the desired 1–4 correlation (Scheme 1.10).
The TMSOTf promoted coupling of 5 and 11 yielded 12 in 84%, which after conversion
into trichloroacetimidate 13 was coupled with 9 forming 14 in high yield. LNnT was
isolated after deprotection and N -acetylation.
Schmidt and co-workers further extended the work by synthesizing the linear hexa-
saccharide lacto-N -neohexaose 1586 and octasaccharide lacto-N -neooctaose 1686 along
with the branched octasaccharide 17 (Figure 1.4).87 They used the block strategy with
trichloroacetimidate donors and acceptors with their anomeric center being TBDMS
protected.
Schmidt and co-workers also synthesized Lacto-N -fucopentaose II and III (LNFP
II and III, see Table 1.2).99,101 Once again trichloroacetimidate donors were utillized
and a temporary protecting group was used at the anomeric center of the acceptor.
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Figure 1.4: Structures of hexasaccharide 15 and octasaccharides 16 and 17.
Two different approches were used; in one of the cases only a single hydroxy group
was left free at C-3,101 and in the other case both C-3 and C-4 have free hydroxy
groups.99 The latter case is particularly interesting as this provides an insight into the
reactivity of the different hydroxy groups on glucosamine and prefered attachments
for different glycosyl donors. In the case of only one free hydroxy group, either the
galactose or fucose building block is coupled with glucosamine 18 (Figure 1.5) followed
by regioselective opening of the benzylidene acetal, leaving a hydroxy group at C-4
open for glycosylation with either a fucose or galactose. All of the glycosylations in
this method proceeded in high yields. In the second method with two free hydroxy
groups, it was attempted to prepare trisaccharide 22 in two different ways (Scheme
1.11); method a by first connecting the galactose donor 5 with the glucosamine acceptor
19, followed by a glucosylation with fucose donor 21 or method b by first connecting
the fucose donor 21 with the glucosamine acceptor 19, followed by a glycosylation with
the galactose donor 5. As seen from this scheme, pathway a leads to disaccharide 20
as the only product, whilst pathway b leads to the two disaccharides 23 and 24 in a
2:1 ratio. This shows that the galactose has a preference for the 4-position while the
fucose has a preference for the 3-position. The formed trisaccharides were transformed
into trichloroacetimidate donors and coupled with a protected lactose acceptor yielding
the fully protected pentasaccharides, which were converted into LNFP II and LNFP
III (Table 1.2).
All methods reviewed until this point involved a temporary protecting group at
the anomeric center of the acceptor, necessitating additional steps for introduction
of an appropriate leaving group for the following glycosylations. The first reactivity-
based synthesis of HMOs was only developed recently.97 Disaccharide donor 26 and
glucosamine 27 were combined and then coupled with lactose acceptor 28 in a one-
pot synthesis giving the pentasaccharide product 29 in moderate yield (Scheme 1.12).
Moreover, it was resently shown that a one-pot synthesis of fully protected LNT could
O
O O
HO
Ph
OTDS
NHTroc
18
Figure 1.5: Glucosamine building block 18 used for the synthesis of LNFP II and LNFP
III.
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Scheme 1.11: Synthesis of the protected trisaccharides 22 and 25.
be carried out by reactivity-based synthesis. The yield depended on the RRVs of the
super-armed donors, giving higher yields with higher RRVs.90
The main part of the synthesized HMOs were formed using trichloroacetimidate
donors,88,89,91,94,99 but other employed glycosyl donors are thioglycosides,90,94,95,97 and
phosphates.91,92,97
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Scheme 1.12: Synthesis of the protected trisaccharide 21 for synthesis of LNFP III.
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1.3 Synthesis of Lacto-N -tetraose (LNT)
LNT (4) is one of the most abundant oligosaccharides in human milk and it is a
backbone core for many of the HMOs identified (Table 1.1). LNT was chosen as target
molecule for several reasons. First of all, LNT is the core of many HMOs, which makes
this tetrasaccharide of high interest for enzymatic studies in synthesis of higher HMOs
and biological activity measurements. Secondly, it would hopefully provide building
blocks for the synthesis of penta- and hexasaccharides. Thirdly, the size and linear
conformation made it a suitable target for development of a new one-pot strategy.
1.3.1 Retrosynthetic strategy
Well known building blocks were chosen for the retrosynthetic strategy. A variety of
well known galactose building blocks 5, 31–37 were chosen as all could be synthesized
in few steps from the same starting material. Furthermore, it was decided to settle for
glucosamine building block 30 along with the lactose building block 9 (Scheme 1.13).
1.3.2 Building block synthesis
As the lactose building block 9 had been used successfully for the synthesis of LNT,
it seamed to be the obvious choice. It renders only one free hydroxy group for the
required β1-3 connection. The benzyl protecting groups improve the solubility in or-
ganic solvents and they can be cleaved off in one synthetic step. Building block 9 was
synthesized from lactose in 6 steps with a low overall yield of 6%. Two steps were es-
pecially lowering the overall yield; the incorporation of a benzyl group at the anomeric
center and the selective allylation of the 3’-position (Scheme 1.14).
Peracetylated lactose 38 was benzylated by an analogous procedure114 yielding
39 in moderate 45%. An explanation for the low yield can be epimerization of the
O
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Scheme 1.13: Retrosynthetic strategy for the synthesis of LNT (4).
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Scheme 1.14: Synthesis of lactose building block 9.
β-acetate 38 into the corresponding α-acetate which is less reactive. An alternative
to the glycosylation of an acetal would be to convert the anomeric OAc group into
a bromide and then perform the glycosylation with benzyl alcohol under lesser acidic
and mare reactive Koenigs-Knorr conditions.
Removal of the acetyl grups with sodium methoxide yielded 40 in 88%. Herefter,
dibutyltinoxide (Bu2SnO) was employed for the selective attachment of the allyl group
at the 3’-position. It is well known that the stannylene activation af hydroxy groups
increases the nucleophilicity of the oxygen atom to react with various electrophiles. Tin
can coordinate either to a primary hydroxy group or a vicinal cis-diol, hence for lactose
4o three positions are able to coordinate with tin; the two primary alcohols and the 3’
and 4’ can coordinate forming a five membered ring with tin. The regioselectivity is
determined by the electrophile. Reactive electrophiles such as acyl or alkyl electrophiles
tend to react with the thermodynamically stable 3’,4’-O-stannylated intermediate to af-
ford 3’-O-acylated/alkylated lactose. On the contrary, 6/6’-O-glycosylation is afforded
when relatively unreactive and bulky electrophiles are employed as they react with
the faster accessible 6-O-stannylated intermediate.37,112 The prefered conformation of
the 3’,4’-O-stannylated intermediate is a trigonal bipyramid (Figure 1.6). In general,
the most electronegative ligands are located on the epical sites,113 hence the hydroxy
group at the 3’-position is more electronegative and the electrophile (allylbromide) will
be attacked from this position. Addition of tetrabutylammonium iodide (TBAI) or
tetrabutylammonium bromide (TBABr) will weaken the strength of the Sn-O bond of
the most nucleophilic oxygen, and therefore catalyze the reaction.
The allylation of the 3’-position of a partly unprotected lactose (except for the re-
ducing end aglycon) has been reported by several groups. Three different solvent sys-
tems have been employed; methanol/toluene (64% yield),111 acetonitrile (47% yield)114
and benzene (70% yield).115 In this work the procedure by Alais et al.115 was followed
O
OH
O
O OH
OR
Sn
R
Bu
Bu
epical
equatorial
Figure 1.6: Trigonal bipyramidal structure of the 3,4-O-stannylated intermediate.
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changing the solvent to toluene instead of benzene. By running the reaction twice, they
were able to drive the reaction nearly to completion with limited formation of further
substituted compounds. In our case, 41 was furnished in 49% yield and small amounts
of starting material was observed, however no additional products could be identified.
The subsequent benzylation generated 42 in 77% yield, which could be converted
into 9 by the use of Wilkinsons catalyst in 69% yield. The most frequently used method
for removing O- allyl ether is by transition metal catalyzed isomerization to the labile
prop-1-enyl ether, which can be cleaved under mild acidic conditions. Wilkinsons
catalyst (ClRh(PPh3)3) together with n-BuLi was used for the isomerisation of the
double bond as the activity of the catalyst is significantly enhanced by n-BuLi. As a
consequence, the catalytic loading can be lowered significantly. The isomerisation was
followed by 1H-NMR.
The glucosamine building block 30 (synthesis shown in Scheme 1.15) was designed
to fulfill several criteria.
1. the N -protecting group should be a participating neighboring group to form the
desired 1,2-trans product. In addition, the protecting group should endure the
glycosylation conditions and the conditions employed for protecting group ma-
nipulations, such as strong base/acid.
2. only the hydroxy group at C3 is unprotected.
3. as few steps as possible is desired.
4. the leaving group (anomer protecting group) should withstand the glycosylation
conditions employed for the first glycosylation and the protecting group manip-
ulations.
5. if the protecting groups at C4 and C6 can be selectively removed one over the
other it will be an advantage, but it is not a requirement. This will enable possible
synthesis of branched penta- and hexasaccharides.
It would be optimal, if no N -protecting group was needed, as the 2-acetamido group
can participate as a neighboring group, however a stable oxazoline is often formed in-
stead of the desired glycoside. A phthalimide was chosen as the N -protecting group,
since the stable oxazoline is not formed in this case and it can endure the basic con-
ditions employed for acetyl removal, whereas many other N -protecting groups such
as tetrachlorophthalimides and dimethylmaleimides are labile to these conditions.116
Thiophenyl was chosen as the leaving group, since it is stable during the protecting
group manipulations. A benzylidine protecting group was chosen, as this renders the
possibility of selective opening of the benzylidine leaving a free hydroxy group at either
the 4- or the 6-position. If two different protecting groups had been employed, it would
result in additional synthetic steps. In addition, compound 30 has been involved in
several glycosylations.117–119
The glucosamine building block 30 was synthesized from glucosamine hydrochloride
in 4 steps with an overall yield of 37% by following literature procedures (Scheme 1.15).
The bottleneck for this synthesis is the first protection of glucosamine hydrochloride as
many parameters can affect the yield of 44. Firstly, if to much heat is evolved when
the amine is generated by addition of NaOMe the yield will be lowered significantly.
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Scheme 1.15: Synthesis of glucosamine building block 30.
Secondly, any presence of phthalic acid will lower the yield, as the reaction is quenched
by protonation of the amine, hence lowering the nucleophilicity. Triethylamine is added
to neutralize the formed acid on compound 43. Thirdly, it is important not to stirr
the glucosamine 43, acetic anhydride and pyridine for too long, as this will generate
more of the thermodynamically stable α product, which is less reactive in the following
step. The thioglycoside 45 was formed in 78% yield when only the β anomer of 44 was
employed. For the deprotection of 45, the reaction was closely monitored by TLC, as
the phthalimido group can be cleaved if the reaction is left for to long. Gratifyingly,
this afforded 46 in 99% yield. The acid catalyzed attachment of the benzylidene group
furnished 30 in 88% yield.
Several galactose building blocks were synthesized from peracetylated galactose 47
or perbenzoylated galactose 48 (Scheme 1.16), giving rise to the needed participating
neighboring group. All galactose donors are known, and they were synthesized following
known analog procedures. The detailes with regard to the synthesis of these donors
will not be further described here, but all reactions are shown in Scheme 1.16 and the
syntheses are described in the experimental section.
1.3.3 Glycosylations
Thiophenyl glycoside32 was the first to be synthesized and coupling with 30 was at-
tempted. None of the desired disaccharide could be isolated when the reaction mixture
was subjected to NIS/TESOTf at -20 – +25 ◦C. All of 32 and most of 30 were isolated.
The RRVs for a similar donor and acceptor (STol instead of SPh) show that 30 is a
better donor than 32, which is an undesired reactivity relation ship between the two
compounds.120 A variety of galactose donors were synthesized assuring the galactose
donor could be selectively activited over glucosamine 30.
In Table 1.3 is shown a selection of the glycosylations tested. The workload was
distributed equally with post doc Thomas Hauch Fenger.
Thioglycosides 31 and 35 (Scheme 1.16) were synthesized as they supposedly are
more reactive than 30. Thomas Hauch Fenger performed the glycosylation studies of
31 (entry 1–3). The most promising promoter was DMTST, although this gained less
than 10% of the disaccharide and 31 was therefore abandoned as donor. Galactose
donor 35 was employed for two reasons, firstly the benzylidine enhances the reactivity
compared to the fully acetylated thiophenyl donor 32,120 secondly, the benzylidene
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Scheme 1.16: Synthesis of galactose donors 5, 31–37.
can be opened selectively leaving a free hydroxy group at the 4- or 6-position, enabling
further expantion of the tetrasaccharide to form larger oligosaccharides. Three differ-
ent promoter systems were tested (entry 4–6) and the most promissing promoter was
NIS/TESOTf yielding the desired product in 26% yield. From this reaction some of
the donor could be reisolated (entry 4). Instead of using the Lewis acid TESOTf, the
stronger Brønsted acid TfOH was employed, which disappointingly resulted in even
more decomposition of both donor and acceptor. Both the BSP-Tf2O (entry 5) and
the NBS/TESOTf (entry 6) promoters resulted in decomposition of both donor and
acceptor.
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Table 1.3: Glycosylation between various galactose donors and glucosamine acceptor30,
CH2Cl2 was used as solvent for all reactions.
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a performed by Thomas Hauch Fenger
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Scheme 1.17: Synthesis of 50 by sequential and one-pot fashion leading to LNT after
deprotection.
The thioglycoside donors were then abandoned and the Koenigs-Knorr glycosylation
method came into use (entry 7–10). Two different donors were employed, the acetylated
33 and the benzoylated 36. The benzoylated donor 36 was employed as it is more stable
than 33 and can be stored in the fridge for several months. First it was attempted to
generate 33 in situ, but the conversion was not quantitative, which required workup
prior to the glycosylation. AgOTf was utilized as the promoter and collidine as acid
scavenger. Unfortunately, only decomposition of both donor and acceptor took place
(entry 7). For the benzoylated donor 36 three different silver salts were employed
as promoters (entry 8–10). The AgOTf promoted reaction was tried both with and
without an acid scavenger (collidine or TMU), which all resulted in decomposition of
the donor. Nevertheless, the reaction allowed the acceptor to be reisolated. Neither
Ag2O nor Ag2CO3 were capable of activating the donor, which resulted in reisolation
of both donor and acceptor.
The most successful galactose donors turned out to be the imidate donors 5, 34 and
37. Thomas Hauch Fenger performed the glycosylation between the trichloroacetimi-
date donor 5 and 30 yielding the desired disaccharide in 75% (entry 11) yield. N -Phenyl
trifluoroacetimidate donor 34 and 37 were synthesized in the hope of getting a better
yield by diminishing the possibility of rearrangment of the trichloroacetimidate into the
unreactive amide (Scheme 1.3). Donor 34 only afforded the desired disaccharide in 28%
yield (entry 12), which was rather low compared to the more successful glycosylation
of donor 37 that yielded the desired disaccharide in 68% yield(entry 13).
The disaccharide 49 formed by the reaction shown in entry 11 was subjected to
NIS/TfOH and the glycoside acceptor 9 yielding the protected tetrasaccharide 50 in
50% (Scheme 1.17). The tetrasaccharide 50 was formed using the same reaction con-
ditions in a one-pot fashion providing 8% yield (Scheme 1.17). The fully protected
tetrasaccharide 50 was deprotected over four steps yielding LNT in 42% (This work
was performed by Thomas Hauch Fenger).
Attempts were also made to couple galactose donor 37 with glucosamine 30 and
lactose 9 in a one-pot fashion with the hope that this would lead to a higher yield than
for the one-pot synthesis of 50. Unfortunately, only the dimer 51 could be isolated,
and 52 was not isolated or detected (Scheme 1.18).
A pentenyl glucosamine acceptor (53) was synthesized in the aim to activate a
glycoside donor prior to the pentenyl glycoside 53. As seen in Table 1.4, none of the
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Scheme 1.18: Attempted one-pot reaction for the synthesis of 52
executed trials was fruitful.
The glucosamine acceptor 53 decomposed when subjected to a NIS/TfOH promoter.
Some of the galactose donor could be reisolated indicating that 53 is more labile than
32. No disaccharide could be identified (entry 1, Tabel 1.4). To avoid decomposition
of the glucosamine acceptor, the promoter Me2S2-Tf2O was chosen. The promoter
contains no halogen and is therefore incapable of activating the pentenyl. Alternatively,
DMTST or BSP-Tf2O can be used as possible promoters. Neither of the thioglycoside
donors 31 and 32 resulted in the desired disaccharide (entry 2 and 3). Surprisingly, a
disaccharide product could be identified as a Gal-Glc structure, but the pentenyl double
bond was reduced (entry 2). Using the Koenigs-Knorr conditions led to decomposition
of the donor, and the acceptor could be reisolated (entry 4). As a result, the pentenyl
strategy was abandoned at this point.
Table 1.4: Glycosylation between various galactose donors and acceptor 53.
# Donor Acceptor (53) Temp. [◦C] Promotor Comment
1
O
OAc
AcO
AcO OAc
SPh
32
O
O O
HO
Ph
O
NPhth -30 NIS/TfOH Acceptor decomp.
2
O
OAc
AcO
AcO OAc
SPh
32
O
O O
HO
Ph
O
NPhth -20 Me2S2-Tf2O Decomp.
3
O
AcO
AcO
AcO OAc
SEt
31
O
O O
HO
Ph
O
NPhth -30 Me2S2-Tf2O Decomp.
4
O
AcO
AcO
AcO OAc
Br
33 O
O O
HO
Ph
O
NPhth -30 – rt AgOTf Donor decomp.
The tetrasaccharide Lacto-N -tetraose (4) was successfully synthesized by a sequen-
tial method. Unfortunately, our aim of develloping a one-pot strategy was not ac-
commodated yet. The amount of LNT synthesized was suficient for our collaborators
to perform initial biological activity and enzymatic studies. The next objective was
to find a new galactose donor suitable for a one-pot method for the formation of a
tetrasaccharide, which in a few steps could be altered into a glycosyl acceptor enabling
enlargement to penta- and/or hexasaccharides.
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1.4 Synthesis of the linear pentasaccharides
Lacto-N -fucopentaose I and Lacto-N -neofucopentaose I
The two linear pentasaccharides Fucα1–2Galβ1–3GlcNAcβ1–3Galβ1–4Glc (LNFP I)
54 and Fucα1–2Galβ1–4GlcNAcβ1–3Galβ1–4Glc (LNnFP I) 55 were the next HMO
target molecules (Figure 1.7).
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Figure 1.7: Structure of target pentasaccharides Lacto-N -fucopentaose I (54) and
Lacto-N -neofucopentaose I (55).
1.4.1 Retrosynthetic strategy for Lacto-N -fucopentaose I (LNFP
I)
The knowledge gained from the synthesis of Lacto-N -tetraose convinced us that, the
benzylidene protecting group caused synthetic problems. Despite the fact that several
groups have published work involving the exact same or similar glycosyl acceptors
providing disaccharides in moderate to high yield.110,121,122 It was suspected that the
benzylidine protecting group was hydrolyzed under the acidic conditions giving rise to
additional di- and trisaccharides, hence lowering the yield of the desired disaccharide. In
general, a trans-fused benzylidine (eg. in Glc) is hydrolyzed faster than a cis-fused (eg.
in Gal) benzylidene. It has been shown that when a week donor is employed the overall
yield drops significantly.128,129 N -protecting group manipulation was attempted by Zhu
et al.129 in order to increase the reactivity of the C-3 hydroxy group in the presence of
the bulky phthalimido group at C-2 that dampens the reactivity. Changing to a NHTroc
group instead of NPhth did not favor glycosylation. Ultimately, a new glucosamine
building block 61 was designed (Scheme 1.19), by keeping the phthalimido group and
then change the benzylidene acetate into two benzyl protecting groups leaving C-3
open for attachment.
A galactose donor bearing a temporary protection group at C-2 was needed, since it
was of interest to introduce a fucose at the C-2 position. In this case, it was important
that the donor was armed and thereby enabling selective activation. On these grounds,
the super-armed galactose donor 60 was chosen. This building block contains a ben-
zoyl protection group at C-2 to form the desired β glycosidic bond. In addition, the
benzoyl group can selectively be removed leaving a free hydroxy group at C-2 available
for fucosylation. A thioethyl group was chosen as the leaving group, as this can be
selectively activated over thiophenyl glycosides (Scheme 1.19).
The benzylated lactose 9 was left untouched, as it fulfills all demands. In Scheme
1.19 is shown the retrosynthetic plan for the synthesis of Lacto-N -fucopentaose I. The
compounds 9, 60 and 61 are to be glycosylated in a one-pot fashion to form 58, which
in one step is converted into 57. Tetrasaccharide 57 and the fucose building block 59
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Scheme 1.19: Retrosynthetic strategy for the synthesis of LNFP I 54.
will furnish fully protected pentasaccharide 56 that finaly can be transformed into the
target molecule 54.
1.4.2 Retrosynthetic strategy Lacto-N -neofucopentaose I (LNnFP
I)
For the synthesis of LNnFP I the same galactose donor 60 and lactose acceptor 9 was
selected (Scheme 1.20). The glucosamine building block 65 is similar to the glucosamine
building block 61, but with the minor difference being that the free hydroxy group is
positioned at C-4. In Scheme 1.20 is shown the retrosynthetic plan for the synthesis of
Lacto-N -neofucopentaose I. This strategy follows the same pattern as for the synthesis
of LNFP I; one-pot glycosylation of 9, 60 and 65 will lead to tetrasaccharide 64, which
can be converted into 63 and coupled with 59 to form fully protected pentasaccharide
62. Ultimately, compound 62 is transformed into the target molecule 55.
1.4.3 Building block synthesis
The super-armed galactose donor 60 was synthesized by Thomas Hauch Fenger and
the glucosamine building block 65 was synthesized by Linda Maria Bruun, under my
supervision. The synthesis of the lactose building block 9 was previously described in
Section 1.3.2.
Several different pathways were considered for the synthesis of the new glucosamine
building block 61. It was of interest to use as few steps as possible and if possible
to avoid the use of NaH as the phthalimido group is labile to strong base especially
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Scheme 1.20: Retrosynthetic strategy for the synthesis of LNnFP I 55.
in the presense of water. The two main routes are illustrated in Scheme 1.21 and
both arise from glucosamine 30. For pathway a, the benzylidene is regioselectively
opened forming the 4-O-benzylether 66 followed by regioselective benzylation of the
primary hydroxy group. For pathway b, the hydroxy group is protected by a temporary
group (67) followed by hydrolysis of the benzylidene (68). The formed hydroxy groups
are then benzylated (69) and in the last step the C-3 hydroxy moiety is liberated by
deprotection of the temporary protecting group (PG). Pathway a is prefered as it only
involves two steps.
Both pathways involve the cleavage of the benzylidene moiety. A benzylidene ac-
etal can be opened using different methods. It can be completely removed by mild
acid hydrolysis, or by hydrogenolysis. The benzylidene group can regioselectively be
opened under oxidative or reductive conditions. Oxidative conditions only give the
O
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Scheme 1.21: Synthetic pathways for the synthesis of 61.
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Scheme 1.22: Selective protection of hydroxy group at 6-position.
4-O-benzoate and can be done by NBS in CCl4 under basic conditions. Using reduc-
tive cleavage of the benzylidene can result in the 4- or 6-O-benzyl ethers depending on
the conditions. Much research have been done since the introduction of regioselective
reductive opening of benzylidene moiety, and today there is a broad array of methods
to choose from. The most common methods for obtaining the 4-O-benzyl is by us-
ing BH3·THF-AlCl3 or LiAlH4-AlCl3. The most common methods for obtaining the
6-O-benzyl is by using BH3·NMe3-AlCl3, NaCNBH3-HCl or Et3SiH-Lewis acid.123
For pathway a, BH3·THF with Cu(OTf)2 as Lewis acid in THF was used yielding
the 4-O-benzyl protected glucosamine 66 in 63%. It was attempted to selectively gly-
cosylate compound 66 6-position following two different procedures. First by refluxing
66 with N,N -diisopropylethylamine (DIPEA), benzylbromide and TBAI. After reflux-
ing for 5 h all starting material was consumed resulting in a mixture of products. The
desired product could only be isolated in 14% yield, giving an overall yield of 9% for
the two steps. The second method conducted, was catalyzed by tin ((Bu3Sn)2O) in
refluxing toluene for 4 h, followed by addition of benzylbromide and Bu4NBr, which
was further refluxed for 16 h. After purification, 35% of compound 66 could be isolated
along with a poor 11% of the desired product 61 (Scheme 1.22).
For pathway b, two different protecting groups at C-3 were employed; an allyl and a
fluorenylmethyloxycarbonyl (Fmoc). Fmoc was chosen, since the protection and depro-
tection can be carried out under mild basic conditions (pyridine/DMAP and piperidine
respectively). As depicted in Scheme 1.23 both the Fmoc-protection leading to 70 and
the regioselective opening of the benzylidene acetal forming compound 71 proceeded
smoothly in 78% and 80% yield respectively. Unfortunately it was not possible to
benzylate 71 under neutral conditions and only decomposition of the starting material
could be observed. Here, most of the starting material was reisolated. It seams that
the Fmoc-group is too bulky for the benzyl-group to be attached.
As an alternative, the 3-position was O-allyl-protected, unfortunately this strategy
involves several steps including NaH, which is the most efficient reagent for the pro-
tection. The most common way of forming ethers is by Williamsons ether synthesis124
employing NaH or NaOH as base in a polar aprotic solvent such as DMF. Both acetates
and esters can be cleaved under these conditions. To get to fully protected glucosamine
30
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Scheme 1.23: Attempts at synthesizing 61 by the use of a temporary Fmoc protecting
group.
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Scheme 1.24: Allyl protection of 30 and benzyl protection of 73 under basic and
neutral conditions.
74, both the common Williamson ether synthesis and an alternative neutral method
were employed (Scheme 1.24). Allylation with NaH did not give reproducible results,
but occured with a varying yield of 22–68%. A tiny amount of water lowered the
yield significantly, and as DMF is difficult to acchive extremely dry, it is challeging
to get anhydrous reaction conditions. A palladium(0) catalyst was employed for the
conversion of the alcohol into the allylether under neutral conditions. Pd2(dba)3, 1,4-
bis(diphenylphosphino)butane (dppb) as ligand and allyl ethyl carbonate were used to
introduce the allyl group by in situ CO2 extrusion (Scheme 1.24). This procedure in-
volves an oxidative addition of the allyl ethyl carbonate to the Pd(0) species, followed
by a decarboxylation to give a (pi-allyl)-palladium ethylate complex. Upon proton
exchange between the ethoxide and the carbohydrate a cationic alkoxide complex is
formed and the allylation can take place.162 By employing this method it was possible
to obtain 70 in reproducible yields. The formed allylether 72 was subjected to acidic
methanol to give 73 in 99% yield. The following benzylation was carried out using NaH
in either DMF or THF both in very poor yield, 40% and 32% respectively. Whilst em-
ploying neutral conditions by the use of Ag2O, KI and benzylbromide in DMF the yield
of compound 74 was markedly higher. The reaction can be carried out without KI, but
several experiments showed that the reaction rate was significantly lowered without KI
and the reaction did not run to completion. The enhanced reactivity could be related
to an in situ Finkelstein halogen exchange, forming KBr and benzyliodide. As iodide is
a better leaving group and silver has a higher affinity for I than Br (HSAB principle),
thus the benzylation is ought to proceed faster.
With the fully protected compound 74 at hand, the last step to reach the target
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Scheme 1.25: Cleavage of allyl to form glucosamine building block 61.
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molecule 61 was deprotection of the allyl group by Wilkinsons catalyst (see the synthe-
sis of 9 for more information Section 1.3.2). The isomerisation could be monitored by
TLC, which is unusual, but convenient as the anaerobic conditions are retained until
74 is fully converted into the prop-1-enyl ether 75 (Scheme 1.25). Amberlite IR-120
H+ in methanol was chosen for the cleavage of the prop-1-enyl ether prior to refluxing
in 1 M HCl, although the amberlite cleavage takes several days for completion. The
desired product 61 was isolated in 64% yield. The overall yield for the four synthetic
steps from glucosamine 30 is 48%, which is significantly better than the 9% following
path a.
The fucose building block 59 was synthesized from fucose over three steps, where
the final benzylation was performed under the standard basic NaH conditions giving
59 in 61% yield.
1.4.4 Di- and tetrasaccharide formation and initial one-pot
glycosylations
With all the building blocks in possession, it was possible to perform the glycosylation
by following the armed-disarmed strategy (Scheme 1.26). Whilst I was in Canada
for my external stay (Chapter 2), some preliminary studies were executed by Thomas
Hauch Fenger. He managed to get the protected disaccharide 76 in an impressive
97% yield. By subsequent glycosylation with lactose building block 9, compound 64
was furnished in 59%. Thomas optimized the conditions for the one-pot glycosylation
giving the fully protected tetrasaccharide 64. When I returned, I repeated the one-pot
method, and got compound 64 in 72% yield (Scheme 1.26).
These results were very promissing, therefore the same conditions were utilized for
the one-pot glycosylation of 60, 61 and 9 into the fully protected LNT 58 (Scheme
1.27). The TLC plate of the coupling between 60 and 61 showed several spots, whereas
the coupling between 60, 65 was spot to spot conversion. As a concequence, the
reaction was quenched at this stage yielding 77 in 44% (entry 1 in Table 1.5). It
was evident that the C-3 OH was significantly less reactive than the C-4 OH and this
is probably due to the bulky phthalimido protecting group at C-2.125 A screening of
promoters was executed in an attempt to increase the yield of the reaction (Table 1.5).
All of the donor 60 was converted in the first trial, hence slow addition of the donor
was attempted, regrettably, this resulted in a lowering of the yield (entry 2). Changing
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Scheme 1.26: Sequential and one-pot synthesis of 64.
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Table 1.5: Glycosylation between 60 and 61 employing different promoters.
Promotor
Temp.
CH2Cl2
OBn
O
BzO
BnO
BnO
SEt
OBnO
OBn
HO
NPhth
SPh
+ BnO
OBn
O
O
NPhth
O
BnO
BnO
OBz
OBn
SPh
60 61 77
# Ratio 60:61 Promotor Temp. [◦C] Time Yield [%]
1 1.1:1 NIS/AgOTf -40 1 h 44
2a 1.1:1 NIS/AgOTf -40 1 h 22
3 1.1:1 NIS/TESOTf -30 80 min 32
4 1.1:1 NIS/TfOH -50 – -20 2 h 34
5 1.2:1 MeOTf -10 7 h 78
6 1.2:1 MeOTf -10 – rt 16 h —
7 1.2:1 MeOTf, TTBP -10 6 h 33
8 1.1:1 Me2S2-Tf2O -20 – rt 3 h —
a slow addition of donor
the catalyst to TESOTf or TfOH gave a similar low yield of 32% and 34%, respectively
(entry 3 and 4). Exposing 60 and 61 to MeOTf for 7 h gave 77 in 78% (entry 5). If
the reaction was left to reach room temperature no product could be obtained (entry
6). In an attempt to increase the yield even more, the acid scavenger 2,4,6-tri-tert-
butylpyrimidine (TTBP) was used (entry 7). Unfortunately, this resulted in a lower
yield. A last attempt to improve the yield was to use Me2S2-Tf2O, but the reaction
was very messy and the desired product could not be observed by TLC. Although the
yield obtained by using MeOTf was satisfactory, the long reaction time is not suitable
when running a one-pot reaction.
A glycosylation between 77 and 9 promoted by the NIS/TESOTf system yielded
58 in 80% (Scheme 1.27). This led to an overall yield of 62% with MeOTf as the
promoter in the first step and 35% when NIS/AgOTf was used as promoter. For the
sequential coupling in the synthesis of 64 the overall yield reached 59% under similar
conditions (Scheme 1.26).
For comparison, a one-pot reaction was carried out using NIS/AgOTf for the first
coupling and NIS/TESOTf for the following glycosylation. The desired product 58 was
obtained in 7% yield as depicted in Scheme 1.27 (for 64 the yield was 72%, Scheme
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Scheme 1.27: Sequential and one-pot synthesis of 58.
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1.26).
Deprotection of benzoyl protecting groups
Methanolic sodium methanolate was intended to execute the chemoselective deprotec-
tion of the benzoyl group in the 2-position of 58 and 64. The results are illustrated in
Scheme 1.28 and as can be seen neither of the two are chemoselective. After stirring
benzoate 64 for 1 day at room temperature, TLC revealed that virtually all starting
material was still present. As a consequense, the temperature was raised to 50 ◦C and
the mixture stirred for an additional 2 days. The reaction was quenched with Amber-
lite IR-120 H+ although some starting material (64) was still visual on TLC. Only
21% of the desired product 63 was isolated along with 30% of the starting material.
A third compound was detected and assumed to be 79. Likewise, compound 58 was
stirred at 30 ◦C for 8 days, the reaction was quenched although there was still starting
material remaining. The crude mixture was examined by NMR, and the main product
was determined as 78.
Other research groups have reported partial cleavage of the phthalimido group,
when a debenzoylation was attempted.126 Instead of executing a deprotection of both
the benzoyl and the phthalimide with hydrazine, it was decided to change the benzoyl
into an acetyl protecting group for the galactose building block. This will be further
explored in the following section.
1.4.5 Glycosylation reactions with super-armed acetyl-protected
galactose donor
The acetyl-protected super-armed galactose donor 80 was synthesized from the super-
armed benzoyl protected galactose donor 60 (Scheme 1.29). The debenzoylation under
alkaline conditions required stirring at 50 ◦C for 48 h to reach completion. It is ev-
ident that the phthalimido group can not endure these conditions and therefore it is
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Scheme 1.28: Attempts of chemoselective benzoyl (Bz) deprotection of 58 and 64.
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Scheme 1.29: Synthesis of galactose donor 80.
understandable that some of the phthalimide was cleaved when the tetrasaccharides
were exposed to such reaction conditions. The reaction was completed by addition of
acetic anhydride, hence providing the galactose donor 80 in 97% (Scheme 1.29)
Glycosylations between the new donor 80 and either 61 or 65 were conducted to
gain the results presented in Scheme 1.30 and Table 1.6. In this case the overall yield
is not significantly better for the 1-4 coupled disaccharide (mix of 83 and 84) than for
the 1-3 coupled disacharides (mix of 81 and 82). For the 1-3 coupled disaccharide 81,
the best yield was obtained whit NIS/AgOTf as promoter (entry 3). When employing
MeOTf only disaccharide 81 was formed in a moderate yield of 52% (entry 1). The
usage of NIS/TESOTf yielded a nearly 1:1 mixture of 81 and 82 in an unimpressive
yield of 53%.
What is evident from these results is the occurence of aglycon transfer when NIS
is utilized. This is not a crucial problem as all disaccharide products can be activated
under similar conditions in the following glycosylation reaction with the lactose building
block 9. Aglycon transfer can be a problematic side reaction, if the donor becomes
inactive because of the aglycon transfer. Aglycon transfer is common for thioglycosides
and have been reported numerous times.45,127,129,130 It is difficult to predict beforehand
whether or not aglycon transfor wil occur as small changes in protecting groups and
promoter systems can have significant effects. Ways to effectively prevent the aglycon
transfer have been reported,131 but it was of no interest to us to perform further
modifications of our donor 80. In previous reported cases of aglycon transfer only
armed thioglycosides suffered from transfer, but this is not true in the present case. The
carbon-sulfur bond of the thioglycoside can break and reform for both the donor and the
acceptor and as the thioethyl group is a better nucleophile than the thiophenyl group,
an attack can take place transforming the acceptor into a thioethyl glycoside instead of
a thiophenyl glycoside. An equilibrium between SEt and SPh could potentially occur
even when formation of the transfer product is not energetically favored. The reason
for the absence of aglycon transfer occuring MeOTf is employed, is that the formed
Table 1.6: Glycosylation between 61 and 80 employing different promoters.
Promotor
Temp.
CH2Cl2
OBn
O
AcO
BnO
BnO
SEt
OBnO
OBn
HO
NPhth
SPh+ BnO
OBn
O
O
NPhth
O
BnO
BnO
AcO
OBn
SPh BnO
OBn
O
O
NPhth
O
BnO
BnO
AcO
OBn
SEt+
80 61 81 82
# 80:61 Promotor Temp. Time 81:82 Yield 81 (overall) [%]a
1 1.3:1 MeOTf -10 ◦C 6 h 100:0 52 (52)
2 1.2:1 NIS/TESOTf -40 ◦C 1 h 55:45 29 (53)
3 1.2:1 NIS/AgOTf -50 ◦C 1 h 81:19 62 (76)
a Estimated from isolated yields and isolated mixtures of 81 and 82 by NMR ratios between the two.
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Scheme 1.30: Formation of 85 by sequential and one-pot glycosylation.
MeSEt is stable opposed to ISEt, which is formed when NIS is employed.
The formed disaccharides 81 and the mix of 83 and 84 were further glycosylated
with 9 utilizing NIS/TESOTf as promoter in each separate reaction (Scheme 1.30
and 1.31). A one-pot reaction was also performed for the synthesis of 85 using the
developed one-pot method. As depicted in Scheme 1.30 all glycosylations proceeded
with excellent yields, especially the one-pot glycosylation furnishing tetrasaccharide
85. For comparison, the sequential glycosylation forming 85 had an overall yield
of ∼61% over the two steps, which is significantly lower than the one-pot reaction.
Tetrasaccharide 86 was created in 80% after the glycosylation between 81 and 9 leading
to an overall yield of ∼61% over two steps (Scheme 1.31).
It is evident, that the one-pot method employed is significantly better than the
sequential method. The improved yield by the one-pot synthesis might be explained
by an enhancement of the formed disaccharide donor by the continuing presence of
SEt in the reaction mixture, leading to possible aglycon transfer. Also any loss during
purification between the sequential glycosylation steps lowers the yield.
These results also prove that the 4-O-position is a better acceptor than 3-O for
glucosamine when a phthalimide is employed as N -protecting group. Moreover, a one-
pot glycosylation between 9, 61 and 80 ought to be carried out to futher emphasize
this assumption and expand the tested compounds for the newly developed one-pot
method.
Deprotection of acetyl protection group
The two tetrasaccharides 85 and 86 were subjected to the standard deacetylation con-
ditions to selectively remove the acetyl group over the phthalimide (Scheme 1.32). Yet
again, the two acetyl protected tetrasaccharides 85 and 86 showed different reactivity
behavoir, as was observed for the two benzoylated tetrasaccharides.
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O
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81 86
Scheme 1.31: Glycosylation between 81 and 9 forming tetrasaccharide 86.
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Scheme 1.32: Deacetylation of 85 and 86.
After stirring 85 in methanolic sodium methanolate for three days at room tem-
perature the deacetylated tetrasaccharide 63 could be isolated in 81% yield. Whereas
none of the desired deacetylated product of 86 could be isolated after 7 days of stirring.
Instead both the alcohol and amine had underwent a deprotection reaction yielding 78
in 68% (Scheme 1.32).
It was puzzling why the two tetrasaccharides were behaving so different under sim-
ilar reaction conditions, with the only conformational difference being the correlation
between the galactose and the glucosamine. Consequently, lowest energy calculations
were performed to see if an explanation could be found on these grounds (Figure 1.8
and 1.9). Indeed, the two lowest energy conformations are markedly different. For
compound 86 the acetyl and the phthalimide moieties are situated side by side, hence
minimizing the possibility for the nucleophile to differentiate between the two groups
(Figure 1.8). On the other hand, the acetyl group and the phthalimido group are sit-
uated far from each other for 85 and the phthalimide is shielded by benzyl protecting
groups whereas there is free access for attack on the acetyl (Figure 1.9). The calcu-
Figure 1.8: Calculated lowest energy
conformation of 86. N-atom is blue, O-
atoms are red. The phthalimido group
and the acetyl group are situated in the
middle of the lower part. Calculations
done by Casper Junker Engelin.
Figure 1.9: Calculated lowest energy
conformation for 85. N-atom is blue,
O-atoms are red. The phthalimido
group is situated in the middle of the
lower part, and the acetyl group is situ-
ated in the top left. Calculations done
by Casper Junker Engelin.
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Scheme 1.33: Deprotection and selective N -acetylation of 86.
lations are in agreement with the experimental results. Taking this into account, it
seems obvious that 86 can not be selectively deprotected to form a free alcohol with-
out affecting the phthalimido group. Hereof the new strategy was to deprotect both
the acetate and the phthalimide with a following selective N -acetylation.
Ethylenediamine (EDA) was employed for the deprotection of the acetate and the
phthalimide parts on 86, as this lowers the reaction time compared to when sodium
methoxide was utilized. The selective N -acetylation was carried out without purifi-
cation of the formed amine 78, as purification of amines by column chromatography
can be very tedious. Treatment of "78" with acetic anhydride and triethylamine in
ethanol furnished tetrasaccharide 87 in good yield (scheme 1.33). A primary amine is
more nucleophillic than a secondary alcohol, and is therefore acetylated more easily.
The conditions employed here are rather mild, but if acetyl chloride had been utilized
instead of acetic anhydride, acetylation of the alcohol would possibly occur as well.
Changing the triethyl amine to pyridine might also result in acetylation of the alcohol,
as pyridine enhance the electrophilicity of acetic anhydride by the formation of an acyl
pyridinium ion.
At this point the two tetrasaccharides 63 and 87 were ready for fucosylation. In
the following section the final steps to form LNFP I and LNnFP I will be outlined
separately.
1.4.6 Fucosylation and full deprotection
The fucosylation and deprotection of 63 proceeded smoothly. Treatment of 63 with
fucose 59 and NIS/TESOTf in CH2Cl2 at -30 ◦C yielded 62 in excellent 89% yield
(Scheme 1.34). At this point the overall yields for the sequential and the one-pot
glycosylations to form 62 were 44% and 68% respectively.
Bröder and Kunz93 synthesized the exact same compound from the lactoseamine
fluoride donor 88 (formed in 17% yield from a galactose donor and a glucosamine
acceptor132) instead of the thiophenyl glycoside employed in the current work together
with the same lactose acceptor 9 (Scheme 1.35). They employed the same conditions
for the deacetylation and fucosyl bromide 89 as donor for the final step. They achieved
an overall yield of 45%, if this was to be compared with the synthesis described in this
thesis, the first step for the formation of the mixture of 83 and 84 (Scheme 1.31)
should not be considered in the overall yield. Thereby the overall yield is 52% for
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Scheme 1.34: Fucosylation of 63 to form fully protected pentasaccharide 62.
the same amount of steps by the sequential method, which is an improvement to their
synthesis. Furthermore, the overall yield for the one-pot synthesis is an even greater
improvement.
LNnFP I (55) was isolated after full deprotection of 62 (Scheme 1.36). First, the ph-
thalimide was removed with EDA and the amine was acetylated with acetic anhydride
and triethylamine, giving compound 90 in 74% yield. The following hydrogenolysis
gave LNFP I 55 in 99% yield. A mixture of MeOH/THF was chosen as solvent to
ensure solvation of both starting material and product throughout the reaction. TFA
was used as catalyst for the reaction.
One of the two target human milk pentasaccharides was hereby synthesized by a
sequential and a one-pot synthesis in good to excelent yields. Full NMR data are
included in the appendix.
The fucosylation of 87 did not proceed as smoothless as for 63 (Scheme 1.37). A
higher temperature was needed for the fucosylation to occur, since nothing happened
below -20 ◦C. The change in reactivity can be due to the topological differences around
the C-2 OH, as the galactose and glucosamine are coupled differently for the two
molecules. Therefore, the lowest energy conformation might be significantly different
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Scheme 1.35: Synthesis of 62 by Bröder and Kunz.93
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Scheme 1.36: Deprotection and N -acetylation of 62.
for the two compounds. Compound 91 was isolated in 68% yield after the glycosylation
was carried out at -10 ◦C with NIS/TESOTf as the promoter (Scheme 1.37).
LNFP I (54) was isolated after hydrogenolysis in 98% yield. Again a mixture of
MeOH and THF was employed to ensure solubility, and TFA was used as catalyst
for the reaction (Scheme 1.37). Hereby the second human milk pentasaccharide was
succesfully synthesized by a sequential and a one-pot process in moderate to good
yields. Full NMR data for LNFP I (54) are included in the appendix.
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Scheme 1.37: Fucosylation of 87 with fucose building block 59 and the following
hydrogenolysis of 91 to furnish LNFP I (54).
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1.5 Towards branched pentasaccharides using partly
protected saccharide building blocks
As can be seen from Table 1.1, the branched penta- and hexasaccharides are also quite
abundant in human milk. Therefore, it was also of great interest to synthesize some
branched oligosaccharides containing either fucose or neuraminic acid attachments.
Moreover, it was desired to apply the newly developed one-pot method for synthesis
for the branched HMOs.
1.5.1 N -Acetyl neuraminic acid containing pentasaccharides
The use of N -acetyl neuraminic acid (Neu5Ac) as glycosyl donors is complicated for
several reasons. For instance, there is no C-3 functionality present to direct the stere-
ochemical outcome of the glycosylation. Furthermore, the electron withdrawing car-
boxylic acid at the anomeric center and the deoxy moiety at C-3 makes Neu5Ac prone
to undergo elimination and thereby forming a glycal. Finally, glycosylation of Neu5Ac
involves attack at a sterically hindred tertiary oxocarbenium ion intermediate. The
commonly most applied glycosyl donors (e.g. thiols, imidates and halogens) are rarely
employed for the attachment of Neu5Ac. On the contrary, phosphites133 and xan-
thates134 are some of the more successful leaving groups for sialyl donors.135
It was of interest to incorporate the Neu5Ac at an early stage of the synthetic route,
primarily to avoid tedious α/β purifications of a pentasaccharide, since the glycosy-
lation with derivatives of Neu5Ac lacks stereospecificity. It was chosen to persue the
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Scheme 1.38: Retrosynthetic strategy for the synthesis of pentasaccharide 92.
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pentasaccharide Galβ1–4[Neu5Acα2–6]GlcNAcβ1–3Galβ1–4Glc (92), which retrosyn-
thetic plan is shown in Scheme 1.38.
Once again both the super-armed galactose donor 60 and the lactose acceptor 9
were selected. They were to be combined with building block 94 containing a Neu5Ac
residue at the 6-position of a glucosamine. Disaccharide 94 was envisioned to be
synthesized from partly unprotected glucosamine 46 and fully protected neuraminic
acid 95. The primary hydroxy group for the glucosamine 46 is the most nucleophilic
of the three hydroxy groups available. Research described in this thesis has proven
that the C-3 OH is shielded by the phthalimido group, and other research groups have
shown the C-4 OH typically is a poor glycosyl acceptor.39
Koenigs-Knorr conditions were attempted for the generation of 94, by the use of
two different silver salts (Table 1.7). Neither of the two silver salts were sufficiently
powerful, since all starting material could be reisolated even after 2 days of stirring at
room temperature (Entry 1 and 2). As an alternative, the thioglycoside donor 96 (syn-
thesized by a former student) was tested. The thioglycoside donor 96 was attempted,
since a similar glycosylation between 96 and a galactose acceptor formed the desired
α adduct in moderate yield.96 Regrettably, both donor and acceptor decomposed with
the use of the NIS/TESOTf promoter system (entry 3). Altering the employed solvent
might be a possibility to get dimer formation.
Table 1.7: Attempts of synthesizing disaccharide 94.
# Donor Acceptor (46) Temp. [◦C] Promotor
1
O
Cl
CO2Me
AcO
AcHN
AcO
AcO
OAc
95
HO O
HO SPh
NPhth
OH
-10 – rt AgOTf
2
O
Cl
CO2Me
AcO
AcHN
AcO
AcO
OAc
95
HO O
HO SPh
NPhth
OH
-10 – rt Ag2O
3
O
CO2Me
SPh
AcO
AcHN
AcO
AcO
OAc
96
HO O
HO SPh
NPhth
OH
-10 – rt NIS/TESOTf
Both of the utilized Neu5Ac donors (95 and 96) contained common leaving groups
with regard to other glycosyl donors, however, a change to either a phosphite/phosphate
or xanthate donor would be of interest, since they usually result in higher yields.
It was not of the highest priority to persue a solution to this problem and due to
time limitations, the project was left at this stage.
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1.5.2 Fucose containing pentasaccharides and hexasaccharides
To broaden the one-pot method employed for the synthesis of 54 and 55 (LNFP I and
LNnFP I), pentasaccharide Galβ1–4[Fucα1–3]GlcNAcβ1–3Galβ1–4Glc (LNFP III) 97
was targeted (Figure 1.10).
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Figure 1.10: Structure of pentasaccharide LNFP III (LNnFP3).
1.5.3 Retrosynthetic strategy and building block synthesis
The galactose donor part can be one of the two super-armed donors 60 or 80 (Scheme
1.39). The glucosamine 100 was designed to have two free hydroxy groups, one at C-4
and one at C-3 as our results have shown that the C-4 OH is more nucleophilic than the
C-3 OH. Furthermore, studies by Schmidt and co-workers had shown that galactose
donor 5 had a preference for the C-4 position (see Scheme 1.11).99 The fucose donor
59 had proven to be a good donor for the attachment on the galactose, thus this was
a good choice. Finally, the same lactose acceptor 9 used for all previous glycosylations
was chosen. The overall idea was to create the backbone core first and then in the
same pot add the fucose donor (last to be added) to form 98 or 99 (Scheme 1.39).
The glucosamine building block was easily synthesized by regioselective cleavage
of the benzylidene by treating 30 with triethylsilane, TFAA and TFA yielding 100
in 69%. The first galactose donor to be tested was 60, which was utilized in both
a sequential and a one-pot glycosylation (Scheme 1.40). Treating 60 and 100 with
NIS/AgOTf resulted in an inseparable 1:2 mixture of the thioethyl glycoside 102 and
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Scheme 1.39: Retrosynthetic strategy for the synthesis of pentasaccharide 97.
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Scheme 1.40: Sequential and one-pot glycosylations in the formation of 103 and one-
pot synthesis of 104.
the thiophenyl glucoside 101 in approximately 61% yield. The mixture of 101 and
102 was subsequently subjected to the NIS/TESOTf promoter in the presence of the
lactose acceptor 9, forming ultimately tetrasaccharide 103 in approximately 43% yield,
resulting in an overall yield of 27% for the two steps. The one-pot glycosylation yielded
103 in 57%, which is fairly good considering the fact that two hydroxy groups can act as
a nucleophile. In addition, it is a significant improvement to the sequential glycosylation
and none of the β1-3-coupled product was observed.
In a similar way galactose donor 80 and 100 were used in a one-pot glycosylation
with lactose 9, giving tetrasaccharide 104 in moderate 51% yield (Scheme 1.40). None
of the β1-3-coupled product was observed.
The 1-4 correlation for 103 and 104 was determined by NMR spectroscopy. A cor-
relation between C-1”’ and the hydrogen at C-4” was observed by HMBC. In addition,
no correlation between C-3” and CH 2Ph could be observed in the HMBC spectra.
The two tetrasaccharides 103 and 104 were ready for fucosylation to form fully
protected pentasaccharides (Scheme 1.41). For both tetrasaccharides NIS/TESOTf
was employed as the promoter. The first glycosylation attempted was between fucose
donor 59 and acceptor 103. The promoter was added at -30 ◦C, but no reaction took
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Scheme 1.41: Attempted fucosylation of 103 and 104.
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Scheme 1.42: Possible future work.
place, so the temperature was slowly raised to reach 0 ◦C. At the elevated temperature,
it was observed that donor 59 was consumed after 1 h, unfortunately, none of the
desired product could be identified. Treating fucose donor 59 and acceptor 104 with
NIS/TESOTf at -10 ◦C and letting it reach room temperature resulted in full conversion
of the donor, but yet again none of the desired product was isolated. It was a very
disappointing result, as it would have been neat to extend the application of one-pot
glycosylation by extending the amounts of glycosylations performed in the same pot.
A change of fucose donor 59 to imidate could be a possibility, as 21 (Scheme 1.11)
could successfully be attached at the C-3 position of a similar glucosamine acceptor.
Regrettably, no more work could be performed on this project, as my PhD enrol-
ment had come to an end. If more work could be put into this project several ideas
could be carried out. Two main ideas for further work on this would be to perform a de-
protection of both tetrasaccharides (103 and 104) followed by selective N -acetylation
to hopefully minimize the shielding at the C-3 position, hence making it possible for a
glycosylation to occur (Scheme 1.42). Stereoselective deprotection of 103 should leave
the benzoyl protecting group untouched so that a following N -acetylation could result
in tetrasaccharide 105, having only a single free hydroxy group at the 3-position of
glucosamine. Subsequent, glycosylation with 59 would result in pentasaccharide 106,
which upon deprotection would give LNFP III. On the other hand, deprotection and
selective N -acetylation of 104 would render a tetrasaccharide with two free hydroxy
groups (107), one at C-2 at the galactose and one at the C-3 at the glucosamine. A
following fucosylation could possibly lead to the branched hexasaccharide 108.
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1.6 Enzymatic synthesis of human milk oligosaccharides
An alternative to chemical synthesis of oligosaccharides is to involve enzymes, which
couple monosaccharides with exquisite regio- and stereospecificity. One advantage with
enzymatic glycosylation compared with chemical synthesis is the fact that protecting
groups or elaborate precursors are unnecessary. On the other hand, preparation of
non-natural oligosaccharide analogs is restricted as no suitable enzymes are available.
Other concerns with employing enzymes is the restricted access to expensive or cloned
enzymes and the requirement for co-factors. Many successful applications of enzymes in
oligosaccharide production have employed chemoenzymatic synthesis, relying on both
chemical and enzymatic steps, which typically begins with chemical synthesis and ends
with an enzymatic extension.136
Two classes of enzymes can be utilized in enzymatic oligosaccharide synthesis, where
the first class is glycosyltransferases that forms a glycosidic bond, while the second class
is glycosidases whose natural function is the cleavage of glycosidic bonds by hydrolysis.
The availability and stability of glycosidases are much greater than glycosyltransferases,
and they are more tolerant to variations in substrate structure as well.136
Glycosidases can be used for glycoside synthesis by shifting the equilibrium of the
glycoside cleavage in the opposite direction. It is possible to shift the equilibrium
by exposing the enzyme to a large excess of the reaction products, hereby force a
glycosidase to run in reverse. However, as the reverse reaction is endothermic, the
equilibrium will always favor the cleavage products. Consequently, the yields obtained
are typically low.38
Some advantages of the glycosyltransferases are that they produce the desired gly-
cosides in higher yields and are highly specific towards donor as well as acceptor sub-
strates. Unfortunately, the availability of glycosyltransferases is rather limited. The
majority of glycosyltransferases used in glycan synthesis catalyze the transfer of a gly-
cosyl donor to a sugar or amino acid acceptor. These transferases generally require
nucleotide mono- or diphosphate saccharides as donor substrates (e.g., CMP-Neu5Ac
or UDP-Gal), which are expensive and difficult to synthesize.38
Glycosyltransferases have been used to synthesize HMOs. For the more simple
tetrasaccharides 2’-fucosyllactose, 3’-sialyllactose and 6’-sialyllactose the focus has been
to find enzymes capable of performing regio- and stereospecific reactions with a possi-
bility of a reaction scale-up.137–139 On the contrary other more complex HMOs mainly
have been subjected to glycosyltransferases for the purpose of finding excellent enzymes
for specific transferase and not to run large scale synthesis of HMOs.140–143
When attachment of sialic acid is wanted, enzymatic synthesis is often to be prefered
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Scheme 1.43: Mechanism for Trans-sialidase.
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prior to chemical synthesis, since the purification step for the separation of alpha and
beta anomers is very tedious in a non stereospecific reaction. And as the sialidase
enzymes are programmed only to produce the desired alpha anomer they are naturally
fabricated to perform the desired glycosylation.
Trans-sialidase catalyzes transfer of preferably α2,3-linked sialic acid directly to the
terminal β-galactose or β-N -acetylgalactosamine-containing acceptors forming a new
α2,3-linkage. In the absence of an appropriate acceptor, the enzyme acts as a hydrolase
releasing glycosidically linked sialic acid. Cleavage is less efficient than transfer so in
the presence of an appropriate acceptor transfer is dominant (Scheme 1.43).144
The activity of trans-sialidase can be monitored with a radioactive assay or a non-
radioactive assay. For radioactive assays the most commonly used method is to apply
sialyl-α2,3-lactose as donor, and a radioactively labeled lactose or N -acetyllactosamine
as acceptor. The reaction can be followed as the radioactive and negatively charged
sialylated products can be separated from labeled uncharged acceptor molecules by an-
ion exchange chromatography, hence quantified to give a measure of enzyme activity.
The nonradioactive trans-sialidase assays are based on a spectrophotometric technique,
where either the donor or acceptor contain a UV-active group. The most commonly
used UV-active moieties are p-nitrophenyl (pNP) or 4-methylumbelliferyl (MU). If the
pNP or MU group is attached to the donor the activity is meassured by the release of
phenol or 4-methylumbelliferone from the donor substrate. Whereas having the pNP
or MU group on the acceptor acquires a workup where unreacted acceptor is washed
away followed by hydrolysis of the pNP or MU group.147
Our collaborators were interested in finding a new enzyme with the ability to per-
form a trans-sialidations to produce 3’-sialyllactose on a large scale. For this purpose
they needed a large amount of pNP-Neu5Ac for screening of their enzymes. I was asked
to aid them by synthesizing pNP-Neu5Ac chemically.
1.6.1 Synthesis of pNP-Neu5Ac
Several research groups have synthesized pNP-Neu5Ac (109),145,146 providing a well
established synthetic pathway for the synthesis of pNP-Neu5Ac. The retrosynthetic
strategy is shown in scheme 1.44.
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Scheme 1.44: Retrosynthetic strategy for the synthesis of pNP-Neu5Ac.
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Synthesis of pNP-Neu5Ac
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Scheme 1.45: Synthetic pathway for the synthesis of the ester 115.
The Fischer esterification of N -acetylneuraminic acid proceeded smoothly yielding
112 in 86% (Scheme 1.45). The first attempt to synthesize 95 was unsuccessful. The
only product isolated after 112 had been subjected to acetylchloride for 36 h was 113.
It was apparent that the formed HCl gas was libarated from the reaction flask before
an attack on C-2 occured. To circumvent this problem two alterations were performed,
firstly, the reaction was carried out in a sealed flask with a screw cap capable of enduring
high pressure, secondly, MeOH was added after 16 h, at which time 113 was formed,
to produce additional HCl gas. With these alterations 95 was isolated in an excelent
100% yield (Scheme 1.45).
To synthesize 110 a two-phase system with benzyltriethylammonium chloride as
phase transfer catalyst was employed. This is an alternative to the Koenigs-Knorr
method and an improvement due to the fact that no expensive silver salt is necessary.
Other advantages with this method is the short reaction time and the conditions are
relatively mild.145 Compound 110 was isolated in a modest 54% yield. The hydrolysis
of the acetyl protecting groups with sodium methanolate yielded 115 in high yield
(Scheme 1.45). Unfortunatly, the ester hydrolysis of 115 showed to be more tedious
than expected.
The first attempt to synthesize 109 was executed following the procedure by Es-
chenfelder and co-workers.146 This resulted in a crude mixture of starting material,
the desired product and N -acetylneuraminic acid. It was attempted to purify the
crude product by column chromatography, both flash column and dry column chro-
matography were employed here. Unfortunately, pNP-Neu5Ac is very unstable in both
methanol and water. The purification resulted in a huge loss of product as p-nitrophenol
was hydrolysed off forming the undesired Neu5Ac. In order to resolve this, a screening
of base and solvents were performed to hopefully find a system only forming the desired
pNP-Neu5Ac. In Table 1.8 can be seen all the hydrolytic systems tested. The same
conditions were applied for entry 1 and 2, but not performed the same day. As of
the ratios between the three compounds differed significantly it can be concluded that
the procedure was not reproducible, and an unnoticed change in base concentration
or reaction time have a significant influence on the outcome. Changing the base from
NaOH to K2CO3 showed promissing results (entry 5–8), the best result being with 0.1
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Table 1.8: Ester hydrolysis of 115.
base, solventO
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AcHN
HO
HO
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O
HO
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NO2115 109
O
OH
CO2H
HO
AcHN
HO
HO
OH
111
+
# Solvent Base Conc. [M] Time Ratio; 115:109:111a
1 H2O NaOH 0.10 0.5 h ∼3:5:4
2 H2O NaOH 0.10 0.5 h ∼0:20:1
3 H2O NaOH 0.01 0.5 h 25:5:6
4 H2O LiOH 0.01 0.5 h 5:15:2
5 H2O K2CO3 0.01 0.5 h 3:1:∼0
6 H2O K2CO3 0.10 1.5 h 1:10:2
7 MeOH/H2O 95:5 K2CO3 0.10 2.0 h 0:3:2
8 THF/H2O 90:10 K2CO3 0.10 3 h 2:∼0:∼0
9 THF LiOH 0.10 0.5 h 1:∼0:∼0
a measured by 1H-NMR
M of K2CO3 in water. Unfortunately, this still resulted in some hydrolysis (entry 6).
A change of solvent was performed in an attempt to lower the amount of hydrolysis,
but unfortunatly this resulted in a two-phase system with no significant conversion of
starting material (entry 7 and 8). None of the attempted alterations showed signifi-
cant improvement, and therefore the the initial method was employed with acceptance
of the small amounts of impurities. The impurities were not crucial for the activity
measurements, as they are also formed in the assays for trans-sialidase activity.
The pNP-Neu5Ac synthesized was used to test trans-sialidase activity of a recom-
binant Pasteurella multocida sialyltransferase exhibiting dual trans-sialidase activities
along with a Trypanosoma rangeli mutant (papers in preparation).
1.7 Summary and Outlook of Chapter 1
In summary, the backbone core Lacto-N -tetraose (4) was synthesized by the use of a
trichloroacetimidate galactose donor. It was possible to perform a one-pot synthesis,
but the yield was very poor. Several galactose donors were tried, for the first coupling
between galactose and glucosamine. Thioglycosidic donors showed not to be efficient
for the glycosylation, and only imidate donors were sufficient for the coupling. The glu-
cosamine building block (30) containing a 4,6-O-benzylidene protecting group showed
to be the problem, as the benzylidene acetal can be cleaved under the employed con-
ditions. In addition, the bulky phthalimido group is lowering the reactivity at the C-3
position. The knowledge gained from this study was utilized in the strategy for the
formation of the larger oligosaccharides.
The linear pentasaccharides Lacto-N -fucopentaose I (54) and Lacto-N -neofucopenta-
ose I (55) were synthesized by sequential and a newly developed one-pot strategy in-
vented in our research group. The synthetic strategy involved the armed-disarmed
concept using a super-armed galactose donor, with an acetyl or benzoyl group in the
C-2 position. Two glucosamine acceptors were synthesized to get the desired 1-3 and
48Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
1.7. Summary and Outlook of Chapter 1
1-4 correlation between the galactose and glucosamine. Different strategies were per-
formed for the synthesis of the glucosamine 61 with a free hydroxy group at the C-3
position. A recurring issue regarding the synthesis of the glucosamine building blocks
were the lability of the phthalimido group under strong alkaline conditions. Neutral
conditions were employed whenever possible, as this increased the yields significantly.
LNFP I showed to be far more difficult to synthesize than LNnFP I for several
reasons. Firstly, the 4-OH proved to be more reactive than the 3-OH, hence giving
significantly lower yields for both the sequential and one-pot glycosylation in the syn-
thesis of tetrasaccharides 58 and 64. The difference between the two glycosylations
(1-3 vs. 1-4) were not as significant for the galactose donor with an acetyl protecting
group (resulting in tetrasaccharides 85 and 86). The one-pot glycosylations to form
86 yielded the desired product in nearly quantitative yield (1-4 coupled). It would be
of interest to perform the one-pot glucosylation to form the 1-3 coupled tetrasaccharide
85. Secondly, the regioselective deprotection of 58, 64, 85 and 86 proved only pos-
sible for the acetyl-protected 1-4 coupled tetrasaccharide 85. Deprotection of the 1-3
coupled tetrasaccharides 58 and 86 also resulted in cleavage of the phthalimido group,
hence selective acetylation was conducted prior to fucosylation. Lastly, the fucosyla-
tion of the phthalimido protected 1-4 coupled pentasaccharide 62 ran in high yield,
whereas the fucosylation of the acetamido protected 1-3 coupled pentasaccharide 91
gave a slightly lower yield.
The developed one-pot glycosylation method was used in an attempt to create
branched pentasaccharides. A glucosamine with both a free hydroxy group at C-3 and
C-4 was utilized giving only 1-4 coupled tetrasaccharides, with a free hydroxy at C-3.
Unfortunately, it was not possible to fucosylate the C-3 position, hence forming the
branched pentasaccharide LNFP III (97). It would be of interest to perform alterations
of the fucose building block, to form LNFP III, all in the same pot.
Few trials in the synthesis of a neuraminic acid containing disaccharides were con-
ducted, but none were successful. The disaccharide was thought as a possible building
block for expanding the scope of the developed one-pot strategy.
pNP-Neu5Ac (109) was successfully synthesized with the purpose to perform en-
zyme activity studies. Due to the fact that pNP-Neu5Ac is readily hydrolyzed in the
presence of water, the ester hydrolysis proved to be tedious, forming a mixture of
N -acetyl neuraminic acid, uncleaved starting material and the desired product. Dif-
ferent bases and solvents were tried to see whether the hydrolysis could be performed
selectively. The initial conditions showed to be the best conditions.
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1.8 Experimental
General Experimental Conditions. Unless otherwise noted, reactions were car-
ried out under an inert atmosphere (Ar) in round bottom flasks with magnetic stirring.
However, reaction work-up was performed in air. Air- or water-sensitive liquids and
solutions were transferred via syringe. Organic solutions were concentrated by rotary
evaporation at 23–30 ◦C under 40 Torr. Purification of products was carried out by
flash chromatography on silica gel (Merck 40–63 micron) or dry column chromatogra-
phy on silica gel (Merck 15–40 micron). Reverse phase chromatograhy was carried out
on silica gel (YMC - C18, 120 Å, 5-10-20 µM). Thin-layer chromatography (TLC) was
carried out using aluminum sheets pre-coated with silica gel 60F (Merck 5554). The
plates were inspected under UV light or developed using a cerium ammoniumsulfate
solution (1% cerium(IV)sulphate and 2.5% hexaammonium molybdate in a 10% sulfu-
ric acid solution).
Instrumentation. Proton nuclear magnetic resonance spectra (1H NMR) and carbon
nuclear magnetic resonance spectra (13C NMR) were recorded with a Bruker 500 (500
MHz/125 MHz) NMR spectrometer equipped with a cryoprobe or a Varian Mercury
300 (300 MHz/75 MHz) or a Varian Unity Inova 500 (500 MHz/125 MHz) or a Bruker
Ascend 400 (400 MHz/100 MHz) equipped with a cryoprobe using the residual solvent
as the internal standard. Recorded chemical shifts are reported in parts per million
(δ = scale) downfield from tetramethylsilane, and all coupling constants (J) are ex-
pressed in Hz. In the APT spectra measured on the Bruker 500 MHz instrument, CH
and CH3 correspond to negative signals and C and CH2 correspond to positive signals
In APT spectras measured on the Bruker ascend 400 MHz instrument the relation is
reversed. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. Melting
points were recorded on a Stuart SMP30 apparatus and are uncorrected.
Reagents. Chemicals were purchased from Aldrich, Merck, and Carbosynth Lim-
ited and were used as received. Dry solvents (DMF, THF, toluene and acetoni-
trile) were obtained from a Solvent Purification System, Innovative Technology Inc.
Dichloromethane was dried over sieves (4 Å). Methanol was dried over sieves (3 Å)
2-3 days prior to use. Acetylchloride was distilled from PCl5 prior to use. Wilkinsons
catalyst was synthesized from RhCl3·(H2O) according to the procedure described in
ref.148 Me2S2-Tf2O reagent was synthesized according to the procedure described in
ref.149 Compound 38 and 47 were synthesized by following the procedure described in
ref.114 Compound 38 was synthesized by following the procedure described in ref.178
Compound 53 was synthesized from 44 following the procedure described in ref.169
Some compounds synthesized have been shown in Scheme 1.16, but not numbered.
In this section they will be refered to by Roman Nomenclature (i-iv) Compounds with
clubs (♣) are new, they have all been submitted for HRMS and the results are pending.
General procedure for one-pot glycosylation reactions
Super-armed galactose donor (1.1 eq.) and the glucosamine acceptor (1 eq.) were
dissolved in CH2Cl2 (1 mL / 100 mg reactants) and stirred under argon with 4 Å MS for
1 h. The mixture was cooled to -30 ◦C, NIS (1.15 eq.) and AgOTf (cat.) were added and
the mixture was stirred for 15 min, where TLC revealed full conversion of the acceptor
(toluene/acetone 9:1). Then a solution of the lactose acceptor (1 eq. in CH2Cl2 (0.5
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mL / 0.1 mmol)) was added to the mixture together with NIS (1.15 eq.) and TESOTf
(0.1 eq.). The mixture was stirred for 40 min where TLC showed full conversion of the
acceptor. The reaction was quenched with Et3N and the mixture stirred for 15 min,
then filtered through Celite and evaporated. Purification by chromatography.
General procedure for sequential glycosylation reactions
Donor (1.1 eq.) and the lactose acceptor 9 (1 eq.) were dissolved in CH2Cl2 (1 mL
/ 100 mg reactants) and stirred under argon with 4 Å MS for 1 h. The mixture was
cooled to -30 ◦C, NIS (1.15 eq.) and TESOTf (0.1 eq.) were added to the mixture,
which was allowed to stirr for 40 min where TLC showed full conversion of the acceptor,
the reaction was quenched with Et3N and the mixture stirred for 15 min, then filtered
through Celite and evaporated. Purification by chromatography.
Benzyl 4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1-4)-2,3,6-tri-O-
acetyl-β-D-glucopyranoside114 (39)
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To a mixture of 38 (40.7 g, 60 mmol), benzylalcohol (21.6 mL, 139 mmol) and 4 Å
MS in dry CH2Cl2 (280 mL), was BF3·OEt2 (21.6 mL, 175 mmol) slowly added at 0
◦C with an argon atmosphere. After stirring for 24 h at rt the reaction mixture was
washed with a saturated solution of NaHCO3 (250 mL), H2O (2×200 mL), and the
organic phase was dried over MgSO4 and evaporated under reduced pressure giving
an yellow oil. Crystallization of the residue from diethyl ether gave a white crystalline
product (19.7 g, 45%). M.p. 150–151 ◦C. M.p. lit. 145–146 ◦C.151 1H-NMR (300
MHz, CDCl3): δ = 7.36–7.14 (m, 5H, Ar), 5.27 (dd, J = 3.4 Hz, 1.0 Hz, 1H), 5.15–4.96
(m, 2H), 4.96–4.84 (m, 2H), 4.79 (d, J = 12.3 Hz, 1H, OCH 2Ph), 4.53 (d, J = 12.3 Hz,
1H, OCH 2Ph), 4.48–4.34 (m, 3H), 4.12–3.93 (m, 3H), 3.86–3.66 (m, 2H), 3.51 (ddd,
J = 9.9, 4.9, 2.0 Hz, 1H), 2.11–2.03 (m, 6H), 2.02–1.94 (m, 9H), 1.94 (s, 3H), 1.89 (s,
3H). 13C-NMR (75 MHz, CDCl3): δ = 170.5, 170.5, 170.3, 170.2, 169.9, 169.7, 169.2,
136.7, 128.6, 128.2, 127.9, 101.2, 99.1, 76.4, 72.9, 72.7, 71.7, 71.1, 70.8, 70.8, 69.2, 66.7,
62.1, 60.9, 21.0, 20.9, 20.8, 20.8, 20.7. NMR data are in accordance with literature
values.152
Benzyl 4-O-β-D-galactopyranosyl- β-D-glucopyranoside114 (40)
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Compound 39 (9.5 g, 13 mmol) was taken op in a solution of NaOMe (0.220 g Na in 170
mL MeOH) and stirred at rt for 3 h whereupon amberlite IR-120 H+ was added and the
mixture stirred for additional 45 min followed by filtration and addition of a few drops
of aqueous ammonia (24%). Upon evaporation under reduced pressure a white solid
precipitated. Recrystallization from methanol resulted in a white crystalline product
(5.0 g, 88%). M.p. 173–174 ◦C. M.p. lit. 180 ◦C.153 1H-NMR (300 MHz, D2O): δ =
7.55–7.33 (m, 5H), 4.92 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.53 (d, J =
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8.0 Hz, 1H), 4.42 (d, J = 7.7 Hz, 1H), 3.97 (dd, J = 12.3, 1.9 Hz, 1H), 3.90 (d, J = 3.2
Hz, 1H), 3.84–3.47 (m, 9H), 3.38–3.29 (m, 1H). 13C-NMR (75 MHz, D2O): δ = 136.7,
128.9, 129.0, 128.6, 103.0, 101.2, 78.5, 75.5, 74.9, 74.6, 73.0, 72.6, 71.6, 71.1, 68.7, 61.2,
60.2. NMR data are in accordance with literature values.154
Benzyl 4-O-(3-O-allyl-β-D-galactopyranosyl)-β-D-glucopyranoside115 (41)
1) Bu2SnO (Toluene)
2) Allyl bromide, Bu4NBr
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A suspension of 40 (3.03 g, 7.00 mmol) in toluene (75 mL) was heated until the
temperature reached 80 ◦C whereupon Bu2SnO (2.09 g, 8.40 mmol) was added and the
mixture refluxed (125 ◦C) overnight in a flask equipped with a Dean-Stark separator.
The temperature was lowered to 80 ◦C followed by addition of allylbromide (10 mL, 0.12
mol) and Bu4NBr (1.0 g, 3.1 mmol). This mixture was heated to reflux (130 ◦C) with
a Dean-Stark separator for 4 h, cooled to rt and evaporated under reduced pressure.
The resulting solid was dissolved in water (100 mL) and washed with EtOAc (2×100
mL). The aqueous phase was concentrated and toluene (75 mL) was added followed by
Bu2SnO (1.92 g, 7.71 mmol) this mixture refluxed (130 ◦C) overnight with a Dean-Stark
separator. The temperature was lowered to 80 ◦C followed by addition of allylbromide
(8.0 mL, 0.092 mol) and Bu4NBr (0.75 g, 2.3 mmol). This mixture was heated to
reflux (130 ◦C) with a Dean-Stark separator for 1 h. Cooled to rt, concentrated under
reduced pressure. Methanol (50 mL) was added to the residue, filtered and washed with
methanol. The filtrate was concentrated under reduced pressure and purified by flash
column chromatography (SiO2, MeOH/CH2Cl2 1:9) resulting in a white solid (1.61 g,
49%). 1H-NMR (300 MHz, CD3OD): δ = 7.42–7.33 (m, 2H), 7.33–7.18 (m, 3H), 5.96
(ddt, J = 17.3, 10.4, 5.7 Hz, 1H, CH=CH2), 5.30 (dq, J = 17.3, 1.6 Hz, 1H), 5.13 (ddt,
J = 10.4, 1.9, 1.2 Hz, 1H), 4.88 (d, J = 11.8 Hz, 1H), 4.63 (d, J = 11.8 Hz, 1H), 4.35
(2×d, J = 7.8 Hz, 2H), 4.19 (ddt, J = 12.7, 5.7, 1.4 Hz, 1H), 4.09 (ddt, J = 12.7, 5.7,
1.4 Hz, 1H), 3.96 (d, J = 2.6 Hz, 1H), 3.90 (dd, J = 12.1, 2.6 Hz, 1H), 3.82 (dd, J =
12.1, 4.2 Hz, 1H), 3.75 (dd, J = 11.4, 7.5 Hz, 1H), 3.70–3.45 (m, 5H), 3.41–3.33 (m,
1H), 3.30–3.25 (m, 2H). 13C-NMR (75 MHz, CD3OD): δ = 139.0, 136.4, 129.3, 129.2,
128.7, 117.5, 105.0, 103.2, 82.0, 80.7, 76.9, 76.5, 76.4, 74.7, 71.8, 71.7, 71.6, 67.0, 62.5,
62.0. NMR data are in accordance with literature values.156
Benzyl 4-O-(3-O-allyl-2,4,6-tri-O-benzyl-β-D-galactopyranosyl)-
2,4,6-tri-O-benzyl-β-D-glucopyranoside (42)
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DMF
77%
O
OHHO
O
HO
O O
OH
HO
HO OBn
41
Coumpound 41 (1.54 g, 3.26 mmol) was dissolved in DMF (30 mL) and Bu4NBr was
added (15 mg, 0.047 mmol) followed by benzylbromide (6.1 mL, 52 mmol). NaH (2.04
g, 60% in an oil suspension, 51 mmol) was added at 0 ◦C and the mixture stirred at
rt for 2 h, quenched with MeOH (1 mL), taken up in H2O (150 mL) and extracted
with ether (2×100 mL), dried over MgSO4, concentrated and purified by flash column
chromatography (SiO2, EtOAc/heptane 2:3) resulting in a colorless amorphous solid
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(2.33 g, 71%). 1H-NMR (300 MHz, CDCl3): δ = 7.43–7.04 (m, 35H), 5.91 (ddt, J =
17.2, 10.5, 5.2 Hz, 1H), 5.31 (dq, J = 17.2, 1.7 Hz, 1H), 5.16 (dq, J = 10.5, 1.4 Hz,
1H), 5.00 (d, J = 10.7 Hz, 1H), 4.96 (d, J = 1.5 Hz, 1H), 4.94–4.85 (m, 2H), 4.79 (d,
J = 11.2 Hz, 1H), 4.76–4.67 (m, 3H), 4.64 (d, J = 12.1 Hz, 1H), 4.57–4.50 (m, 2H),
4.48 (d, J = 7.5 Hz, 1H), 4.45–4.36 (m, 2H), 4.32 (d, J = 11.8 Hz, 1H), 4.22 (d, J =
11.8 Hz, 1H), 4.14 (ddd, J = 5.2, 2.6, 1.2 Hz, 2H), 3.93 (dd, J = 9.7, 8.7 Hz, 1H),
3.85 (d, J = 2.8 Hz, 1H), 3.80 (dd, J = 11.0, 4.3 Hz, 1H), 3.76–3.64 (m, 2H), 3.60–3.41
(m, 3H), 3.40–3.25 (m, 4H). NMR data are in accordance with literature values.111
13C-NMR (75 MHz, CDCl3): δ = 139.3, 139.2, 139.0, 138.8, 138.6, 138.2, 137.7, 135.1,
129.2, 128.5, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7,
127.6, 127.5, 127.2, 125.4, 116.5, 102.9, 102.6, 83.2, 82.5, 81.9, 80.0, 77.0, 75.5, 75.4,
75.4, 75.2, 74.8, 73.6, 73.5, 73.2, 73.1, 71.6, 71.1, 68.5, 68.2.
Benzyl 4-O-(2,4,6-tri-O-benzyl-β-D-galactopyranosyl)-2,4,6-tri-O-benzyl-β-
D-glucopyranoside155 (9)
1) ClRh(PPh3)3, n-BuLi
2) H+, MeOH
O
OBnBnO
O
BnO
O O
OBn
BnO
BnO OBn
O
OBnBnO
HO
BnO
O O
OBn
BnO
BnO OBn
69%
THF
42 9
Wilkinson’s catalyst [ClRh(PPh3)3] (463 mg, 1.0 mmol, prepared from RhCl3·3H2O)
was dissolved in anhydrous THF (27 mL) and the solution was degassed. n-BuLi
(0.75 mL, 1.6 M in hexane, 1.2 mmol) was added and the mixture was degassed for
additional 10 min. A degassed solution of 42 (5.0 g, 4.9 mmol) in anhydrous THF (40
mL) was heated to reflux and the solution of the catalyst was added. The reaction
mixture was refluxed for 2 h, whereupon 1H-NMR revealed full conversion into the
vinyl ether. It was cooled to 50 ◦C followed by addition of MeOH (150 mL) and
Amberlite IR-120 H+(15 mL). The resulting mixture was stirred for 48 h where TLC
showed full conversion to the alcohol. The resin was filtered off, washed with CH2Cl2
and the filtrate was concentrated and purified by flash column chromatography (SiO2,
EtOAc/heptane 2:3) resulting in an amorphous colorless solid (3.3 g, 69%). 1H-NMR
(300 MHz, CDCl3): δ = 7.62–6.76 (m, 35H), 4.93 (d, J = 10.7 Hz, 1H), 4.85 (d, J = 8.5
Hz, 1H), 4.81 (d, J = 7.3 Hz, 1H), 4.76–4.44 (m, 8H), 4.43–4.23 (m, 4H), 4.16 (d, J =
11.8 Hz, 1H), 3.98–3.84 (m, 1H), 3.77–3.62 (m, 3H), 3.53–3.22 (m, 8H), 2.16 (s, 1H).
NMR data are in accordance with literature values.111 13C-NMR (75 MHz, CDCl3):
δ = 139.1, 138.7, 138.6, 138.5, 138.3, 138.0, 137.5, 128.5, 128.4, 128.4, 128.3, 128.3,
128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 127.6, 127.2, 102.7, 102.5, 82.9,
81.8, 80.6, 76.7, 75.9, 75.4, 75.2, 75.1, 75.1, 75.0, 74.1, 73.4, 73.2, 73.2, 71.0, 68.3, 68.0.
Phenyl 2,3,4-tri-O-benzyl-1-thio-β-D-fucopyranoside157,158 (59)
O SPh
BnOOBn
OBn
59
NaH, BnBr, TBAI
DMF
61%
O
SPh
HOOH
OH
Phenyl-1-thio-α/β-L-fucopyranoside (2.5 g, 0.0098 mol) was dissolved in DMF (40 mL)
and NaH (2.33 g, 60% in an oil suspension, 0.059 mol) was added. After stirring for
10 min BnBr (7.0 mL, 0.059 mol) was added followed by TBAI (0.18 g, 0.49 mmol),
and the mixture was stirred for 2 h. The reaction was quenched by addition of water
(50 mL), extracted with a EtOAc:Heptane solution (1:1, 100 mL), the organic phase
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was washed with water (3×50 mL), a saturated aqueous solution of NH4Cl (50 mL),
dried over MgSO4 and evaporated under vacuum to a yellow oil, which crystallized
overnight. Recrystallization from Et2O:Hexane gave the benzylether as white crystals
(3.1 g, 61%) M.p. 105.5-106 ◦C. M.p. lit. 107-109 ◦C.157 1H-NMR (300 MHz, CDCl3):
δ = 7.58–7.47 (m, 2H), 7.45–7.02 (m, 18H), 4.94 (d, J = 11.7 Hz, 1H), 4.72 (d, J =
10.2 Hz, 1H), 4.69–4.63 (m, 3H), 4.60 (d, J = 11.7 Hz, 1H), 4.53 (d, J = 9.6 Hz, 1H),
3.86 (dd, J = 9.6, 9.1 Hz, 1H), 3.56 (dd, J = 2.8, 0.8 Hz, 1H), 3.52 (dd, J = 9.1, 2.8
Hz, 1H), 3.49–3.40 (qd, J = 6.4, 0.8 Hz 1H), 1.19 (d, J = 6.4 Hz, 3H). 13C-NMR (75
MHz, CDCl3): δ = 138.8, 138.5, 138.5, 134.5, 131.6, 128.9, 128.6, 128.5, 128.5, 128.3,
128.1, 127.8, 127.8, 127.7, 127.6, 127.1, 109.9, 87.7, 84.6, 77.2, 75.7, 74.7, 74.7, 73.0,
17.5. NMR data are in accordance with literature values.117
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside159 (44)
AcO O
AcO OAc
NPhth
OAc
44
O
OH
NH2
HO
OH
HO
HCl
1) NaOMe, MeOH
then
Et3N, phthalic anhydride
2) Ac2O, pyridine
54%
D-Glucosamine hydrochloride (10.7 g, 0.0496 mol) was purred into a solution of NaOMe
(1.1 g Na, 100 mL MeOH) at 0 ◦C, and the solution stirred for 10 min. The solution was
filtered into phthalic anhydride (3.75 g, 0.025 mol) which had been heated to assure
there was no phthalic acid present, and the filter cake was washed with MeOH (50
mL). The solution was stirred for 10 min followed by addition of Et3N (7 mL). After
an additional 5 min of stirring phthalic anhydride (3.7 g, 0.025 mol) was added and the
solution was stirred for additional 3 hours. The solvent was evaporated under reduced
pressure and the residue was treated with pyridine (50 mL) and acetic anhydride (60
mL) with stirring for 16 hours at rt. The reaction mixture was poured into ice water
(250 mL) and stirred for 20 min, followed by extraction with CH2Cl2 (2×150 mL). The
organic phases were washed with 2 M aqueous H2SO4 (2×100 mL), H2O (2×75 mL),
saturated aqueous solution of NaHCO3 (75 mL) and H2O (75 mL), dried over MgSO4
and concentrated under reduced pressure. Purified by flash column chromatography
(SiO2, EtOAc/heptane 1:1) resulting in a white crystalline product of only the β-
anomer (12.9 g, 54%). M.p. 107–109 ◦C. M.p. lit. 100–103 ◦C.160 1H-NMR (300
MHz, CDCl3): δ = 7.86 (dd, J = 5.5, 3.0 Hz, 2H), 7.75 (dd, J = 5.5, 3.0 Hz, 2H),
6.51 (d, J = 8.9 Hz, 1H), 5.88 (dd, J = 10.6, 9.1 Hz, 1H), 5.21 (dd, J = 10.2, 9.2 Hz,
1H), 4.47 (dd, J = 10.6, 8.9 Hz, 1H), 4.37 (dd, J = 12.5, 4.4 Hz, 1H), 4.14 (dd, J =
12.2, 2.3 Hz, 1H), 4.02 (ddd, J = 10.3, 4.4, 2.1 Hz, 1H), 2.11 (s, 3H), 2.04 (s, 3H), 1.99
(s, 3H), 1.86 (s, 3H). 13C-NMR (75 MHz, CDCl3): δ = 170.74, 170.11, 169.56, 168.72,
167.45, 134.60, 131.29, 123.89, 89.83, 72.70, 70.57, 68.34, 61.60, 53.56, 20.88, 20.85,
20.72, 20.50. NMR data are in accordance with literature values.159
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside161 (45)
AcO O
AcO SPh
NPhth
OAc
PhSH, BF3 OEt2
CH2Cl2
78%
45
AcO O
AcO OAc
NPhth
OAc
44
BF3·OEt2 (1.7 mL, 13.4 mmol) was added slowly to a solution of 44 (3.5 g, 7.3 mmol)
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and thiophenol (1.0 mL, 9.8 mmol) in CH2Cl2 (35 mL) and the reaction mixture
stirred for 20 h. The reaction mixture was diluted with CH2Cl2 (20 mL), washed with
saturated aqueous NaOMe (3×50 mL), dried over MgSO4 and evaporated in vacuo
resulting in a yellow oil which crystallized overnight. The resulting white crystals were
washed thoroughly with MeOH and was dried (3.0 g, 78 %). 1H-NMR (300 MHz,
CDCl3): δ = 7.99–7.66 (m, 4H), 7.45–7.23 (m, 5H), 5.79 (dd, J = 10.2, 9.2 Hz, 1H),
5.71 (d, J = 10.6 Hz, 1H), 5.14 (dd, J = 10.2, 9.2 Hz, 1H), 4.48–4.08 (m, 3H), 3.90
(ddd, J = 10.2, 5.0, 2.4 Hz, 1H), 2.10 (s, 3H), 2.02 (s, 3H), 1.83 (s, 3H). 13C-NMR (75
MHz, CDCl3): δ = 170.8, 170.2, 169.6, 168.0, 167.1, 134.6, 134.5, 133.4, 131.7, 131.3,
131.1, 129.0, 128.6, 123.9, 83.2, 76.0, 71.7, 68.8, 62.3, 53.7, 20.9, 20.8, 20.6. NMR data
are in accordance with literature values.159
Phenyl 2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside161 (46)
NaOMe
99%
MeOHAcO
O
AcO SPh
NPhth
OAc
HO O
HO SPh
NPhth
OH
45 46
Compound 45 (3.1 g, 5.9 mmol) was taken op in a solution of NaOMe (0.1 g Na in 50 mL
MeOH) and the mixture stirred at rt for 20 min whereupon Amberlite IR-120 H+was
added and the mixture stirred for 1 h followed by filtration and evaporation under
reduced presure. Purified by flash column chromatography (SiO2, EtOAc) resulting in
a white crystalline product (2.34 g, 99%). 1H-NMR (300 MHz, CD3OD): δ = 7.97–7.77
(m, 4H), 7.44–7.32 (m, 2H), 7.30–7.14 (m, 3H), 5.59 (d, J = 10.3 Hz, 1H), 4.26 (dd, J =
10.3, 8.2 Hz, 1H), 4.10 (t, J = 10.3 Hz, 1H), 3.94 (dd, J = 12.1, 1.9 Hz, 1H), 3.76 (dd,
J = 12.1, 5.3 Hz, 1H), 3.53 - 3.39 (m, 2H). NMR data are in accordance with literature
values.161 13C-NMR (75 MHz, CD3OD): δ = 169.7, 169.2, 135.6, 135.6, 134.4, 133.1,
132.9, 132.8, 130.0, 128.7, 124.5, 124.2, 85.4, 82.6, 73.8, 72.2, 62.8, 57.7.
Phenyl
4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (30)
HO O
HO SPh
NPhth
OH
O
O O
HO
Ph
SPh
NPhth
PhCH(OCH3)2
p-TsOH, MeCN
88% 3046
A mixture of 46 (9.0 g, 23 mmol), benzaldehyde dimethyl acetal (5.8 mL, 39 mmol)
and p-toluenesulfonic acid monohydrate (0.25 g, 1.3 mmol) in acetonitril (150 mL)
was stirred for 3 h. The reaction was quenched by addition of Et3N until neutral
medium and the mixture was concentrated to a yellow oil. Purified by flash column
chromatography (SiO2, EtOAc/heptane 2:3) resulting in a viscous oil (9.7 g 88 %).
1H-NMR (300 MHz, CDCl3): δ = 7.94–7.79 (m, 2H), 7.79–7.66 (m, 2H), 7.52–7.15 (m,
10H), 5.68 (d, J = 10.4 Hz, 1H), 5.56 (s, 1H), 4.69–4.56 (m, 1H), 4.38 (dd, J = 10.7,
5.0 Hz, 1H), 4.32 (t, J = 10.4 Hz, 1H), 3.81 (t, J = 10.0 Hz, 1H), 3.67 (td, J = 9.5, 4.6
Hz, 1H), 3.58 (t, J = 9.0 Hz, 1H), 2.69 (s, 1H). 13C-NMR (75 MHz, CDCl3): δ = 168.4,
137.0, 134.4, 132.8, 131.9, 131.7, 129.9, 129.5, 129.1, 128.5, 128.3, 126.4, 124.0, 123.5,
102.1, 84.4, 82.0, 70.4, 69.8, 68.7, 55.6. NMR data are in accordance with literature
values.117
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Phenyl 3-O-allyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside162 (72) ♣
O
O O
O
Ph
SPh
NPhthPd2(dba)3, THF, 65 
oC
O O
O
O
O O
HO
Ph
SPh
NPhth
92%30 72
A Schlenk flask charged with 30 (1.50 g, 3.1 mmol), Pd2(dba)3 (71 mg, 0.078 mmol)
and dppb (132 mg, 0.031 mmol) was degassed and the solids were dissolved in THF
(5 mL). Efter stirring for 5 min allylethylcarbonate (404 mg, 3.1 mmol) in THF (2.5
mL) was added and the mixture was heated to 65 ◦C and stirred for 30 min whereupon
additional allylethylcarbonate (404 mg, 3.1 mmol) in THF (2.5 mL) was added and
the mixture stirred for 1 h. Cooled to rt, concentrated and purified by flash column
chromatography (SiO2, acetone/toluene 1:99) resulting in a viscous oil (1.49 mg, 92
%). 1H-NMR (400 MHz, CDCl3): δ = 7.88 (m, 2H), 7.81–7.72 (m, 2H), 7.52–7.44 (m,
2H), 7.43–7.33 (m, 5H), 7.31–7.21 (m, 3H), 5.68 (d, J = 10.4 Hz, 1H), 5.59 (s, 1H),
5.52 (m, 1H), 5.01 (dq, J = 17.2, 1.6 Hz, 1H), 4.84 (dt,J = 10.4, 1.6, 1.2 Hz, 1H), ,
4.47–4.37 (m, 2H), 4.33 (t, J = 10.2 Hz, 1H), 4.26 (ddt, J = 13.1, 5.1, 1.4 Hz, 1H), 3.95
(ddt, J = 13.1, 6.3, 1.2 Hz, 1H), 3.88–3.80 (m, 1H), 3.78–3.66 (m, 2H). 13C-NMR (100
MHz, CDCl3): δ = 168.5, 167.4, 137.4, 134.4, 134.3, 132.8, 131.9, 129.2, 129.1, 128.4,
128.2, 126.2, 124.0, 123.5, 117.3, 101.4, 84.4, 82.6, 76.3, 73.4, 70.6, 68.8, 55.0.
Phenyl 3-O-allyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (73) ♣
O
O O
O
Ph
SPh
NPhth
MeOH, CSA
99%
72
OHO
OH
O
NPhth
SPh
73
Compound 72 (1.5 g, 2.8 mmol) was suspended in MeOH (45 mL), and CSA (100 mg,
0.43 mmol) was added. After stirring for 16 h the reaction was quenched with Et3N,
concentrated and purified by flash column chromatography (SiO2, toluene/EtOAc 1:1)
resulting in a colorless foam (1.24 g, 99%). 1H-NMR (300 MHz, CDCl3): δ = 7.98–7.82
(m, 2H), 7.82–7.70 (m, 2H), 7.43–7.32 (m, 2H), 7.31–7.17 (m, 3H), 5.73–5.51 (m, 2H),
5.04 (dq, J = 17.2, 1.5 Hz, 1H), 4.93–4.83 (m, 1H), 4.36–4.13 (m, 3H), 4.07–3.93 (m,
2H), 3.88 (dd, J = 12.0, 4.4 Hz, 1H), 3.78 (dd, J = 9.6, 8.4 Hz, 1H), 3.59 (ddd, J = 9.7,
4.4, 3.5 Hz, 1H), 2.79 (br, 2H). 13C-NMR (75 MHz, CDCl3): δ = 168.6, 167.5, 134.4,
132.3, 132.2, 131.6, 129.1, 128.0, 123.9, 123.5, 117.6, 83.8, 80.3, 79.6, 73.5, 71.4, 62.4,
54.8.
Phenyl 3-O-allyl-4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside (74) ♣
OBnO
OBn
O
NPhth
SPh
Ag2O, KI, BnBrOHO
OH
O
NPhth
SPh
73 74
DMF
82%
Compound 73 (1.9 g, 4.3 mmol) was dissolved in DMF, and the mixture was stirred
with 4Å MS for 10 min. The mixture was cooled to 0 ◦C whereupon Ag2O (4.25
g, 1.8 mmol), BnBr (1.6 mL, 13 mmol) and KI (1.7 g, 10 mmol) were added. After
stirring for 10 min the icebath was removed and the mixture stirred at rt for 4 h.
Diluted with CH2Cl2 (250 mL) and filtered through a pad of Celite, washed with 10%
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aqueous solution of Na2S2O3 (2×80 mL), H2O (2×150 mL), dried over MgSO4 and
evaporated under reduced pressure. Purified using flash column chromatography (SiO2,
acetone/toluene 1:49) resulting in a colorless foam (2.2 g, 82%). 1H-NMR (300 MHz,
CDCl3): δ = 7.87–7.62 (m, 4H), 7.40–7.04 (m, 15H), 5.55–5.36 (m, 2H), 4.89 (dq, J =
17.2, 1.5 Hz, 1H), 4.77–4.65 (m, 2H), 4.59–4.43 (m, 3H), 4.26–4.17 (m, 2H), 4.12 (ddt,
J = 12.7, 5.3, 1.3 Hz, 1H), 3.81 (ddt, J = 12.7, 6.4, 1.2 Hz, 1H), 3.76–3.56 (m, 4H).
13C-NMR (75 MHz, CDCl3): δ = 168.5, 167.5, 138.4, 138.1, 134.3, 132.6, 132.4, 131.8,
128.9, 128.5, 128.5, 128.0, 127.9, 127.9, 127.8, 127.7, 123.9, 123.4, 117.5, 83.5, 80.5,
79.5, 79.0, 75.0, 74.0, 73.5, 69.0, 55.2.
Phenyl 4,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-
glucopyranoside155 (61) ♣
OBnO
OBn
HO
NPhth
SPh
ClRh(PPh3)3, n-BuLi  H+, MeOH
64%
OBnO
OBn
O
NPhth
SPh
OBnO
OBn
O
NPhth
SPhTHF
74 75 61
Wilkinson’s catalyst [ClRh(PPh3)3] (357 mg, 0.39 mmol) was dissolved in anhydrous
THF (10 mL) and the solution was degassed. n-BuLi (0.29 mL, 1.6 M in hexane, 0.46
mmol) was added and the mixture was degassed for an additional 10 min. A degassed
solution of 74 (1.2 g, 1.9 mmol) in anhydrous THF (15 mL) was heated to reflux
and the solution of the catalyst was added. The reaction mixture was refluxed for 3
h, whereupon TLC revealed full conversion into the vinyl ether. It was cooled to 50
◦C followed by addition of MeOH (60 mL) and Amberlite IR-120 H+ (6 mL). The
resulting mixture was stirred for 48 h where TLC showed full conversion to the alcohol.
The resin was filtered off, washed with CH2Cl2 and the filtrate was concentrated and
purified by flash column chromatography (SiO2, acetone/toluene 1:19) resulting in a
white foam (0.87 g, 77%) 1H-NMR (300 MHz, CDCl3): δ = 7.97–7.64 (m, 4H), 7.55–
7.06 (m, 15H), 5.59 (d, J = 10.4 Hz, 1H), 4.76–4.63 (m, 3H), 4.58 (d, J = 12.0 Hz,
1H), 4.53–4.34 (m, 1H), 4.24 (t, J = 10.4 Hz, 1H), 3.96–3.76 (m, 2H), 3.77–3.53 (m,
2H), 2.17 (br, 1H). 13C-NMR (75 MHz, CDCl3): δ = 168.4, 167.8, 138.3, 138.2, 134.3,
132.6, 132.3, 131.7, 128.9, 128.7, 128.5, 128.1, 128.0, 127.9, 127.9, 127.7, 123.8, 123.5,
83.5, 79.3, 79.2, 74.9, 73.6, 73.0, 69.0, 55.7.
Phenyl 6-O-benzyl-4-fluorenylmethyloxycarbonyl-2-deoxy-2-phthalimido-1-
thio-β-D-glucopyranoside (68) ♣
30
FmocCl, DMAP
pyridine
Et3SiH, TFA, TFAA
CH2Cl2
80%78%
O
O O
FmocO
Ph
SPh
NPhth
67
HO O
FmocO SPh
NPhth68
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O
O O
HO
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SPh
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Fluorenylmethyloxycarbonyl chloride (0.62 g, 2.4 mmol) was added to a solution of
30 (0.98 g, 2.0 mmol) and DMAP (cat.) in pyridine (18 mL) at 0 ◦C. The mixture
was quenched with MeOH after stirring for 3 h, concentrated in vacuo and purified
by flash column chromatography (SiO2, EtOAc/heptane 1:3) resulting in a white foam
(1.11 g, 78%). The residue was dissolved in CH2Cl2 (5 mL) whereupon trifluoroacetic
anhydride (0.68 mL, 4.8 mmol) and triethylsilane (1.26 mL, 7.9 mmol) were added at
0 ◦C. After stirring for 5 min trifluoroacetic acid (0.58, 7.6 mmol) was added dropwise
over a 2 min period. The mixture was diluted with EtOAc (100 mL) after it had stirred
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for 4 h, washed with a saturated aqueous solution of NaHCO3 (100 mL), H2O (100
mL) and dried over MgSO4. The residue was evaporated under reduced pressure and
purified by flash column chromatography (SiO2, EtOAc/heptane 1:2) resulting in a
white foam (0.88 g, 80%) 1H-NMR (300 MHz, CDCl3): δ = 7.94–7.54 (m, 6H), 7.54–
7.13 (m, 16H), 5.78 (d, J = 10.5 Hz, 1H), 5.63 (dd, J = 10.3, 8.9 Hz, 1H), 4.72–4.54
(m, 2H), 4.46 (t, J = 10.4 Hz, 1H), 4.23–4.05 (m, 2H), 4.03–3.75 (m, 5H), 3.15 (br,
1H). 13C-NMR (75 MHz, CDCl3): δ = 168.1, 167.2, 155.3, 143.2, 143.1, 141.2, 141.1,
137.8, 134.4, 134.2, 132.9, 131.7, 131.3, 129.0, 128.6, 128.2, 128.0, 127.9, 127.9, 127.3,
127.3, 125.3, 125.2, 123.8, 120.0, 83.4, 78.4, 78.1, 73.9, 71.0, 70.5, 70.2, 53.6, 46.5.
Phenyl 6-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside
(100)
O
HO
NPhth
SPhHO
OBn
10030
Et3SiH, TFA, TFAA
CH2Cl2
69%
O
O O
HO
Ph
SPh
NPhth
Trifluoroacetic anhydride (0.79 g, 5.6 mmol) and triethylsilane (1.47 mL, 9.2 mmol)
were added to 30 (0.89 g, 1.8 mmol) in CH2Cl2 (5 mL) at 0 ◦C. After stirring for 5
min trifluoroacetic acid (0.68 mL, 8.9 mmol) was added dropwise over a 2 min period.
The mixture was diluted with EtOAc (100 mL) after it had stirred for 4 h, washed
with a saturated aqueous solution of NaHCO3 (100 mL), H2O (100 mL) and dried
over MgSO4. The residue was evaporated under reduced pressure and purified by flash
column chromatography (SiO2, EtOAc/heptane 4:5) resulting in a white foam (620 mg,
69%) 1H-NMR (300 MHz, CDCl3): δ = 7.94–7.63 (m, 4H), 7.48–7.11 (m, 10H), 5.59
(d,J = 10.3 Hz, 1H), 4.70–4.50 (m, 2H), 4.34 (dd, J = 10.4, 8.1 Hz, 1H), 4.20 (t, J =
10.3 Hz, 1H), 3.90–3.73 (m, 2H), 3.73–3.52 (m, 2H), 2.96 (br, 2H). NMR data are in
accordance with literature values.167 13C-NMR (75 MHz, CDCl3): δ = 137.8, 134.3,
132.5, 132.3, 131.7, 129.0, 128.6, 128.0, 128.0, 127.9, 83.7, 78.0, 73.8, 73.5, 72.8, 70.5,
55.4.
Phenyl
4-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside168 (66) ♣
O
O O
HO
Ph
SPh
NPhth
BnO O
HO SPh
NPhth
OH
BH3 THF, Cu(OTf)2
THF
63 %30 66
Compound 30 (2.00 g, 4.09 mmol) was treated with BH3·THF as a 1 M solution in THF
(16 mL). After stirring at rt for 10 min Cu(OTf)2 (73 mg, 0.20 mmol) was added at 0
◦C. After stirring for 5 h the mixture was cooled down to 0 ◦C, and the reaction was
quenched by sequential addition of triethylamine and methanol. The resulting mixture
was concentrated followed by co-evaporation with methanol. The residue was purified
by flash column chromatography (SiO2, EtOAc/heptane 2:3) resulting in a white foam
(1.27 mg, 63%). 1H-NMR (400 MHz, CDCl3): δ = 7.85 (br, 2H), 7.76–7.65 (m, 2H),
7.44–7.18 (m, 10H), 5.63 (d, J = 10.5 Hz, 1H), 4.84–4.68 (m, 2H), 4.49 (dd, J = 10.3,
8.3 Hz, 1H), 4.21 (t, J = 10.4 Hz, 1H), 3.95 (d, J = 12.1 Hz, 1H), 3.78 (dd, J = 12.2, 2.3
Hz, 1H), 3.65–3.46 (m, 2H), 1.98 (br, 2H). 13C-NMR (100 MHz, CDCl3): δ = 138.03,
58Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
1.8. Experimental
134.38, 132.51, 132.12, 131.75, 129.13, 128.83, 128.28, 128.15, 128.09, 123.91, 123.50,
83.59, 79.53, 78.94, 75.05, 72.78, 62.12, 55.83.
Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside173 (32)
O
OAc
AcO
AcO
AcO OAc BF3 OEt2,
CH2Cl2
HSPh
66 %
O
AcO
AcO
AcO OAc
SPh
47 32
Compound 47 (40 g, 0.10 mol) was dissolved in anhydrous CH2Cl2 (500 mL) followed
by addition of thiophenol (13.7 mL, 134 mol) and the mixture was stirred for 10 min.
Then BF3·OEt2 (30 mL, 24 mol) was slowly added to the solution. After stirring for 24
hours the reaction mixture was pourred into CH2Cl2 (300 mL), washed with saturated
aqueous NaHCO3 (2×150 mL), H2O (2×150 mL), dried over MgSO4 and evaporated
under reduced pressure. The residue was purified by flash column chromatography
(SiO2, EtOAc/heptane 1:5) resulting in a white solid (30 g, 67%) 1H-NMR (300 MHz,
CDCl3): δ = 7.59–7.40 (m, 2H), 7.38–7.27 (m, 3H), 5.41 (d, J = 3.3 Hz, 1H), 5.23 (t,
J = 9.9 Hz, 1H), 5.04 (dd, J = 9.9, 3.3 Hz, 1H), 4.71 (d, J = 10.0 Hz, 1H), 4.23–4.05 (m,
2H), 3.98–3.89 (m, 1H), 2.11 (s, 3H), 2.08 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H). 13C-NMR
(75 MHz, CDCl3): δ = 170.5, 170.3, 170.1, 169.5, 132.6, 132.5, 129.2, 129.0, 128.2,
86.7, 74.5, 72.1, 67.3, 67.3, 61.7, 20.9, 20.8, 20.7, 20.7. NMR data are in accordance
with literature values.174
2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide (33)
O
OAc
AcO
AcO
AcO OAc
47
O
AcO
AcO
AcO OAc
Br
HBr, HOAc
Quant.
33
Compound 47 (0.10 g, 0.23 mmol) was dissolved in CH2Cl2 (1 mL) and Br2 (0.23 mL,
1 M in CH2Cl2, 0.23 mmol) was added at 0 ◦C. The mixture stirred at rt for 30 min.
Concentrated and purified by dry column chromatography (SiO2, EtOAc/heptane, 0
to 72% in steps of 6%) resulting in a clear oil (0.83 mg, 88%). 1H-NMR (300 MHz,
CDCl3): δ = 6.68 (d, J = 4.0 Hz, 1H), 5.50 (dd, J = 3.3, 1.3 Hz, 1H), 5.39 (dd, J =
10.6, 3.3 Hz, 1H), 5.03 (dd, J = 10.6, 4.0 Hz, 1H), 4.47 (t, J = 6.7 Hz, 1H), 4.24–4.03
(m, 2H), 2.14 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H). 13C-NMR (75 MHz,
CDCl3): δ = 170.5, 170.2, 170.0, 169.9, 88.2, 71.2, 68.1, 67.9, 67.1, 61.0, 20.9, 20.8,
20.7, 20.7. NMR data are in accordance with literature values.176
Phenyl 1-thio-β-D-galactopyranoside173 (i)
O
AcO
AcO
AcO OAc
SPh
NaOMe
Quant.
O
HO
HO
HO OH
SPh
32
MeOH
i
Compound 32 (30 g, 0.068 mol) was taken up in a solution of NaOMe (0.626 g, 0.027
mol Na in 200 mL MeOH) and stirred at room temperature for 16 hours whereupon
Amberlite IR-120 H+ was added and the mixture stirred for an additional 45 minutes
followed by filtration. Evaporation under reduced pressure and recrystallization from
EtOAc resulted in a white crystalline product (18 g, 99%). M.p. 105–109 ◦C. M.p.
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lit. 105–107 ◦C.175 1H-NMR (300 MHz, DMSO-d6): δ = 7.45 (d, J = 7.5 Hz, 2H),
7.38–7.15 (m, 3H), 5.14 (d, J = 5.8 Hz, 1H), 4.89 (d, J = 5.5 Hz, 1H), 4.64 (t, J =
4.9 Hz, 1H), 4.59 (d, J = 9.3 Hz, 1H), 4.49 (d, J = 4.4 Hz, 1H), 3.75–3.68 (m, 1H),
3.59–3.32 (m, 5H). 13C-NMR (75 MHz, DMSO-d6): δ = 135.6, 129.2, 128.9, 126.1,
87.8, 79.2, 74.3, 69.3, 68.4, 60.6. No NMR data reported in DMSO-d6.
Phenyl 4,6-O-benzylidene-1-thio-β-D-galactopyranoside (ii)
O
HO
HO
HO OH
SPh
i
O
HO
HO SPh
O
O
Ph
81 %
PhCH(OCH3)2
p-TsOH, MeCN
ii
Benzaldehyde dimethyl acetal (2.7 mL, 18 mmol) was added to a suspension of i (3.0 g,
11 mmol) in acetonitrile (70 mL) followed by p-toluenesulfonic acid monohydrate (0.10
g, 0.53 mmol). After stirring for 6 h the reaction was quenched with Et3N, evaporated
under reduced pressure and recrystalized from EtOAc resulting in a white crystalline
product (3.2 g, 81%). 1H-NMR (300 MHz, CD3OD): δ = 7.72–7.61 (m, 2H), 7.54–7.41
(m, 2H), 7.40–7.31 (m, 3H), 7.31–7.17 (m, 3H), 5.59 (s, 1H), 4.59 (d, J = 9.3 Hz, 1H),
4.28–4.16 (m, 2H), 4.10 (dd, J = 12.4, 1.7 Hz, 1H), 3.72–3.58 (m, 3H). NMR data are in
accordance with literature values.177 13C-NMR (75 MHz, CD3OD): δ = 139.8, 133.8,
129.9, 129.8, 129.0, 128.4, 127.7, 102.4, 88.8, 77.6, 75.1, 71.3, 70.4, 69.6.
Phenyl
2,3-di-O-acetyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (35)
O
HO
HO SPh
O
O
Ph
ii
Ac2O, pyridine
68 %
O
AcO
AcO SPh
O
O
Ph
35
Acetic anhydride (20 mL, 0.21 mol) was slowly added to a suspension of ii (1.4 g,
3.8 mmol) in pyridine (20 mL) at 0 ◦C, and the mixture stirred at rt for 16 h. The
reaction was quenched with MeOH at 0 ◦C, and diluted with EtOAc (60 mL). The
organic mixture was washed with 1M HCl (50 mL), saturated aqueous NaHCO3 (50
mL), brine (50 mL), dried over MgSO4 and evaporated to dryness. The residue was
purified by flash column chromatography (SiO2, EtOAc/heptane 2:3) resulting in a
white foam (1.2 g, 68%). 1H-NMR (300 MHz, CDCl3): δ = 7.69–7.55 (m, 2H), 7.45–
7.19 (m, 8H), 5.47 (s, 1H), 5.35 (t, J = 9.9 Hz, 1H), 5.00 (dd, J = 9.9, 3.5 Hz, 1H), 4.71
(d, J = 9.9 Hz, 1H), 4.38 (m, 2H), 4.03 (dd, J = 12.5, 1.7 Hz, 1H), 3.60 (m, 1H), 2.09
(s, 3H), 2.03 (s, 3H). NMR data are in accordance with literature values.177 13C-NMR
(75 MHz, CDCl3): δ = 170.9, 169.2, 137.6, 133.7, 131.4, 129.3, 128.9, 128.3, 128.2,
126.7, 101.3, 85.3, 73.6, 73.3, 69.9, 69.2, 66.9, 21.0.
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2,3,4,6-Tetra-O-acetyl-D-galactopyranose183 (iii)
O
OAc
AcO
AcO
AcO OAc
47
O
AcO
AcO
AcO OAc
OH85 %
BnNH2
 THF
iii
Benzylamine (0.84 mL, 7.7 mmol) was added to a solution of 47 (2.0 g, 5.1 mmol) in
THF (12 mL), and the reaction stirred for 16 h. The mixture was diluted with H2O
(40 mL) and extracted with CH2Cl2 (3×50 mL). The combined organic layers was
washed with 2 M HCl (2×50 mL), saturated aqueous NaHCO3 (100 mL), and brine
(75 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by
flash column chromatography (SiO2, EtOAc/heptane 2:3) resulting in a clear oil (1.5
g, 85%). 1H-NMR (300 MHz, CDCl3): δ = 5.50 (t, J = 3.6 Hz, 1H), 5.46 (dd, J = 3.4,
1.2 Hz, 1H), 5.44–5.35 (m, 1H), 5.14 (dd, J = 10.7, 2.8 Hz, 1H), 5.08–5.04 (m, 1H),
4.74–4.64 (m, 0.25H), 4.46 (dd, J = 7.6, 6.6 Hz, 1H), 4.15–4.05 (m, 3H), 3.98–3.91 (m,
0.25H), 3.66 (dd, J = 3.6, 1.1 Hz, 1H), 2.14 (s, 0.75H), 2.13 (s, 3H), 2.09 (s, 0.75H),
2.08 (s, 3H), 2.04 (s, 3.75 H), 1.98 (s, 3.75H). 13C-NMR (75 MHz, CDCl3): δ = 170.7,
170.6, 170.4, 170.2, 96.1 (beta), 90.7 (alpha), 71.1 (beta), 70.5 (beta), 68.4 (alpha),
68.3 (alpha), 67.4 (alpha), 67.2 (beta), 66.3 (alpha), 61.9 (alpha), 61.6 (beta), 29.1,
21.0, 20.8, 20.8, 20.8, 20.7. NMR data are in accordance with literature values.184
2,3,4,6-Tetra-O-acetyl-D-galactopyranosyl N -phenyl trifluoroacetimidate
(34)
O
AcO
AcO
AcO OAc
OH
iii
O
AcO
AcO
AcO OAc
O CF3
N
Ph34
Cl CF3
N
Ph
Cs2CO3, CH2Cl2
90 %
Compound iii (0.50 g, 1.4 mmol) was dissolved in CH2Cl2 (15 mL) whereupon N -
phenyl trifluoroacetimidoyl chloride (0.60 mL, 2.9 mmol) and Cs2CO3 (0.94 g, 2.9
mmol) were added at 0 ◦C. The reaction mixture was stirred for 1 h at 0 ◦C followed
by 1 h at rt. The suspension was filtered through Celite, concentrated and purified by
flash column chromatography (SiO2, EtOAc/heptane 2:3) resulting in an amorphous
solid (0.65 g, 90%). 1H-NMR (300 MHz, CDCl3): δ = 7.32 (t,J = 7.9 Hz, 2H), 7.14
(t,J = 7.4 Hz, 1H), 6.83 (d, J = 7.6 Hz, 2H), 5.74 (s, 1H), 5.53–5.35 (m, 2H), 5.07 (d,
J = 8.5 Hz, 1H), 4.16 (d, J = 6.5 Hz, 2H), 3.96 (s, 1H), 2.19 (s, 3H), 2.09 (s, 3H),
2.02 (s, 3H), 2.01 (s, 3H). 13C-NMR (75 MHz, CDCl3): δ = 170.4, 170.3, 170.1, 169.2,
143.1, 129.0, 124.8, 119.3, 95.1, 71.9, 70.7, 67.9, 66.8, 61.1, 20.8, 20.8, 20.7. NMR data
are in accordance with literature values.185
2,3,4,6-Tetra-O-benzoyl-α-D-galactopyranosyl bromide178 (36)
HBr, HOAc
84%
O
OBzBzO
BzO
BzO OBz
CH2Cl2
O
Br
BzO
BzO
BzO OBz
3648
Compound 48 (6.0 g, 8.6 mmol) was dissolved in CH2Cl2 (20 mL) and a 30% solution
of HBr in AcOH (6.6 mL) was added, and the mixture was stirred in the darkness at
rt for 16 h. The reaction mixture was diluted with CH2Cl2 (35 mL) and poured over
ice. The organic layer was washed with H2O (2×50 mL), saturated aqueous NaHCO3
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(2×50 mL), brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue
was crystallized from Et2O resulting in a white crystalline product (4.8 g, 84%). 1H-
NMR (300 MHz, CDCl3): δ = 8.08–7.87 (m, 6H), 7.78–7.68 (m, 2H), 7.64–7.26 (m,
10H), 7.26–7.12 (m, 2H), 6.91 (d, J = 4.0 Hz, 1H), 6.05 (dd, J = 3.4, 1.2 Hz, 1H),
5.99 (dd, J = 10.4, 3.4 Hz, 1H), 5.60 (dd, J = 10.4, 4.0 Hz, 1H), 4.91–4.80 (m, 1H),
4.57 (dd, J = 11.5, 6.8 Hz, 1H), 4.39 (dd, J = 11.5, 6.0 Hz, 1H). 13C-NMR (75 MHz,
CDCl3): δ = 166.0, 165.7, 165.5, 165.4, 133.9, 133.5, 133.5, 130.1, 130.1, 129.9, 129.9,
129.3, 128.9, 128.9, 128.7, 128.6, 128.6, 128.5, 88.4, 71.9, 69.0, 68.7, 68.2, 61.9. NMR
data are in accordance with literature values.180
2,3,4,6-Tetra-O-benzoyl-D-galactopyranose178 (iv)
O
Br
BzO
BzO
BzO OBz
36
O
BzO
BzO
BzO OBz
OH
Ag2CO3
acetone/H2O
95%
iv
Compound 36 (1.4 g, 2.2 mmol) was dissolved in acetone (8 mL) and H2O (0.3 mL)
followed by addition of Ag2CO3 (0.31 g, 1.1 mmol). The reation mixture was stirred
for 3 h, filtered through Celite and concentrated in vacuo, giving a white foam (1.2
g, 95%). 1H-NMR (300 MHz, CDCl3): δ = 8.20–7.91 (m, 6H), 7.87–7.74 (m, 2H),
7.71–7.16 (m, 12H), 6.01 (dd, J = 3.4, 1.0 Hz, 1H), 5.74 (dd, J = 10.4, 3.4 Hz, 1H),
5.62 (dd, J = 10.4, 7.9 Hz, 1H), 5.05 (dd, J = 8.5, 7.9 Hz, 1H), 4.68 (dd, J = 11.0,
6.3 Hz, 1H), 4.52–4.32 (m, 2H), 4.01 (d, J = 8.6 Hz, 1H). NMR data are in accordance
with literature values.181 13C-NMR (75 MHz, CDCl3): δ = 167.3, 166.2, 165.6, 165.6,
133.8, 133.5, 133.5, 130.1, 130.1, 130.0, 129.9, 129.4, 129.1, 128.9, 128.8, 128.6, 128.6,
128.5, 96.5, 72.6, 71.8, 71.0, 68.3, 62.2. Anomer C-atom in accordance with literature
values.182
2,3,4,6-Tetra-O-benzoyl-D-galactopyranosyl N -phenyl trifluoroacetimidate
(37)
O
BzO
BzO
BzO OBz
OH
iv
Cl CF3
N
Ph
Cs2CO3, CH2Cl2
90 %
O CF3
N
Ph
O
BzO
BzO
BzO OBz
37
Compound iv (0.59 g, 1.0 mmol) was dissolved in CH2Cl2 (10 mL) whereupon N -
phenyl trifluoroacetimidoyl chloride (0.42 mL, 2.0 mmol) and Cs2CO3 (0.65 g, 2.0
mmol) were added at 0 ◦C. The reaction mixture stirred for 1 h at 0 ◦C followed by 1
h at rt. The suspension was filtered through Celite, concentrated and purified by flash
column chromatography (SiO2, EtOAc/heptane 1:3) resulting in a white foam (0.59
g, 78%). 1H-NMR (300 MHz, CDCl3): δ = 8.19–7.93 (m, 6H), 7.88–7.76 (m, 2H),
7.74–7.18 (m, 11H), 7.11 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 7.5 Hz, 0.1H), 6.72 (d, J =
7.4 Hz, 2H), 6.45 (s, 0.1H), 6.22–5.96 (m, 3H), 5.70 (d, J = 8.5 Hz, 1H), 4.89–4.78 (m,
0.1H), 4.66 (dd, J = 11.4, 7.1 Hz, 1H), 4.49 (dd, J = 12.0, 4.8 Hz, 2H). 13C-NMR (75
MHz, CDCl3): δ = 166.1, 165.6, 165.1, 143.1, 133.9, 133.7, 133.6, 133.4, 130.2, 129.9,
129.9, 129.4, 129.0, 128.9, 128.9, 128.8, 128.6, 128.6, 128.5, 124.7, 119.3, 95.3, 72.8,
71.6, 68.9, 68.0, 62.2.
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Ethyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-β-D-galactopyranoside (80)
O
BnO OBn
BnO
AcO
SEt
O
BnO OBn
BnO
BzO
SEt
1) NaOMe, MeOH
50 oC, 2 days
2) Ac2O, pyridine
97%60 80
Compound 60 (1.21 g, 2.02 mol) was taken up in a solution of NaOMe (0.10 g, 4.4
mmol Na in 25 mL MeOH) and stirred at 50 ◦C for 48 h whereupon Amberlite IR-120
H+ was added and the mixture stirred for an additional 60 min followed by filtration
and concentration. The residue was azeotropically distilled with toluene whereupon
pyridine (24 mL) was added and the mixture was cooled to 0 ◦C. Acetic anhydride
(24 mL) was added during 15 min and the mixture stirred for 3 h at rt. The reaction
was quenched with MeOH, diluted with EtOAc (100 mL) and the reaction mixture
was washed with 2M HCl (2×100 mL), H2O(100 mL), saturated aqueous NaHCO3 (50
mL), and brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue
was purified by flash column chromatography (SiO2, acetone/toluene 1:39) resulting in
a buff solid (1.05 g, 97%). 1H-NMR (300 MHz, CDCl3): δ = 7.46–7.20 (m, 15H), 5.42
(t, J = 9.8 Hz, 1H), 4.94 (d, J = 11.7 Hz, 1H), 4.68 (d, J = 12.2 Hz, 1H), 4.58 (d,J =
11.7 Hz, 1H), 4.53 (d, J = 12.2 Hz, 1H), 4.50–4.37 (m, 2H), 4.33 (d, J = 9.9 Hz, 1H),
3.99 (d,J = 2.7 Hz, 1H), 3.60 (br, 3H), 3.54 (dd, J = 9.6, 2.7 Hz, 1H), 2.81–2.58 (m,
2H), 2.04 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H). NMR data are in accordance with literature
values, but they are 3H short.186 13C-NMR (75 MHz, CDCl3): δ = 169.8, 138.7, 138.1,
137.9, 129.1, 128.6, 128.5, 128.3, 128.1, 128.1, 128.0, 127.9, 127.6, 127.6, 83.8, 81.5,
77.6, 74.5, 73.7, 72.9, 72.0, 69.7, 68.6, 23.7, 21.2, 14.9.
Methyl 5-acetamido-3,5-dideoxy-β-D-glycero-D-galacto-2-
nonulopyranosonate187 (112)
O
OH
CO2H
HO
AcHN
HO
HO
OH
O
OH
CO2Me
HO
AcHN
HO
HO
OH
MeOH, H+
86%
111 112
A suspension of N -acetylneuraminic acid (10 g, 0.032 mol) in anhydrous MeOH (500
mL) containing Amberlite IR-120 H+ resin (30 g) was stirred overnight at rt. The clear
solution was filtered and the resin washed with MeOH. The filtrate was evaporated
under reduced presure resulting in a white solid (9.0 g, 86%). M.p. 178–180 ◦C
(decomp.). M.p. lit. 180–182 ◦C (decomp.).188 [α] 25D –28.4 (c 0.01, H2O). Lit.[α]
25
D
–28 (c 1, H2O).188 1H-NMR (300 MHz, CD3OD): δ = 4.12–3.93 (m, 2H), 3.88–3.75
(m, 5H), 3.74–3.66 (m, 1H), 3.62 (dd, J = 11.0, 5.6 Hz, 1H), 3.48 (dd, J = 9.1, 1.2 Hz,
1H), 2.22 (dd, J = 12.9, 4.9 Hz, 1H), 2.02 (s, 3H), 1.89 (dd, J = 12.9, 11.4 Hz, 1H).
13C-NMR (75 MHz, CD3OD): δ = 175.1, 171.8, 96.6, 72.0, 71.6, 70.1, 67.8, 64.8, 54.3,
53.2, 40.7, 22.7. NMR data are in accordance with literature values.187
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Methyl 5-acetamido-2-chloro-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-β-D-
glycero-D-galacto-2-nonulopyranosonate189 (95)
O
OH
CO2Me
HO
AcHN
HO
HO
OH
112
O
Cl
CO2Me
AcO
AcHN
AcO
AcO
OAc
AcCl, MeOH
CH2Cl2
100% 95
Freshly distilled AcCl (50 mL) was slowly added to an ice-cooled suspension of 112
(2.1 g, 6.5 mmol) in CH2Cl2 (20 mL) in a flask with screw cap capable of enduring
high pressure. The ice-bath was removed and the reaction stirred overnight at rt.
Anhydrous MeOH (9 mL) was added dropwise to AcCl (10 mL) with cooling in an ice
water bath. The 112 AcCl solution was cooled on a icebath, and the cap was carefully
taken off, whereupon the MeOH/AcCl mixture was added with moderate haste and
the cap was quickly closed. The reaction mixture stirred overnight at rt, where NMR
showed full conversion into the desired product, which was obtained by evaporation
to dryness and co-evaporating with toluene (3×50 mL), resulting in a clear viscous oil
(3.3 g, 100%). 1H-NMR (300 MHz, CDCl3): δ = 5.58 (d, J = 10.1 Hz, 1H), 5.47 (dd,
J = 6.9, 2.4 Hz, 1H), 5.39 (ddd, J = 11.2, 10.4, 4.8 Hz, 1H), 5.17 (ddd, J = 6.9, 5.9, 2.7
Hz, 1H), 4.43 (dd, J = 12.5, 2.7 Hz, 1H), 4.35 (dd, J = 10.7, 2.4 Hz, 1H), 4.21 (dd, J =
10.7, 10.4 Hz, 1H), 4.06 (dd, J = 12.5, 5.9 Hz, 1H), 3.89–3.84 (m, 3H), 2.78 (dd, J =
13.9, 4.8 Hz, 1H), 2.27 (dd, J = 13.9, 11.2 Hz, 1H), 2.12 (s, 3H), 2.07 (s, 3H), 2.05 (s,
3H), 2.05 (s, 3H), 1.90 (s, 3H). NMR data are in accordance with literature values.190
13C-NMR (75 MHz, CDCl3): δ = 171.2, 170.9, 170.6, 170.2, 169.9, 165.8, 96.8, 74.1,
70.2, 69.0, 67.0, 62.3, 54.1, 48.9, 40.9, 23.4, 21.2, 21.1, 21.0, 21.0.
Methyl (4-nitrophenyl-5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-α-D-
glycero-D-galacto-2-nonulopyranosid)onate145 (110)
O
Cl
CO2Me
AcO
AcHN
AcO
AcO
OAc
p-nitrophenol, 0.1 M NaOH (aq.),
benzyltrietylammnium chloride O
CO2Me
O
AcO
AcHN
AcO
AcO
OAc
NO2
CH2Cl2
54%95 110
Compound 95 (3.3 g, 6.5 mmol) was dissolved in CH2Cl2 (150 mL) and p-nitrophenol
(4.4 g, 32 mmol) was dissolved in 0.1 M aqueous NaOH (150 mL). The two-phase
system was refluxed (49 ◦C) for 0.5 h in the presence of benzyltriethylammonium
chloride (3.2 g, 14 mmol) as phase-transfer catalyst. The organic phase was washed
with aqueous 0.1 M NaOH saturated with NaCl (3×150 mL), brine (150 mL) and dried
over MgSO4. After evaporation in vacuo and the product was purified by flash column
chromatography (SiO2, EtOAc) and crystallized from EtOAc/heptane resulting in a
white solid (2.14 g, 54%). 1H-NMR (300 MHz, CDCl3): δ = 8.17 (d, J = 9.3 Hz, 2H),
7.13 (d, J = 9.3 Hz, 2H), 5.44–5.29 (m, 3H), 4.96 (ddd, J = 12.2, 10.4, 4.6 Hz, 1H),
4.60 (dd, J = 10.8, 1.4 Hz, 1H), 4.27–4.01 (m, 3H), 3.64 (s, 3H), 2.73 (dd, J = 13.1,
4.6 Hz, 1H), 2.36–2.22 (m, 1H), 2.17 (s, 3H), 2.10 (s, 3H), 2.04 (2 s, 6H), 1.91 (s, 3H).
13C-NMR (75 MHz, CDCl3): δ = 171.0, 170.7, 170.4, 170.2, 170.1, 168.2, 159.1, 143.5,
125.8, 118.7, 99.6, 73.8, 68.5, 68.3, 67.1, 62.2, 53.5, 49.4, 38.8, 23.3, 21.1, 21.0, 20.9.
NMR data are in accordance with literature values.145
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Methyl (4-nitrophenyl-5-acetamido-3,5-dideoxy-α-D-glycero-D-galacto-2-
nonulopyranosid)onate146 (115)
NaOMe, MeOH
 99%
O
CO2Me
O
AcO
AcHN
AcO
AcO
OAc
NO2
O
CO2Me
O
HO
AcHN
HO
HO
OH
NO2110 115
To a suspension of 110 (2.0 g, 3.2 mmol) in MeOH (250 mL) was added a NaOMe
solution (2.5 mL, 1.6 M) added and the mixture stirred for 1 h whereupon Amberlite
IR-120 H+ was added at 0 ◦C. After stirring for 30 min the mixture was filtered and
concentrated. Purified by flash column chromatography (SiO2, MeOH/CH2Cl21:9)
resulting in a white solid (1.4 g, 99%). 1H-NMR (400 MHz, CD3OD): δ = 8.20 (d, J =
9.3 Hz, 1H), 7.34 (d, J = 9.3 Hz, 1H), 4.18 (dd, J = 10.5, 1.5 Hz, 1H), 3.91 (t, J = 10.5
Hz, 1H), 3.85–3.74 (m, 1H), 3.72 (s, 3H), 3.67–3.59 (m, 1H), 3.53 (dd, J = 9.2, 1.5 Hz,
1H), 2.78 (dd, J = 12.9, 4.6 Hz, 1H), 2.04 (dd, J = 12.9, 12.0 Hz, 1H), 2.02 (s, 3H).
NMR data are in accordance with literature values.146 13C-NMR (100 MHz, CD3OD):
δ = 175.2, 170.0, 160.9, 144.9, 126.3, 121.2, 101.9, 76.2, 71.9, 70.1, 67.9, 65.1, 53.6,
53.5, 42.2, 22.7.
p-Nitrophenyl-5-acetamido-3,5-dideoxy-α-D-glycero-D-galacto-2-
nonulopyranosidonic acid146 (109)
0.1 M NaOHO
CO2Me
O
HO
AcHN
HO
HO
OH
NO2
O
CO2H
O
HO
AcHN
HO
HO
OH
NO2115 109
0.5 h
~95%
Compound 115 (50 mg, 0.11 mmol) was dissolved in a aqueous solution of NaOH (50
mL, 0.1 M) and the mixture stirred for 30 min. The reaction was quenched by addition
of Amberlite IR-120 H+ and the mixture stirred for 30 min, filtered and evaporated
under reduced pressure yielding a yellow oil (45 mg, ∼95%). Purified by reverse phase
dry column chromatography (CH2Cl2/MeOH, 0 to 80% in steps of 5%) resulting in a
clear amorphous solid (9.9 mg, 21%). 1H-NMR (300 MHz, D2O): δ = 8.17 (dd, J =
9.3, 1.1 Hz, 2H), 7.34–7.17 (m, 2H), 4.17 (dd, J = 10.4, 1.4 Hz, 1H), 3.95 (t, J =
10.1 Hz, 1H), 3.88–3.74 (m, 3H), 3.66–3.59 (m, 1H), 3.57 (dd, J = 8.9, 1.3 Hz, 1H),
2.82 (dd, J = 12.8, 4.6 Hz, 1H), 2.08–1.97 (m, 4H). NMR data are in accordance with
literature values.146 13C-NMR (75 MHz, D2O): δ = 175.2, 173.0, 160.1, 143.1, 125.7,
120.0, 102.5, 73.8, 71.5, 68.3, 67.8, 62.9, 51.8, 41.0, 22.2.
Phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-
benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (83) and ethyl
2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-benzyl-
2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (84) ♣
OBn
O
AcO
BnO
BnO
OO
OBn
BnO
NPhth
SPh
OBn
O
AcO
BnO
BnO
OO
OBn
BnO
NPhth
SEt
+OHO
OBn
BnO
NPhth
SPh
+
NIS, AgOTf
-30 °C
CH2Cl2
~84%
(~58%) (~26%)
O
BnO OBn
BnO
AcO
SEt
80 65 83 84
Compound 80 (113 mg, 0.21 mmol) and 65 (110 mg, 0.19 mmol) were dissolved in
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CH2Cl2 (3 mL) and stirred under argon with 4 Å MS for 1 h. The mixture was cooled
to -30 ◦C, NIS (51 mg, 0.23 mmol) and AgOTf (cat.) were added and the mixture
was stirred for 15 min. Quenched with Et3N and stirred for 15 min, then filtered
through Celite and evaporated in vacuo. The residue was purified by dry column
chromatography (SiO2, acetone/toluene, 0 to 60% in steps of 3%) resulting in 84 (10
mg) and 83 (87 mg, 44%) and a mix of the two (7:11, 72 mg), further purification was
not nessesary as both could be used in subsequent reactions. 83 1H-NMR (300 MHz,
CDCl3): δ = 7.84–7.64 (m, 4H), 7.40–7.15 (m, 20H), 7.02–6.76 (m, 5H), 5.36 (dd, J =
10.0, 8.0 Hz, 1H), 5.22 (d, J = 10.0 Hz, 1H), 4.97–4.80 (m, 2H), 4.77–4.62 (m, 2H),
4.54–4.19 (m, 9H), 4.08–3.97 (m, 1H), 3.93 (d, J = 2.6 Hz, 1H), 3.85–3.71 (m, 2H),
3.59 (t, J = 9.4 Hz, 1H), 3.49–3.32 (m, 4H), 2.75–2.52 (m, 2H), 2.01 (s, 3H) 1.17 (t,
J = 7.4 Hz, 3H). 13C-NMR (75 MHz, CDCl3): δ = 169.5, 168.0, 167.7, 138.9, 138.9,
138.3, 138.2, 138.1, 133.9, 132.6, 131.8, 128.9, 128.6, 128.5, 128.5, 128.2, 128.0, 127.9,
127.9, 127.8, 127.4, 127.4, 126.9, 123.5, 123.4, 100.8, 81.2, 80.4, 79.5, 78.0, 77.8, 74.8,
74.5, 73.6 (2×C), 73.4, 72.7, 72.1, 71.7, 68.2, 54.9, 24.0, 21.2, 15.1. 84 1H-NMR (500
MHz, CDCl3): δ = 7.81 (d, J = 6.7 Hz, 1H), 7.78–7.60 (m, 3H), 7.43–7.12 (m, 25H),
7.03–6.90 (m, 2H), 6.90–6.75 (m, 3H), 5.51 (d, J = 10.0 Hz, 1H), 5.36 (dd, J = 10.1,
7.9 Hz, 1H), 4.91 (d, J = 11.6 Hz, 1H), 4.84 (d, J = 12.2 Hz, 1H), 4.73–4.62 (m, 2H),
4.55–4.45 (m, 4H), 4.42 (d, J = 12.2 Hz, 1H), 4.36–4.21 (m, 4H), 4.02–3.95 (m, 1H),
3.93 (d, J = 2.5 Hz, 1H), 3.84–3.74 (m, 2H), 3.60 (d,J = 10.0 Hz, 1H), 3.49–3.33 (m,
4H), 2.00 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ = 169.4, 168.1, 167.5, 138.9, 138.8,
138.3, 138.2, 138.1, 134.0, 133.9, 132.6, 132.4, 131.8, 131.8, 128.9, 128.6, 128.5, 128.5,
128.2, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.8, 127.8, 127.5, 127.4, 126.9, 123.6,
123.5, 100.9, 83.6, 80.5, 79.5, 78.1, 77.8, 77.4, 77.2, 76.9, 74.9, 74.6, 73.6, 73.4, 72.8,
72.1, 71.8, 68.2, 54.9, 21.2.
Phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-
benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (81) ♣
OBn
O
AcO
BnO
BnO
SEt
OBnO
OBn
HO
NPhth
SPh+ BnO
OBn
O
O
NPhth
O
BnO
BnO
AcO
OBn
SPh
80 61 81
MeOTf
CH2Cl2, -10 oC
52%
Compound 61 (150 mg, 0.26 mmol) and 80 (198 mg, 0.34 mmol) were dissolved in
CH2Cl2 (3 mL) and stirred under argon with 4 Å MS for 1 h, whereupon MeOTf
(0.13 mL, 1.2 mmol) was added at -10 ◦C and the mixture was left to stir for 6 h. The
reaction was quenched with pyridine, evaporated in vacuo and purified by flash column
chromatography (SiO2, acetone/toluene 1:33) resulting in a clear oil (142 mg, 52%).
1H-NMR (300 MHz, CDCl3): δ = 7.94–7.72 (m, 4H), 7.48–7.01 (m, 30H), 5.44 (d, J =
10.5 Hz, 1H), 5.31 (dd, J = 10.1, 7.9 Hz, 1H), 5.04 (d, J = 10.3 Hz, 1H), 4.92 (d, J =
11.3 Hz, 1H), 4.85–4.73 (m, 1H), 4.63 (d, J = 12.0 Hz, 1H), 4.60–4.18 (m, 8H), 4.14 (d,
J = 7.9 Hz, 1H), 3.88 (d, J = 2.7 Hz, 1H), 3.85–3.77 (m, 2H), 3.71–3.60 (m, 2H), 3.48
(t, J = 10.0 Hz, 1H), 3.40–3.30 (m, 2H), 3.10 (dd, J = 10.1, 2.7 Hz, 1H), 2.02 (s, 3H).
13C-NMR (75 MHz, CDCl3): δ = 169.9, 168.6, 167.2, 138.7, 138.4, 138.3, 138.0, 137.8,
134.4, 132.6, 132.0, 129.1, 128.9, 128.5, 128.4, 128.4, 128.3, 128.2, 128.0, 128.0, 128.0,
127.8, 127.7, 127.6, 127.5, 127.3, 127.2, 125.4, 123.6, 100.8, 83.7, 80.2, 79.4, 77.6, 76.7,
75.2, 74.7, 73.5, 73.5, 73.4, 72.6, 71.5, 71.3, 69.1, 67.7, 55.1, 21.0.
66Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
1.8. Experimental
Phenyl 2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-4,6-di-
O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (77) ♣
OBn
O
BzO
BnO
BnO
SEt
OBnO
OBn
HO
NPhth
SPh
+ BnO
OBn
O
O
NPhth
O
BnO
BnO
OBz
OBn
SPh
60 61 77
MeOTf
CH2Cl2, -10 oC
78%
Compound 60 (119 mg, 0.20 mmol) and 61 (97 mg, 0.17 mmol) were dissolved in
CH2Cl2 (3 mL) and stirred under argon with 4 Å MS for 1 h, whereupon MeOTf
(0.09 mL, 0.8 mmol) was added at -10 ◦C and the mixture was left to stir for 6 h. The
reaction was quenched with pyridine, evaporated in vacuo and purified by dry column
chromatography (SiO2, acetone/toluene, 0 to 50% in steps of 2.5%) resulting in a clear
oil (0.148 mg, 78%). 1H-NMR (500 MHz, CDCl3): δ = 7.67 (d, J = 7.4 Hz, 2H),
7.62–7.56 (m, 3H), 7.53 (t, J = 7.4 Hz, 1H), 7.33 (t, J = 7.7 Hz, 3H), 7.29–6.94 (m,
28H), 6.91 (d, J = 7.3 Hz, 2H), 5.50–5.39 (m, 1H), 5.31 (d, J = 10.5 Hz, 1H), 5.02 (d,
J = 10.7 Hz, 1H), 4.84 (d, J = 11.4 Hz, 1H), 4.78 (dd, J = 10.1, 7.8 Hz, 1H), 4.53–4.37
(m, 6H), 4.28–4.20 (m, 3H), 4.15 (d, J = 11.7 Hz, 1H), 3.85 (d, J = 2.3 Hz, 1H), 3.74
(d, J = 10.7 Hz, 1H), 3.69 (dd, J = 10.7, 4.3 Hz, 1H), 3.63–3.56 (m, 2H), 3.39 (t, J =
8.1 Hz, 1H), 3.34–3.25 (m, 3H). 13C-NMR (75 MHz, CDCl3): δ = 165.4, 138.7, 138.68,
138.4, 138.1, 137.5, 134.1, 133.0, 132.8, 131.8, 131.5, 130.4, 130.1, 128.9, 128.5, 128.4,
128.3, 128.3, 128.1, 128.1, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 127.3, 100.8, 84.0,
80.3, 79.4, 77.9, 77.3, 74.9, 74.8, 73.6, 73.5, 73.4, 72.9, 72.5, 71.7, 69.3, 67.9, 55.1. Phth
peaks from C=O missing.
Phenyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl-(1→3)-4,6-O-
benzylidene-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (51) ♣
TESOTf
+O CF3
N
Ph
O
BzO
BzO
BzO OBz
O
O O
O
Ph
NPhth
O
BzO
BzO
BzO
OBz
SPh
51
CH2Cl2, -40 °C
3037
O
O O
HO
Ph
SPh
NPhth 68%
Compound 30 (100 mg, 0.20 mmol) and 37 (184 mg, 0.24 mmol) were dissolved in
CH2Cl2 (2 mL) and stirred under argon with 4 Å MS for 1 h. The mixture was
cooled to -40 ◦C, TESOTf (5.3 mg, 0.02mmol) was added and the mixture was stirred
for 2h. Quenched with Et3N and the mixture stirred for 15 min followed by evap-
oration in vacuo. The residue was purified by flash column chromatography (SiO2,
EtOAc/heptane 1:1) resulting in a clear oil (146 mg, 68%). 1H-NMR (300 MHz,
CDCl3): δ = 8.02–7.98 (m, 2H), 7.91–7.86 (m, 2H), 7.66–7.09 (m, 34H), 5.81 (d,
J = 3.0 Hz, 1H), 5.63 (s, 1H), 5.61–5.49 (m, 2H), 5.34 (dd, J = 10.3, 3.5 Hz, 1H), 4.97
(d, J = 8.1 Hz, 1H), 4.91–4.81 (m, 1H), 4.49 (t, J = 10.3 Hz, 1H), 4.41 (dd, J = 10.0,
4.3 Hz, 1H), 4.35–4.20 (m, 2H), 3.97 (t, J = 9.0 Hz, 1H), 3.88 (t, J = 10.1 Hz, 1H),
3.81–3.70 (m, 2H). 13C-NMR (75 MHz, CDCl3): δ = 165.7, 165.6, 165.5, 164.7, 136.9,
133.9, 133.6, 133.3, 132.9, 132.8, 131.6, 130.3, 130.1, 129.8, 129.7, 129.6, 129.3, 129.1,
129.0, 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 126.4, 126.2, 102.1, 100.8, 84.5, 81.3,
77.2, 72.0, 71.0, 70.6, 70.3, 68.8, 67.6, 61.1, 55.1. Phth peaks from C=O missing.
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Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→3)-4,6-O-
benzylidene-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (49)
TESOTf
+O CF3
N
Ph
O
AcO
AcO
AcO OAc
O
O O
O
Ph
NPhth
O
AcO
AcO
AcO
OAc
SPh
49
CH2Cl2, -30 °C
3034
O
O O
HO
Ph
SPh
NPhth 28%
Compound 30 (100 mg, 0.20 mmol) and 34 (114 mg, 0.22 mmol) were dissolved in
CH2Cl2 (2 mL) and stirred under argon with 4 Å MS for 1 h. The mixture was
cooled to -30 ◦C, TESOTf (5.3 mg, 0.02 mmol) was added and the mixture was stirred
for 1h. Quenched with Et3N and the mixture stirred for 15 min followed by evap-
oration in vacuo. The residue was purified by flash column chromatography (SiO2,
EtOAc/heptane 9:11) resulting in a clear oil (46 mg, 28%). 1H-NMR (400 MHz,
CDCl3): δ = 8.03–7.71 (m, 4H), 7.51–7.23 (m, 10H), 5.61–5.54 (m, 2H), 5.22–5.16
(m, 1H), 4.98 (dd, J = 10.4, 8.0 Hz, 1H), 4.81–4.70 (m, 2H), 4.55 (d, J = 8.0 Hz,
1H), 4.46–4.35 (m, 2H), 4.03 (dd, J = 11.0, 8.2 Hz, 1H), 3.92–3.78 (m, 3H), 3.72 (td,
J = 9.7, 4.7 Hz, 1H), 3.50–3.42 (m, 1H), 2.07 (s, 3H), 1.92 (s, 3H), 1.84 (s, 3H), 1.53
(s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 170.4, 170.2, 170.1, 169.0, 137.1, 132.9,
131.5, 129.5, 129.1, 128.5, 128.3, 126.2, 101.6, 100.5, 84.4, 80.9, 76.7, 71.1, 70.7, 70.4,
69.3, 68.7, 66.7, 60.9, 54.4, 20.7, 20.7, 20.6, 20.2. NMR data are in accordance with
literature values.191
Phenyl 2,3,-di-O-acetyl-4,6-O-benzylidene-β-D-galactopyranosyl-(1→3)-4,6-
O-benzylidene-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (116) ♣
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Compound 30 (92 mg, 0.19 mmol) and 35 (100 mg, 0.22 mmol) were dissolved in
CH2Cl2 (2 mL) and stirred under argon with 4 Å MS for 1 h. The mixture was cooled
to -30 ◦C, NIS (54 mg, 0.40 mmol) and TESOTf (5.3 mg, 0.02 mmol) were added
and the mixture was stirred for 1h. Quenched with Et3N and the mixture stirred for
15 min followed by evaporation in vacuo. The residue was purified by flash column
chromatography (SiO2, EtOAc/heptane 1:1) resulting in a clear oil (40 mg, 26%). 1H-
NMR (300 MHz, CDCl3): δ = 7.99–7.76 (m, 4H), 7.46–7.21 (m, 15H), 5.59 (d, J = 10.6
Hz, 1H), 5.55 (s, 1H), 5.34–5.20 (m, 3H), 5.12 (dd, J = 10.6, 3.4 Hz, 1H), 4.84–4.75
(m, 1H), 4.47–4.34 (m, 2H), 4.19 (d, J = 2.4 Hz, 1H), 3.89–3.71 (m, 3H), 3.30 (s, 1H),
3.26–3.17 (m, 2H), 1.99 (s, 3H), 1.38 (s, 3H). 13C-NMR (75 MHz, CDCl3): δ = 170.6,
169.8, 137.4, 136.8, 134.9, 132.9, 132.7, 131.7, 129.6, 129.2, 128.9, 128.5, 128.4, 128.3,
126.4, 126.3, 124.0, 102.0, 100.7, 99.3, 84.6, 81.6, 77.6, 73.7, 70.5 68.7, 68.4, 68.3, 67.1,
63.0, 55.0, 21.1, 20.1. Phth peaks from C=O missing.
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Benzyl 2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-3,6-di-
O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-
benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-
glucopyranoside (64) ♣
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then
NIS, AgOTf (cat.)
60 65 64
Synthesized using the general one-pot glycosylation method, using 60 (124 mg, 0.21
mmol), 65 (110 mg, 0.19 mmol) and 9 (184 mg, 0.19 mmol). Purified by flash column
chromatography (SiO2, Acetone/toluene 1:19) resulting in a clear oil (270 mg, 72%).
1H-NMR (500 MHz, CDCl3): δ = 7.99 (d, J = 7.4 Hz, 2H), 7.62 (t, J = 7.4 Hz, 2H),
7.48 (t, J = 7.7 Hz, 3H), 7.39–7.10 (m, 53H), 7.07 (t, J = 7.3 Hz, 2H), 6.94 (d, J =
6.8 Hz, 2H), 6.90–6.76 (m, 5H), 5.67 (dd, J = 9.8, 8.1 Hz, 1H), 5.30 (d, J = 8.3 Hz,
1H), 5.04 (d, J = 11.4 Hz, 1H), 4.99 (d, J = 11.6 Hz, 1H), 4.94 (d,J = 12.1 Hz, 1H),
4.91–4.81 (m, 3H), 4.73–4.62 (m, 3H), 4.60–4.52 (m, 4H), 4.52–4.19 (m, 14H), 4.16 (d,
J = 11.9 Hz, 1H), 4.06 (t, J = 9.2 Hz, 1H), 4.04–3.97 (m, 2H), 3.95 (d, J = 1.8 Hz,
1H), 3.83 (t, J = 9.0 Hz, 1H), 3.70 (dd, J = 10.9, 3.3 Hz, 1H), 3.55 (dd, J = 10.1, 2.6
Hz, 1H), 3.53–3.24 (m, 14H), 2.92 (d, J = 7.6 Hz, 1H). 13C-NMR (75 MHz, CDCl3):
167.9, 167.8, 165.2, 139.5, 139.1, 139.0, 138.8, 138.7, 138.6, 138.4, 138.4, 138.3, 138.0,
137.8, 137.7, 133.5, 133.2, 131.3, 130.0, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2,
128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 127.5, 127.5, 127.2, 127.1, 126.8, 126.7,
126.5, 123.1, 102.5 (2×C), 100.9, 99.7, 83.0, 82.1, 81.7, 79.9, 78.8 77.8, 77.4, 76.9, 76.1,
75.5, 75.1 (2×C), 74.8 (2×C), 74.6, 74.5, 74.1, 73.6 (2×C), 73.4, 73.3, 73.0, 73.0, 72.6,
72.6, 71.4, 70.9, 68.3, 68.1 (2×C), 67.7, 56.4.
Benzyl
2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-4,6-di-O-benzyl-
2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (86) ♣
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Synthesized by the general sequential glycosylation method, using 81 (270 mg, 0.256
mmol) and 9 (207 mg, 0.213 mmol). Purified by dry column chromatography (SiO2,
EtOAc/toluene, 0 to 33% in steps of 1.65%) resulting in a clear oil (240 mg, 58%).
1H-NMR (500 MHz, CDCl3): δ = 7.72–7.52 (m, 2H), 7.47–7.01 (m, 60H), 6.96–6.80
(m, 2H), 5.31–5.21 (m, 2H), 5.08–4.99 (m, 2H), 4.94–4.79 (m, 5H), 4.69 (d, J = 10.9
Hz, 1H), 4.63–4.39 (m, 9H), 4.38–4.14 (m, 10H), 4.08 (d, J = 7.9 Hz, 1H), 4.01 (d, J =
2.8 Hz, 1H), 3.93–3.75 (m, 5H), 3.70 (ddd, J = 9.9, 4.6, 1.8 Hz, 1H), 3.66–3.60 (m,
1H), 3.53–3.43 (m, 4H), 3.43–3.24 (m, 8H), 3.04 (dd, J = 10.1, 2.7 Hz, 1H), 2.90 (ddd,
J = 9.9, 3.4, 1.7 Hz, 1H), 1.92 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ = 169.9, 139.6,
139.2, 138.8, 138.8, 138.5, 138.4, 138.3, 138.1, 137.9, 137.8, 133.9, 128.6, 128.6, 128.5,
128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.1, 128.1, 128.0,
128.0, 128.0, 127.9, 127.8, 127.8, 127.8, 127.7, 127.6, 127.6, 127.6, 127.5, 127.3, 127.2,
126.9, 126.4, 102.6, 102.5, 100.8, 99.5, 83.2, 81.7, 81.7, 80.4, 78.8, 77.1, 76.8, 76.3, 76.1,
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75.6, 75.3, 75.2, 75.1, 75.0, 74.9, 74.8, 73.9, 73.8, 73.6, 73.4, 73.4, 73.3, 73.2, 72.7, 71.6,
71.4, 70.9, 69.5, 68.5, 67.8, 67.7, 56.6, 21.0.
Benzyl
2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-benzyl-
2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (85)
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O
BnO
BnO
O
OBn
O
BnO
O
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OO
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Synthesized by the general sequential glycosylation method, using a mixture of 83/84
(300 mg, ∼0.284 mmol) and 9 (215 mg, 0.221 mmol). Purified by flash column chro-
matography (SiO2, EtOAc/heptane 1:2) resulting in a clear oil (310 mg, 73%).
Synthesized by the general one-pot glycosylation method, using 80 (686 mg, 1.3 mmol),
65 (620 mg, 1.1 mmol) and 9 (1.00 g, 1.0 mmol). Purified by flash column chromatog-
raphy (SiO2, EtOAc/heptane 1:2) resulting in a clear oil (1.86 g, 94%).
1H-NMR (500 MHz, CDCl3): δ = 7.42–7.04 (m, 58H), 6.94–6.76 (m, 6H), 5.37 (m, 2H),
5.07 (d, J = 11.4 Hz, 1H), 4.95–4.82 (m, 5H), 4.72–4.62 (m, 3H), 4.57–4.22 (m, 18H),
4.17 (d, J = 11.9 Hz, 1H), 4.06–3.98 (m, 3H), 3.93 (d, J = 2.7 Hz, 1H), 3.88–3.83 (m,
1H), 3.82–3.74 (m, 2H), 3.63–3.57 (m, 1H), 3.54 (dd, J = 9.8, 3.0 Hz, 1H), 3.53–3.31
(m, 12H), 2.98–2.88 (m, 1H), 2.01 (s, 3H). 13C-NMR (125 MHz, CDCl3): δ = 169.4,
139.6, 139.2, 139.0, 138.9, 138.8, 138.6, 138.5, 138.5, 138.2, 138.2, 138.1, 137.7, 133.5,
128.6, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.0, 128.0, 128.0,
127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 127.3, 127.2, 126.9,
126.8, 126.6, 102.6, 101.0, 99.9, 83.1, 82.1, 81.8, 80.5, 78.9, 78.0, 76.8 (2×C), 76.1,
75.6, 75.2, 75.2, 74.9 (2×C), 74.8, 74.6, 74.2, 73.8, 73.6, 73.4, 73.4, 73.2, 73.1, 72.8,
72.1, 71.8, 71.0, 68.4, 68.4, 68.2, 67.8, 56.5, 21.2. NMR data are in accordance with
literature values.93
Benzyl
2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-6-O-benzyl-2-
deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (103) ♣
OBn
O
BnO
BnO
O
OBn
O
BnO
O
BnO
OBn
OBn
O
BzO
BnO
BnO
OO
OBn
HO
NPhth
103
CH2Cl2
57%
OHO
OBn
HO
NPhth
SPh
100
9, NIS, TESOTf
then
NIS, AgOTf (cat.)
-30 °C
OBn
O
BzO
BnO
BnO
SEt
60
+
Synthesized by the general one-pot glycosylation method, using 60 (120 mg, 0.20
mmol), 100 (83 mg, 0.17 mmol) and 9 (164 mg, 0.17 mmol). Purified by flash column
chromatography (SiO2, EtOAc/heptane 1:2) resulting in a clear oil (183 mg, 57%).
1H-NMR (400 MHz, CDCl3): δ = 8.09–7.94 (m, 2H), 7.69–6.81 (m, 62H), 5.65 (dd,
J = 10.0, 8.0 Hz, 1H), 5.35 (d, J = 8.4 Hz, 1H), 4.98 (d, J = 11.4 Hz, 1H), 4.92 (d,
J = 11.7 Hz, 1H), 4.89–4.75 (m, 3H), 4.68–4.36 (m, 11H), 4.31–4.13 (m, 8H), 4.12–3.99
(m, 3H), 3.96–3.84 (m, 3H), 3.84–3.75 (m, 1H), 3.67–3.25 (m, 17H), 2.94–2.84 (m, 1H).
13C-NMR (100 MHz, CDCl3): δ = 167.9, 165.2, 139.5, 139.1, 138.7, 138.6, 138.5, 138.4,
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138.3, 138.1, 137.7, 137.4, 137.4, 134.6, 133.7, 133.5, 133.4, 131.5, 130.2, 130.1, 129.9,
129.9, 129.1, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.1,
128.1, 128.0, 128.0, 127.9, 127.9, 127.9, 127.7, 127.7, 127.7, 127.6, 127.6, 127.5, 127.2,
127.2, 127.1, 126.9, 126.6, 123.2, 102.5, 102.4, 102.1, 99.7, 83.0, 82.3, 82.1, 81.7, 79.8,
78.9, 76.8, 76.0, 75.5, 75.1 (C×2), 74.8, 74.6, 74.2, 74.0, 73.8, 73.7, 73.3, 73.1, 73.1,
73.1, 72.2, 72.1, 71.8, 70.9, 69.4, 68.7, 68.7, 68.4, 67.7, 56.6.
Benzyl 2-O-benzoyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-4,6-di-
O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-
benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-
glucopyranoside (58) ♣
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Synthesized by the general sequential glycosylation method, using 77 (120 mg, 0.11
mmol) and 9 (104 mg, 0.11 mmol). Purified by dry column chromatography (SiO2,
acetone/toluene, 0 to 75% in steps of 5%) resulting in a clear oil (170 mg, 80%).
Synthesized by the general one-pot glycosylation method, using 60 (124 mg, 0.21
mmol), 61 (110 mg, 0.19 mmol) and 9 (184 mg, 0.19 mmol). Purified by flash column
chromatography (SiO2, Acetone/toluene 1:19) resulting in a clear oil (27 mg, 7%).
1H-NMR (400 MHz, CDCl3): δ = 7.68 (dd, J = 8.2, 1.2 Hz, 2H), 7.59–7.53 (m, 1H),
7.41–7.02 (m, 62H), 7.00–6.94 (m, 2H), 6.88–6.81 (m, 2H), 5.51 (dd, J = 9.9, 7.9 Hz,
1H), 5.22 (d, J = 8.4 Hz, 1H), 5.12 (d, J = 10.6 Hz, 1H), 4.99–4.81 (m, 6H), 4.69 (d,
J = 10.9 Hz, 1H), 4.58–4.40 (m, 10H), 4.36–4.11 (m, 10H), 3.97 (d, J = 2.9 Hz, 1H),
3.94 (d, J = 2.6 Hz, 1H), 3.86–3.65 (m, 6H), 3.53–3.28 (m, 12H), 3.25 (d, J = 9.4 Hz,
1H), 2.92–2.84 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ = 165.5, 139.5, 139.1, 138.8,
138.7, 138.7, 138.7, 138.5, 138.3, 138.2, 138.1, 137.7, 137.6, 133.6, 132.7, 131.1, 130.3,
130.0, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1,
128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.7, 127.6, 127.6, 127.6,
127.5, 127.3, 127.2, 126.8, 126.4, 102.5, 102.5, 100.7, 99.6, 83.0, 81.7, 81.5, 80.3, 78.7,
77.5, 76.7, 76.3, 76.0, 75.5, 75.1, 75.1, 75.0, 75.0, 74.8, 74.8, 73.8, 73.7, 73.5, 73.4, 73.3,
73.3, 73.1, 72.9, 72.9, 71.7, 70.9, 69.5, 68.6, 67.9, 67.6, 56.4.
Benzyl
2-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-6-O-benzyl-2-
deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (104) ♣
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104
Synthesized by the general one-pot glycosylation method, using 80 (107 mg, 0.20
mmol), 100 (83 mg, 0.17 mmol) and 9 (145 mg, 0.15 mmol). Purified by flash column
chromatography (SiO2, EtOAc/heptane 1:2) resulting in a clear oil (140 mg, 51%).
1H-NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 6.8 Hz, 1H), 7.50 (t, J = 7.5 Hz, 1H),
7.41–7.02 (m, 55H), 6.96–6.87 (m, 2H), 5.45 (d, J = 8.4 Hz, 1H), 5.38 (dd, J = 10.0, 8.0
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Hz, 1H), 5.07 (d, J = 11.4 Hz, 1H), 4.94–4.81 (m, 4H), 4.75–4.38 (m, 13H), 4.38–4.21
(m, 8H), 4.18 (d, J = 11.9 Hz, 1H), 4.10 (d, J = 11.9 Hz, 1H), 4.02 (d, J = 2.8 Hz,
1H), 3.92–3.80 (m, 2H), 3.77–3.65 (m, 4H), 3.63–3.29 (m, 13H), 2.95 (dd, J = 9.8, 1.8
Hz, 1H), 1.98 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 169.5, 167.9, 139.6, 139.1,
138.8, 138.6, 138.4, 138.4, 138.1, 137.8, 137.7, 137.4, 133.7, 133.6, 132.7, 131.5, 128.9,
128.6, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.2, 128.2, 128.2, 128.0, 128.0,
128.0, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 127.6, 127.2, 127.2, 126.9,
126.7, 123.2, 102.5(C×2), 101.9, 99.7, 83.1, 82.1, 82.0, 81.8, 80.4, 79.0, 76.8, 76.1, 75.6,
75.2, 75.1, 74.9, 74.6, 74.3, 74.1, 73.9, 73.8, 73.7, 73.4, 73.1, 73.1, 72.3, 72.3, 71.3, 70.9,
69.3, 68.8, 68.6, 68.4, 67.8, 56.7, 21.1.
Benzyl 2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzyl-β-D-glucopyranoside (62)
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NIS (112 mg, 0.50 mmol) and TESOTf (13 mg, 0.049 mmol) were added to a solution
of 63 (711 mg, 0.38 mmol), 59 (253 mg, 0.48 mmol) and 4 Å MS in CH2Cl2 (7
mL) at -30 ◦C. After stirring for 20 min the reaction was quenched with Et3N and
the mixture stirred for 15 min, and was then filtered through Celite and evaporated
in vacuo. Purification by flash column chromatography (SiO2, Acetone/toluene 1:24)
resulted in a clear oil (657 mg, 89%). 1H-NMR (400 MHz, CDCl3): δ = 7.69 (br, 1H),
7.52 (br, 1H), 7.39–7.04 (m, 70H), 6.93–6.80 (m, 5H), 6.75 (t, J = 7.3 Hz, 2H), 5.73 (d,
J = 3.8 Hz, 1H), 5.38 (d, J = 7.9 Hz, 1H), 5.10 (d, J = 11.4 Hz, 1H), 4.97 (d, J = 11.5
Hz, 1H), 4.94–4.16 (m, 34H), 4.15–3.99 (m, 4H), 3.95 (d, J = 2.5 Hz, 1H), 3.94–3.75
(m, 5H), 3.64 (dd, J = 9.7, 2.8 Hz, 1H), 3.59 (dd, J = 9.8, 2.9 Hz, 1H), 3.57–3.29 (m,
12H), 3.00–2.90 (m, 1H), 1.39 (d, J = 6.5 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ =
139.5, 139.1, 138.9, 138.9, 138.8, 138.7, 138.6, 138.6, 138.5, 138.4, 138.2, 138.2, 138.1,
137.7, 133.6, 131.3, 128.6, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3,
128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 129.0, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6,
127.6, 127.5, 127.4, 127.3, 127.3, 127.2, 127.0, 126.9, 126.5, 126.3, 123.2, 102.5, 102.5,
100.9, 100.2, 97.7, 84.1, 83.1, 82.5, 81.8, 79.4, 78.9, 78.2, 76.8, 76.8, 76.7, 76.1, 75.8
(2×C), 75.6, 75.3, 75.2, 75.0, 75.0, 74.7, 74.5, 74.3, 73.9, 73.7, 73.6, 73.5, 73.3, 73.2,
73.1, 72.7, 72.4, 72.3, 71.0, 70.9, 68.8, 68.5, 68.3, 67.8, 66.6, 56.5, 17.0. Phth peaks
from C=O missing. NMR data are in accordance with literature values.93
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Benzyl 2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→3)-2-acetamido-4,6-di-O-benzyl-2-deoxy-β-D-
glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzyl-β-D-glucopyranoside (91) ♣
59, NIS, TESOTf
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CH2Cl2, -30 °C
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NIS (17 mg, 0.077 mmol) and TESOTf (1.9 mg, 0.0077 mmol) were added to a solution
of 87 (100 mg, 0.056 mmol), 59 (38 mg, 0.073 mmol) and 4 Å MS in CH2Cl2(1.5 mL)
at -20 ◦C. The mixture was left to reach 10 ◦C, where the reaction was quenched
with Et3N and the mixture stirred for 15 min, and then filtered through Celite and
evaporated in vacuo. Purification by flash column chromatography (deactivated with
Et3N) (SiO2, Acetone/toluene 1:9) resulted in a clear oil (84 mg, 68%). 1H-NMR (400
MHz, CDCl3): δ = 7.43–6.96 (m, 75H), 5.60 (d,J = 3.7 Hz, 1H), 5.06 (d, J = 11.1 Hz,
2H), 4.99 (d, J = 10.6 Hz, 1H), 4.95–4.34 (m, 31H), 4.26 (d, J = 11.8 Hz, 1H), 4.19
(dd, J = 9.5, 7.6 Hz, 1H), 4.05 (dd, J = 10.5, 2.5 Hz, 1H), 4.02–3.91 (m, 5H), 3.89 (d,
J = 1.4 Hz, 1H), 3.87–3.37 (m, 18H), 3.33–3.22 (m, 1H), 1.63 (s, 3H), 1.20 (d, J = 6.5
Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ = 169.3, 139.7, 139.6, 139.3, 139.2, 138.9,
138.7, 138.7, 138.4, 138.3, 138.3, 138.1, 137.6, 129.0, 128.8, 128.6, 128.5, 128.5, 128.4,
128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8,
127.8, 127.7, 127.6, 127.6, 127.5, 127.3, 127.2, 127.2, 127.1, 126.4, 126.3, 102.7, 102.5,
102.0, 101.6, 98.2, 84.0, 83.0, 81.8, 81.5, 80.2, 79.3, 78.1, 78.0, 77.5, 77.2, 77.1, 76.8,
76.6, 76.4, 75.7, 75.6, 75.3, 75.3, 75.2, 75.1, 75.1, 75.0, 74.8, 74.7, 74.1, 73.7, 73.6, 73.6,
73.5, 73.5, 73.4, 72.8, 72.4, 72.0, 71.2, 71.0, 69.5, 68.9, 68.4, 68.3, 66.4, 55.8, 23.6, 16.8.
2-acetamido-
Benzyl 3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-benzyl-2-
deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (63)
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Compound 85 (1.55 g, 0.81 mmol) was dissolved in CH2Cl2 (10 mL) whereupon a
solution of NaOMe (40 mg, 1.74 mmol Na in 100 mL MeOH) was added. Amberlite IR
120 H+ was added after the mixture had stirred at rt for 48 h, and the mixture stirred
for an additional 2 h followed by concentration in vacuo, The residue was purified by
flash column chromatography (SiO2, EtOAc/heptane 1:3) resulting in a clear oil (1.23
g, 81%). 1H-NMR (500 MHz, CDCl3): δ = 7.49–6.77 (m, 64H), 5.37 (d, J = 8.4 Hz,
1H), 5.06 (d, J = 11.4 Hz, 1H), 4.92–4.81 (m, 5H), 4.73–4.67 (m, 2H), 4.65–4.60 (m,
2H), 4.58–4.44 (m, 8H), 4.38 (d, J = 12.3 Hz, 1H), 4.35–4.11 (m, 10H), 4.08 (dd, J =
11.3, 3.5 Hz, 1H), 4.02–3.81 (m, 6H), 3.72 (ddd, J = 9.9, 3.2, 1.9 Hz, 1H), 3.59–3.26 (m,
13H), 2.92 (ddd, J = 9.9, 3.6, 1.7 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ = 139.5,
139.2, 139.0, 138.9, 138.8, 138.7, 138.5, 138.5, 138.3, 138.0, 138.0, 137.7, 133.5, 128.6,
128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8,
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127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 126.9, 126.8, 126.5, 123.2,
103.6, 102.6, 102.5, 100.0, 83.1, 82.1, 82.0, 81.8, 79.0, 78.4, 78.1, 76.8, 76.1, 75.6, 75.2,
75.2, 74.9, 74.8, 74.7, 74.6, 74.1, 73.8, 73.6, 73.6, 73.5, 73.2, 73.1, 72.9, 72.4, 72.3, 70.9,
68.8, 68.4, 68.4, 67.8, 56.6. Phth peaks from C=O missing. Synthesized, but NMR
data not reported.93
Benzyl 3,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→3)-2-acetamido-4,6-di-
O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside (87) ♣
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1) EDA, tBuOH, reflux
2) Ac2O, Et3N, EtOH
86 87
A mixture of 86 (301 mg, 0.162 mmol) and ethylenediamine (4.7 mL, 0.070 mmol) in t-
BuOH (20 mL) was stirred at 100 ◦C for 16 h. The volatiles were removed in vacuo and
co-evaporated with toluene (2×10 mL) then ethanol (10 mL). The residue was taken up
in ethanol (4.5 mL), acetic anhydride (1.5 mL, 0.016 mol) and Et3N (3 mL) were added
at 0 ◦C and the mixture stirred at rt for 15 h. The residue was diluted with EtOAc (40
mL), then washed with a saturated aqueous solution of NaHCO3 (2×20 mL), H2O (30
mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash
column chromatography (deactivated with Et3N) (SiO2, EtOAc/heptane 2:3) resulting
in a clear oil (209 mg, 72%). 1H-NMR (400 MHz, CDCl3): δ = 7.40–7.11 (m, 60H),
5.09 (d, J = 8.6 Hz, 1H), 5.04–4.87 (m, 7H), 4.80–4.32 (m, 19H), 4.28–4.20 (m, 2H),
4.15 (d, J = 7.5 Hz, 1H), 4.03–3.85 (m, 5H), 3.85–3.58 (m, 9H), 3.57–3.43 (m, 6H),
3.42–3.34 (m, 2H), 3.34–3.27 (m, 2H), 1.55 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ =
171.2, 139.4, 139.4, 139.2, 139.0, 138.7, 138.6, 138.5, 138.3, 138.2, 138.2, 137.6, 128.7,
128.7, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9,
127.9, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 127.4, 127.3, 127.3,
126.5, 104.3, 102.6, 102.5, 101.5, 83.0, 81.8, 81.7, 81.4, 81.1, 80.8, 76.7, 76.5, 76.4, 75.6,
75.2, 75.2, 75.1, 75.1, 74.8 (C×2), 74.6, 73.9, 73.6 (C×2), 73.6, 73.6, 73.5, 73.5, 72.5,
71.8, 71.0, 69.4, 68.6, 68.4, 68.2, 56.1, 23.2.
Benzyl 2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1→2)-3,4,6-tri-O-benzyl-β-D-
galactopyranosyl-(1→4)-2-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranosyl-(1→3)-2,4,6-tri-O-benzyl-β-D-galactopyranosyl-(1→4)-
2,3,6-tri-O-benzyl-β-D-glucopyranoside (90) ♣
1) EDA, tBuOH, reflux
2) Ac2O, Et3N, DMAP, CH2Cl2
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A mixture of 62 (475 mg, 0.207 mmol) and ethylenediamine (5.7 mL, 0.085 mmol) in
t-BuOH (25 mL) was stirred at 100 ◦C for 16 h. The volatiles were removed in vacuo
and co-evaporated with toluene (2×10 mL) then ethanol (10 mL). The residue was
taken up in CH2Cl2(6 mL), and acetic anhydride (2 mL, 0.021 mol), Et3N (4 mL) and
DMAP (25 mg, 0.21 mmol) were added at 0 ◦C and the mixture stirred at rt for 15 h.
The residue was diluted with EtOAc (50 mL), then washed with a saturated aqueous
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solution of NaHCO3 (2×30 mL), H2O (40 mL), dried over MgSO4 end concentrated
in vacuo. The residue was purified by flash column chromatography (deactivated with
Et3N) (SiO2, EtOAc/toluene 1:9) resulting in a clear oil (336 mg, 74%). 1H-NMR (400
MHz, CDCl3): δ = 7.44–7.00 (m, 75H), 5.71 (d, J = 3.6 Hz, 1H), 5.10 (d, J = 8.3
Hz, 1H), 5.05–4.97 (m, 2H), 4.96–4.87 (m, 5H), 4.83–4.71 (m, 5H), 4.70–4.17 (m, 24H),
4.07–3.91 (m, 5H), 3.86 (d, J = 10.4 Hz, 1H), 3.81–3.33 (m, 19H), 3.30–3.23 (m, 1H),
1.47 (s, 3H), 1.27 (d, J = 6.4 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ = 170.1, 139.5,
139.2, 139.1, 138.9, 138.9, 138.8, 138.7, 138.6, 138.5, 138.3, 138.2, 138.0, 137.7, 128.5,
128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8,
127.7, 127.7, 127.6, 127.5, 127.4, 127.4, 127.3, 127.2, 126.9, 126.3, 102.7, 102.6, 101.8,
101.1, 97.6, 84.1, 83.0, 81.9 (C×2), 80.1, 79.4, 78.5, 78.1, 77.5, 77.2, 76.8, 76.6, 76.4,
75.9, 75.8, 75.7, 75.6, 75.3, 75.2, 75.0, 75.0, 74.8, 74.7, 74.3, 73.7, 73.6, 73.6, 73.5, 73.3,
73.3, 73.2, 72.7, 72.5, 72.4, 71.2, 71.0, 68.9, 68.3, 68.3 (C×2), 66.5, 56.4, 23.3, 17.0.
α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-2-acetamido-2-
deoxy-β-D-glucopyranosyl-(1→3)-β-D-galactopyranosyl-(1→4)-β-D-
glucopyranose (55)
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A solution of 90 (140 mg, 0.064 mmol) in THF (5 mL) and MeOH (5 mL) was flushed
thoroughly with argon, whereupon 5% Pd/C (78 mg, 0.037 mmol) and TFA (0.1 mL,
0.0013 mmol) were added. The mixture was subjected to a hydrogen atmosphere
(balloon) at rt for 16 h, filtered through a pad of Celite, and concentrated in vacuo. The
residue was purified by reverse phase dry column chromatography (CH2Cl2/MeOH, 0
to 100% in steps of 10%) resulting in an amorphous solid (53 mg, 99%). 1H-NMR (400
MHz, D2O): δ = 5.30 (d, J = 2.6 Hz, 1H, H-1””), 5.22 (d, J = 3.7 Hz, 0.4H, H-1α),
4.70 (d, J = 8.4 Hz, 1H, H-1”), 4.66 (d, J = 8.0 Hz, 0.6H, H-1β), 4.55 (d, J = 7.8
Hz, 1H, H-1”’), 4.44 (d, J = 7.8 Hz, 1H, H-1’), 4.21 (q, J = 6.6 Hz, 1H, H-5””), 4.14
(d, J = 3.2 Hz, 1H, H-4’), 4.01–3.54 (m, 25H), 3.50–3.42 (m, 1H), 3.32–3.23 (m, 0.6H,
H-2β), 2.04 (s, 3H), 1.22 (d, J = 6.6 Hz, 3H, H-6””). NMR data are in accordance
with literature values.192,193 13C-NMR (100 MHz, D2O): δ = 174.9, 102.9 (C-1’), 102.7
(C-1”), 100.2 (C-1”’), 99.4 (C-1””), 95.7 (C-1β), 91.8 (C-1α), 81.9, 78.3, 78.2, 76.4,
75.8, 75.2, 75.1, 74.8, 74.8, 74.3, 73.8 (C-2β), 73.5, 72.0, 71.6, 71.4, 71.1, 70.1, 70.0,
69.6, 69.1, 68.3 (C-4’), 68.2, 66.9 (C-5””), 61.1, 60.9, 60.0, 60.0, 55.4, 22.2, 15.3. NMR
data are in accordance with literature values.193
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α-L-fucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→3)-2-acetamido-2-
deoxy-β-D-glucopyranosyl-(1→3)-β-D-galactopyranosyl-(1→4)-β-D-
glucopyranose (54)
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THF/MeOH
H2, Pd/C, TFA (cat.)
98%
A solution of 91 (30 mg, 0.014 mmol) in THF (1 mL) and MeOH (1 mL) was flushed
thoroghly with argon, whereupon 5% Pd/C (16 mg, 0.0075 mmol) and TFA (0.05 mL,
0.65 µmol) were added. The mixture was subjected to a hydrogen atmosphere (balloon)
at rt for 16 h, was filtered through a pad of Celite and concentrated in vacuo. The
residue was purified by reverse phase dry column chromatography (CH2Cl2/MeOH, 0
to 100% in steps of 10%) resulting in an amorphous solid (11.5 mg, 98%). 1H-NMR
(400 MHz, D2O): δ = 5.22 (d, J = 3.7 Hz, 0.4H, H-1α), 5.19 (d, J = 4.0 Hz, 1H,
H-1””), 4.70–4.58 (m, 2.6H, H-1β, H1”’, H1”), 4.42 (d, J = 7.8 Hz, 1H, H-1’), 4.29 (q,
J = 6.6 Hz, 1H, H-5””), 4.14 (d, J = 3.2 Hz, 1H, H-4’), 4.04–3.44 (m, 27H), 3.28 (t,
J = 8.5 Hz, 0.6H, H-2β), 2.05 (s, 3H), 1.23 (d, J = 6.6 Hz, 3H).194 13C-NMR (100
MHz, D2O): δ = 174.2, 103.2 (C-1”), 102.9 (C-1’), 100.2 (C-1”’), 99.5 (C-1””), 95.7
(C-1β), 91.8 (C-1α), 81.5, 78.2, 78.1, 77.1, 76.6, 75.2, 75.0, 74.8, 74.3, 73.8, 73.5, 71.8,
71.3, 71.1, 70.2, 69.4, 69.1, 68.6, 68.4, 68.0, 66.5, 61.1, 60.9, 60.4, 60.0, 55.9, 22.1, 15.2.
(35 carbon signals so 3 extra from α/β).
Table 1.3: Glycosylation between various galactose donors and 30
In all cases accept entry 5, prior to glycosylation a mixture of donor and acceptor 30
were co-evaporated with dry toluene (3×3 mL), and subjected to high vacuum 2-16
h (2 h for entry 7–10, 16 h for entry 4 and 6). The mixtures were then dissolved in
CH2Cl2 and stirred under argon with 4 Å MS for 1 h.
Entry 4 See synthesis of 116
Entry 5 Compound 30 (82 mg, 0.16 mmol) and 36 (100 mg, 0.22 mmol) were co-
evaporated with dry toluene (3×3 mL) in separate flasks and subjected to high vacuum
for 16 h. BSP, 36 and sym-collidine (0.1 mL) were dissolved in CH2Cl2 (1 mL) and
Tf2O (68 mg, 0.24 mmol) was added at -40 ◦C. A solution of 30 in CH2Cl2 (1 mL)
was added after 15 min and the solution stirred for 2 h. Both donor and acceptor
decomposed.
Entry 6 Same procedure as entry 4, using NBS (43 mg, 0.24 mmol) instead of NIS.
Both donor and acceptor decomposed.
Entry 7 AgOTf (150 mg, 0.59 mmol) was added to a mixture of 33 (200 mg, 0.49
mmol) and 30 (171 mg, 0.35 mmol) in CH2Cl2 (5 mL) at -30 ◦C, and the mixture was
left to reach rt (4 h). The reaction mixture was washed with 1M HCl (50 mL), H2O
(50 mL), saturated aqueous NaHCO3 (50 mL), dried over MgSO4 and evaporated to
dryness. Donor decomposed and acceptor reisolated.
Entry 8 AgOTf (62 mg, 0.24 mmol) was added to a mixture of 36 (129 mg, 0.20
mmol) and 30 (80 mg, 0.16 mmol) in CH2Cl2 (2.5 mL) at -30 ◦C. The mixture was
left to reach rt and stirred for 16 h. Filtered through Celite, washed with a 10% aqueous
solution of Na2S2O3 (20 mL), H2O (30 mL), dried over MgSO4 and concentrated un-
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der reduced pressure. Purified by flash column chromatography (SiO2, EtOAc/heptane
2:3). Donor decomposed and acceptor reisolated.
Entry 9 Ag2CO3 (74 mg, 0.27 mmol) was added to a mixture of 36 (129 mg, 0.20
mmol) and 30 (80 mg, 0.16 mmol) in CH2Cl2 (2 mL) at -60 ◦C. The mixture was left
to reach rt and stirred for 16 h. No reaction occured.
Entry 10 Ag2O (70 mg, 0.3 mmol) was added to a mixture of 36 (129 mg, 0.20 mmol)
and 30 (80 mg, 0.16 mmol) in CH2Cl2 (2 mL) at -30 ◦C. The mixture was left to reach
rt and stirred for 60 h. No reaction occured.
Entry 12 See synthesis of 49
Entry 13 See synthesis of 51
Table 1.4: Glycosylation between various galactose donors and 53
In all cases, prior to glycosylation a mixture of donor and acceptor 53 was co-evaporated
with dry toluene (3×3 mL) and subjected to high vacuum for 16 h.
Entry 1 TfOH (11 mg, 0.07 mmol) was added to a mixture of 32 (169 mg, 0.27
mmol), 53 (107 mg, 0.22 mmol) and NIS (75 mg, 0.33 mmol) in CH2Cl2 (2 mL) at
-30 ◦C. Quenched with Et3N and purified by flash column chromatography (SiO2,
EtOAc/heptane 2:3). Donor reisolated and acceptor decomposed.
Entry 2 Me2S2-Tf2O (0.45 mL, 0.45 mmol) was added to a mixture of 32 (169 mg,
0.27 mmol) and 53 (107 mg, 0.22 mmol) in CH2Cl2 (2 mL) at -20 ◦C. The reaction
mixture was quenched with Et3N after 2 h of stirring and was washed with 1M HCl (50
mL), H2O (50 mL), saturated aqueous NaHCO3 (50 mL), dried over MgSO4 and evap-
orated to dryness. Purified by dry column chromatography (SiO2, EtOAc/heptane, 0
to 90% in steps of 6%). Product could be identified as a Gal-Glc dimer with a pentanyl
in the reducing end.
Entry 3 Same procedure as entry 2, utilizing 31 (106 mg, 0.23 mmol) and 53 (75
mg, 0.19 mmol) and Me2S2-Tf2O (0.23 mL, 0.23 mmol). Both donor and acceptor
decomposed.
Entry 4 Same procedure as entry 7 in Table 1.3, employing AgOTf (62 mg, 0.24
mmol), 33 (100 mg, 0.24 mmol) and 53 (75 mg, 0.16 mmol) in CH2Cl2 (2.5 mL).
Donor decomposed and acceptor reisolated.
Table 1.5 Glycosylation between 60 and 61 employing different promotors.
In all cases accept for entry 2, prior to glycosylation a mixture of donor 60 and acceptor
61 was co-evaporated with dry toluene (3×3 mL) and subjected to high vacuum for 16
h.
Entry 1 Compound 60 (118 mg, 0.20 mmol) and 61 (110 mg, 0.19 mmol) were dis-
solved in CH2Cl2 (2 mL) and stirred under argon with 4 Å MS for 1 h. The mixture
was cooled to -40 ◦C, NIS (48 mg, 21 mmol) and AgOTf (cat.) were added. The
solution was stirred for 1 h, quenched with Et3N and stirred for 15 min followed by
evaporation in vacuo. Purified by dry column chromatography (SiO2, acetone/toluene,
0 to 50% in steps of 2.5%). Yield of 77: 94 mg, 44%.
Entry 2 Compound 60 (118 mg, 0.20 mmol) and 61 (100 mg, 0.18 mmol) were co-
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evaporated with dry toluene (3×3 mL) in separate flasks and subjected to high vacuum
for 16 h. Compound 60 in CH2Cl2 (1 mL) was added over 5 min to a solution of 61,
NIS (48 mg, 21 mmol) and AgOTf (cat.) at -40 ◦C. Purified as entry 1. Yield of 77:
44 mg, 22%.
Entry 3 Compound 60 (118 mg, 0.20 mmol) and 61 (100 mg, 0.18 mmol) were dis-
solved in CH2Cl2 (2 mL) and stirred under argon with 4 Å MS for 1 h. The mixture
was cooled to -30 ◦C, NIS (48 mg, 0.21 mmol) and TESOTf (5.3 mg, 0.02 mmol) was
added and the mixture was stirred for 80 min. Purified as entry 1. Yield of 77: 68
mg, 32%.
Entry 4 TfOH (3.6 mg, 0.04 mmol) was added to a mixture of 60 (120 mg, 0.20
mmol), 61 (110 mg, 0.19 mmol) and NIS (51 mg, 0.23 mmol) in CH2Cl2 (2 mL) at -50
◦C. The mixture was left to reach -20 ◦C, and was purified as entry 1. Yield of 77: 71
mg, 34%.
Entry 5 See synthesis of 77
Entry 6 Same procedure as entry 5, but TTBP (49, 0.20 mmol) was added prior to
addition of MeOTf. Yield: 61 mg, 33%.
Entry 7 Same procedure as entry 5, but the mixture was left to reach rt and stirred
for 16 h. Decomposition of both donor and acceptor.
Entry 8 Same proceedure as entry 2 in Table 1.4, utilizing 60 (125 mg, 0.21 mmol),
61 (108 mg, 0.19 mmol) and Me2S2-Tf2O (0.38 mL, 0.38 mmol). Both donor and
acceptor decomposed.
Table 1.6: Glycosylation between 61 and 80 employing different
promotors.
Entry 1 Same proceedure as entry 5 in Table 1.5, utilizing 61 (150 mg, 0.26 mmol)
and 80 (198 mg, 0.34 mmol). Yield 81: 142 mg, 52%.
Entry 2 Same proceedure as entry 3 in Table 1.5, utilizing 61 (195 mg, 0.34 mmol)
and 80 (216 mg, 0.40 mmol). Yield 81: 60 mg, 17%; mix 81 and 82: 127 mg, ∼36%.
Entry 3 Same proceedure as entry 1 in Table 1.5, utilizing 61 (150 mg, 0.26 mmol)
and 80 (167 mg, 0.31 mmol). Yield 81: 116 mg, 42%; mix 81 and 82: 94 mg, ∼34%.
Table 1.7: Attempts at synthesizing disaccharide 94
In all cases, prior to glycosylation a mixture of donor and acceptor 46 was co-evaporated
with dry toluene (3×3 mL) and subjected to high vacuum for 2 h.
Entry 1 AgOTf (96 mg, 0.38 mmol) was added to a mixture of 46 (96 mg, 0.24 mmol)
and 95 (128 mg, 0.25 mmol) in THF (2 mL) at -10 ◦C. The mixture was allowed to
reach rt, and stirred at rt for 48 h. Quenched with Et3N and starting materials were
isolated after flash column chromatography.
Entry 2 Ag2O (88 mg, 0.38 mmol) was added to a mixture of 46 (96 mg, 0.24 mmol)
and 95 (128 mg, 0.25 mmol) in THF (2 mL) at -10 ◦C. The mixture was allowed to
reach rt, and stirred at rt for 48 h. Quenched with Et3N and starting materials were
isolated after flash column chromatography.
Entry 3 To a solution of 46 (100 mg, 0.25 mmol) and 96 (175 mg, 0.32 mmol) in
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THF (2 mL) were added NIS (76 mg, 0.34 mmol) and TESOTf (9 mg, 0.034 mmol) at
-10 ◦C. The mixture was allowed to reach rt, and stirred at rt for 24 h. Both donor
and acceptor decomposed.
Table 1.8: Ester hydrolysis of 115
A mixture of 115 (0.10 g, 0.23 mmol) and the base (0.01–0.10 M) in the solvent was
stirred for 0.5–2.0 h cooled to 0 ◦C and neutralized with Amberlite IR-120 H+by stirring
for 20 min, filtered end concentrated. 1H-NMR was recorded of the crude mixture.
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Synthesis of Potential Protein Bcl-XL
Antagonists by Regioselective Ring Opening
Reactions of Enantiopure Oxabicycles
This chapter will introduce transition metal-catalyzed enantioselective and regioselective
ring opening reactions of oxabicycles mainly by carbon-carbon bond formations. These
methods will be utilized for synthesis of potential protein Bcl-XL antagonists.
2.1 Antiapoptotic protein Bcl-XL a potential drug target for
cancer
Physiological or programmed cell death generally occurs by apoptosis, and when apop-
tosis is dysregulated it can contribute to many diseases, including cancer, autoimmunity
and neurodegenerative disorders.195 A reasonable estimate is that either too little or
too much cell death contributes to half of the main medical illnesses for which ad-
equate therapy is lacking. Consequently, a great interest in development of selective
modulation of the apoptotic machinery has been the goal for more than two decades.196
The two apoptosis pathways of interest when looking for new drugs are the ex-
trinsic pathway and the intrinsic pathway. The extrinsic pathway operates through
cell-surface death receptors, and the intrinsic pathway is controlled by the Bcl-2 family
of proteins and involves the disruption of mitochondrial membrane integrity in response
to cellular insults or other danger signals. The Bcl-2 family of proteins consists of pro-
and anti-apoptotic members, which regulate apoptosis by maintaining or disrupting
the outer mitochondrial membrane. Upregulation of antiapoptotic members of this
family including Bcl-XL is observed in many cancers. This overexpression protects
the cancer cells from the activation of apoptosis, favoring their proliferation and their
survival to the anticancer compounds. Thus suppressing or inhibiting one or more of
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the Bcl-2 family proteins may decrease cancer cell survival and cause cancer cell death
instead.197 A wide range af gene transfer, peptide inhibitor, antisense and other types
of experiments have proven that Bcl-2 and Bcl-XL have a role in preventing tumor cell
apoptosis.198
Experimental three-dimensional structures of some antiapoptotic proteins have shown
the presence of a hydrophobic surface groove, formed by the Bcl-2 BH1, BH2 and BH3
regions (homology 1, 2 and 3), this is called the BH3 binding groove. This hydrophobic
cleft constitutes the binding cavity for the proteins that promote apoptosis, such as
Bax and Bak.199 For proteins that promote cell death, only the BH3 region is required
for activity.200,201
Several research groups have identified potent inhibitors of Bcl-2 and Bcl-XL. One
inhibitor worth mentioning is the natural compound Gossypol (see Scheme 2.1), a con-
stituent of the cotton plant Gossypium.202 However, several side effects of Gossypol
limit its usefulness in using it as a proapoptotic drug. These side effects are probably
due to Schiff’s base-type reactions between the aldehydes on Gossypol and primary
amines of proteins and nucleic acids making Gossypol less stable in vivo. Thus modifi-
cations of Gossypol were made to eliminate the undesired side effects one such analog is
Apogossypol (see Scheme 2.1), which displays a proapoptotic activity in the hydropho-
bic groove on the surface of Bcl-XL. The residues most affected by Apogossypol binding
are located in the same pocket of Bcl-XL, which is known to bind the BH3 peptides of
endogenous Bcl-XL antagonist proteins. Apogossypol also showed cytotoxicity against
primary leukemic cells freshly isolated from patients affected by chronic lymphocytic
leukemia, which indicates potential applications of selective Bcl-2/Bcl-XL antagonists
as chemosensitizers.198
HO
HO
O
HO
OH
O
OH
OH
HO
HO
HO
OH
OH
OH
NaOH 40 %
Heating
Gossypol Apogossypol
Scheme 2.1: Structures of Gossypol and Apogossypol
The group of Andrea Basso have applied diversity orientated synthesis to a library
of enantiopure oxabicyclic substrates creating a small library of compounds, which was
subjected to a combined docking-NMR spectroscopy aterative approach leading to the
identification of novel potential inhibitory scaffolds against Bcl-XL.199 Some of the
most promissing results were found in products generated from metal catalyzed ring-
opening of enatiopure oxabicycles. Initial docking studies of compound 1 in Figure 2.1
and similar coumpounds showed that the pyridine ring seems to be able to establish
cation-pi interactions with the Arg143 side chain, and the CH2OH group seems to form
hydrogen bonds with NH(CO) of Gly142 and with the Arg143 side chain of Bcl-XL. As
no hydrogen bonding between the pyridine nitrogen and the protein was observed, this
functional group can be substituted by a phenyl ring. The benzyl group and/or phenyl
ring in 1 was not directly involved in interactions with the protein, and these groups
could therefore be removed and/or substituted with a different group without affecting
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Figure 2.1: Structure of compound 1 used for docking studies
the activity but presumably resulting in compounds with increased solubility.199
This work will be further elaborated upon in section 2.2.3, as it was the starting
point for the studies performed in the Mark Lautens group in collaboration with the
Andrea Basso group.
2.2 Transition metal-catalyzed ring opening reactions of
heterobicyclic alkenes
During the past 30 years there has been a drastic growth in the use of transition
metal catalysts in synthetically important organic transformations.203–206 One area,
which has been widely explored since the end of the 1990th is the metal-catalyzed
ring opening of heterobicyclic alkenes. These reactions can be carried out with a
wide range of nucleophiles including hydride, stabilized and nonstabilized carbanions,
alcohols, amines, and carboxylates. The transition metals employed in the ring-opening
reactions are mainly copper, nickel, palladium, iridium and rhodium since these metals
have led to a wide range of selective ring-cleaving reactions generating products in high
yield with varying enantiomeric excess (ee) and diastereomeric ratio (dr).206
Three areas of research that have been investigated is, firstly, to utilize desym-
metrization reactions of heterobicyclic meso compounds, secondly, asymmetric ring
opening of racemic oxabicyclic alkenes and thirdly, regioselective ring opening of enan-
tiopure oxabicycles. Much work have been done on the desymmetrisation reaction of
meso compunds whereas the regioselective ring opening of enantiopure oxabicycles is a
field which has hardly been explored.
The advances within the field of metal-catalyzed reactions have led to the discovery
of new reactions that control the relative and absolute stereochemistry in cyclic and
acyclic compounds. It is an efficient way to create new compounds containing many
stereocenters in one step. These methods are of interest within drug discovery as many
of the drugs known today contain alternating stereocenters.
2.2.1 Enantioselective ring opening desymmetrization reactions of
meso compounds
The ring opening chemistry of oxabicyclic compounds underwent significant growth in
the late 1970s as a result of the development of new methods to assemble the [3.2.1]
core207 and advances in the Diels-Alder reactions with furans.208,209 Moreover, the
oxabicyclic template has become increasingly common as a starting material in the
preparation of both cyclic and acyclic compounds.206,210,211 A lot of effort has been put
into obtaining enantiomerically pure products from oxabicyclic precursors, including
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Scheme 2.2: First reported enantioselective ring opening of an oxabicyclic alkene.
strategies of diastereo- or enantioselective cycloaddition with furan,212,213 chemical
and enzymatic esterification of meso oxabicycles,214–216 and lastly, desymmetrization
by ring opening of meso oxabicycles and azabicycles, which is the field of research
explored in this thesis.
The first ring opening of the oxabicyclic system was reported in 1971, where Caple
and co-workers opened an oxabenzonorbornadiene using BuLi and alkyl nucleophiles.217
It was not before 1995 that examples of highly enantioselective ring opening reactions
of oxabicyclic alkenes were reported. Here oxabicycle 2 was treated with a palla-
dium(0)complex with various phosphine ligands (Scheme 2.2) and phenyl iodide or
phenyl triflate as nucleophiles. The highest ee was observed using phenyl triflate as
nucleophile with a Pd/BINAP complex. Here the minor product 3, arising from car-
bopalladation and subsequent β-oxygen elimination was generated in 13% yield with
a 96% ee. The major product 4, arising from carbopalladation without following β-
oxygen elimination, was obtained in 71% yield with a 64% ee. Using phenyl iodide and
a Pd/(S,S)-Chiraphos complex the product 3 could be isolated as the only product,
but in a low yield and close to be a racemic mixture of isomers.218
Since then asymmetric ring opening of oxabicycles has been well studied in many
research groups giving the field a broad range of useful metals and nucleophiles. The
OH
boronic acid or 
ester nucleophiles
R
Pd(II) or Rh(I) cat.
chiral ligand
RB(OR)2
OH
alkylzinc/Grignard nucleophiles
R
Cu(I)/Cu(II) cat.
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R2Zn or RMgBr
OH
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R
Pd(II) cat.
(S)-Tol-BINAP
R2Zn
OH
heteroatom nucleophiles
X
X = F, OR, NR2, SR
Rh(I) cat.
Josiphos ligand
RXH
OH
Ni(0) cat.
(S)-BINAP
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(S)-Tol-BINAP
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HOAr
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O
Figure 2.2: Catalysts and nucleophiles used for asymmetric ring opening of oxabicycles.
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most efficient catalysts for the asymmetric ring opening of oxabicycles till date are cop-
per,219–222 iridium,223 nickel,224–228 palladium206 and rhodium206, as they each give
rise to high yield and enantioselectivity with a given set of nucleophiles. The most
utilized nucleophiles span from a hydride source,224–226 through alcohols,229–231 and
amines,229,232–234 to the recently employed fluoride235 nucleophile. For products with
C-C bond formation alkylzinc219,236–238, and boronic acid/ester239,240 nucleophiles
have been most successful tried (Figure 2.2). As the desired nucleophiles for this study
are boronic acid or ester nucleophiles, only prior work using these nucleophiles with
palladium and rhodium catalysis will be further reviewed.
2.2.2 Asymmetric ring opening with boronic acids and boronic
esters
Tremendous success has been achieved in the rhodium-catalyzed asymmetric 1,4-conju-
gate addition of organoboronic acids to electron-deficient olefins with significant ad-
vances gained since the first paper by Miyaura.241 Highly enantioselective conjugate
addition of boronic acids to olefins have been reported by Hayashi242 where a common
step is the carborhodation of the carbon-carbon double bond followed by hydrolysis of
the organorhodium intermediate. This work established the basis for the rhodium cat-
alyzed addition of an organoboron reagent to one of the two enantiotopic olefinic carbon
atoms of an oxabicyclic substrate followed by β-elimination instead of hydrolysis.239
Excellent results were obtained for the addition of a wide variety of arylboronic acids
to 5 in the presence of a [Rh(COD)Cl]2/PPF(tBu)2 catalytic system. It was found that
the enantioselectivity of the asymmetric ring opening reaction increases with decreasing
temperature. Also the reaction is faster when an excess of base is used, which is in
agreement with the hypothesis that the use of base accelerates the transmetalation of
the boronic acid to palladium in a Suzuki reaction.243 The reaction requires a minimum
amount of water for catalytic turnover and 1.2 eq. of ArB(OH)2 is necessary for full
conversion. They found the optimal conditions to be treatment of 5 with 2.5 mol%
[Rh(COD)Cl]2, 5.0 mol% PPF(tBu)2, 1.2 eq. of the arylboronic acid, and 0.5 eq. of
Cs2CO3 (5.0 M in H2O) in THF at room temperature (scheme 2.3). Ring opening of
oxabicycle 5 works equally well with both electronrich and electronpoor arylboronic
acids, but it lacks the skill to perform the ring opening with ortho substituents on the
boron-phenyl ring.
Applying the same conditions as used for 5 to the asymmetric ring opening of 7
leads to a complex mixture of products. Much better results were optained changing
the arylboronic acid to the corresponding ethylene glycol ester. The yield was improved
(1.2 eq.)
B(OH)2
6a: R= 4-Me,  88%, 95% ee
6b: R= 3-Cl, 73%, 99% ee
6c: R= 4-Ac, 71%, 94% ee
6d: R= 3-OMe, 91%, 95% ee
O
OMe
OMe
OH
OMe
OMe[Rh(COD)Cl]2 (2.5 mol %) 
R,S-PPF-P(tBu)2 (5 mol %) 
Cs2CO3 (5M) in H2O (0.5 eq) 
THF, rt.
R
5
R
Scheme 2.3: Asymmetric ring opening reactions of 5 with arylboronic acids.
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R,S-PPF-P(tBu)2 (5 mol %) 
Cs2CO3 (5M) in H2O (0.5 eq) 
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(1.2 eq.)
B(OH)2 B
O
O
or
8a 8b
7 9a: 20%, 93% ee
9b: 78%, 92% ee
Scheme 2.4: Asymmetric ring opening reaction of 7.
from 20% to 78% using the ethylene glycol ester without loosing the selectivity (Scheme
2.4).239
As a challenge the amount of enantiopure oxabicycles provided by the Basso group
was relatively small (30 mg - 500 mg), hence preliminary studies was carried out on
3 meso compounds to ensure that the same results as those described above could be
achieved. Two of the oxabicycles attempted desymmetrized was the well described ox-
abicycles 5 (Scheme 2.3) and 7 (Scheme 2.4). The third oxabicycle (exo-cis-dimethyl-
7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate) 10 had not been exposed to desym-
metrization reactions before and was chosen to ensure the reaction conditions would
work in the presense of a methylester residue. For all reactions the boronic ester 8b
was used. In this case the ring opening of 5 and 7 gave similar results as those re-
ported.239 The ring opening of 10 proceeded faster than for both 5 and 7 with a ratio
between the two enantiomers 11 and 12 of 4:1 (determined by 1H-NMR) and in good
yield (Scheme 2.5). These results proved that the reaction conditions could be used for
oxabicycles containing an ester moiety.
The proposed mechanism for the asymmetric ring opening of oxabicyclic alkenes
is given in scheme 2.6. The first step involves a transmetalation of the arylboronic
acid to a rhodium(I)chloride or hydroxide to generate arylrhodium complex 13, which
then undergoes an exo-selective asymmetric carborhodation at the oxabicycle olefin to
generate an organorhodium intermediate, 14. Rhodium chelation of the olefin and the
oxygen atom of the oxabicycle may help to contribute to the high exo selectivity. β-
hydride elimination is not possible, as a result, β-oxygen elimination occurs to generate
the ring opened rhodium alkoxide intermediate 15, which upon hydrolysis liberates the
product and regenarates the catalyst.239
Difficulties with the asymmetric ring opening of oxabicyclic alkenes using het-
eroarylboronic acids and a rhodium catalyst have been observed, as this leads to un-
opened addition products as well as oligomeric products.240 An example of this is the
ring opening of 7 with furan-3-boronic acid, which gave the desired product 16 in only
+
11 12
O
CO2Me
OH
CO2Me
CO2Me
CO2Me
OH
CO2Me
CO2Me
[Rh(COD)Cl]2 (2.5 mol %) 
R,S-PPF-P(tBu)2 (5 mol %) 
Cs2CO3 (5M) in H2O (0.5 eq) 
THF, rt.
(1.2 eq.)
B
O
O
8b
10 4:1
70%
Scheme 2.5: Asymmetric ring opening of 10.
86Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
Stereoselective ring opening reactions of enantiopure oxabicycles
P
P
Rh X
ArB(OH)2
X = Cl or OH
P
P
Rh Ar
O
H2O
XB(OH)2
O
O
Ar
Rh
P
P
Rh
P
P
Ar
OH
Ar
*
*
*
*
13
14
15
Scheme 2.6: Propossed mechanism for rhodium catalyzed asymmetric ring opening
reactions with arylboronic acid nucleophiles.
16% yield with 96% ee (Scheme 2.7). It might be possible to circumvent this problem
using the corresponding ethylene glycol ester, however a palladium catalyst was used
as an alternative in this case. Lautens and co-workers used a Pd(II) catalyst with
Tol-BINAP as ligand to open 7 with furan-3-boronic acid, which enhanced the yield
from 16 % to 82% yield but lowered the ee to 71% (Scheme 2.7). They observed poor
enantioselectivities with the ferrocene-based ligands and a palladium catalyst, which
gives excellent enantioselectivities in the analogous rhodium-catalyzed reactions.240
O
[Rh(COD)Cl]2 (2.5 mol %) 
S,R-PPF-P(tBu)2 (5 mol %) 
Cs2CO3 (5M) in H2O (0.5 eq) 
THF, rt.
O
7
7
B(OH)2
O (1.2 eq.)
B(OH)2
O (1.2 eq.)
OHO
OHO
[Pd(Tol-BINAP)OH]2
2+(OTf)-2 (2.5 mol%) 
Cs2CO3 (5M) in H2O (0.5 eq)
 MeOH, rt
16 (16%, 96% ee)
16 (82%, 71% ee)
Scheme 2.7: Ring opening of 7 with furan-3-boronic acid using a Pd(II) or Rh(I)
catalyst.
2.2.3 Stereoselective ring opening reactions of enantiopure
oxabicycles
As can be seen from the previous sections enantioselective ring opening desymmetriza-
tion reactions of meso compounds have been widely explored, however regioselective
ring opening of enantiopure oxabicycles is a field that is still to be investigated more
thoroughly. The aim of the project in hand was to find a general method for regiose-
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Figure 2.3: Enantiopure oxabicycles for stereoselective ring opening.
lective transition metal catalyzed ring opening of the enantiopure oxabicycles (shown
i Figure 2.3) provided by the Basso group. Important features, which makes this
work novel, are, firstly, the possibility for various functional groups attached to these
substrates interfering with the reaction, secondly, as the bicyclic system is non symmet-
rical two distinct regioisomeric products should be possible to synthesize. In addition
to this, because of the intrinsic chiral information in the substrates the need for an
enantioselective catalyst should theoretically relinquish.
Prior to the collaboration between the Lautens group and the Basso group some
work had been done by Basso et al.,244 as they tried to open their synthesized enan-
tiopure oxabicycles by metal catalysis. The ring opening was investigated using two
different catalytic systems, one with a nickel/zinc catalyst and another using a palla-
dium catalyst. When they used Ni(PPh3)2Cl2, zinc dust, 3-iodoanisole in acetonitrile
at 50 ◦C for the ring opening of 30, they obtained a 60% yield of a 1:1 mixture of the
O
CO2Me
N
N
H
O
Bn MeO I Ni(PPh3)2Cl2Zn, MeCN
50 oC
N
N
H
Bn
CO2Me
N
O
N
H
Bn
CO2MeOH
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MeO
MeO
N
N
H
O
Bn
MeO2C
++
30
31 32 33
+
Scheme 2.8: Ring opening of 30 using a nickel catalyst.
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Scheme 2.9: Ring opening of 34 using a palladium catalyst.
regioisomers 31 and 32 (Scheme 2.8). Besides the none excisting selectivity another
problem is the stability of substrate 30 to the moderately high temperatures required,
as the retro Diels-Alder adduct 33 was isolated in 10% yield.
To disfavor the retro Diels-Alder process the ester moiety was reduced to the alcohol,
diminishing the strong electron withdrawing properties, thus kinetically disfavoring
the retro cycloaddition process. Using the same conditions as used in scheme 2.8
on the altered oxabicycle 34 no reaction took place. Changing the catalytic system
to [Pd(C6H5CN)2]Cl2, 1,3-bis(diphenylphosphino)propane, phenylboronic acid and an
aqueous solution of Cs2CO3 in methanol at 60 ◦C resulted in the regioisomers 35 and
36 in 80% yield as a 7:3 mixture favoring 36 (Scheme 2.9).
These reaction conditions were utilized for similar oxabicycles and the outcome of
these studies revealed that the reaction was highly substrate dependent. In one case
only one regioisomer was isolated whilst other substrates yielded cyclic boronates as
37 (Figure 2.4) and similar, which could be hydrolyzed into the expected regioisomer.
Using a 3-pyridylboronic acid as nucleophile instead of the phenylboronic acid did not
result in a cyclic boronate. The explanation why cyclic boronates is only formed in some
cases is supposedly the specific conformations adopted by the cyclohexenol derivative
along with the reactivity of the boronic acids employed.
What is worth noting in these results is that the substituents of the bicyclic moiety
could not direct the ring opening process to the selective formation of one regioisomer.
Hence a solution might be to utilize an enantioselective catalyst.
Excellent results of regioselective ring opening of enantiopure oxabicycles were
achieved by Webster et al.246 using methanol as nucleophile. Here they employed
a Rh(COD)2OTf catalyst and a josiphos ligand in THF at 80 ◦C resulting in the ring
opening of 38. One regioisomer was isolated exclusively in each case in high yield with
retained ee (Scheme 2.10). When the (R,S)-PPF(tBu)2 was employed 39 was the only
product isolated and changing to (S,R)-PPF(tBu)2 40 was the only product isolated.
These results imply that the enantiomeric ligand overrides the inherent preference of
the substrate.
N
Bn
N
H
Bn
O
Ph
Bn O
O
B
Ph
37
Figure 2.4: Structure of a cyclic boronate isolated after reactions where the same
conditions as in Scheme 2.9 was used.
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Scheme 2.10: Enantiopure oxabicycles for stereoselective ring opening.
In the present study oxabicycle 17 was chosen for the first attempts of stereoselective
ring opening of oxabicycles 17–29. As the ring opening of 10 showed encouraging
results the same conditions were employed for the ring opening of 17. Using the (S,R)-
PPF(tBu)2 ligand compound 41 was isolated in 61% yield as a crystaline compound,
and a crystal structure was recorded to prove the stereochemistry, shown in Figure 2.5.
Whereas using the (R,S)-PPF(tBu)2 ligand compound 42 was isolated in 66% yield
as an oil. To find the ratio between 41 and 42 a small sample of the crude reaction
mixture was taken out for the two reactions. The two reaction mixtures were analyzed
by HPLC giving the regioselectivities of the two diasteriomers shown in Scheme 2.11.
Figure 2.5: Crystal structure of 41.
The ring opening occurred with syn stereoselectivity, as a result of exo attack of
the nucleophile on the oxabicyclic unit, and is in accordance with the literature.206
The selectivity of the attack with regard to the two carbon atoms in the alkene is the
same as observed for other oxabicyclic ring opening reactions where a josiphos ligand
is used. This result supports the discoveries made by Webster et al.246 implying that
the enantiomeric ligand overrides the inherent preference of the substrate.
Unfortunately implementing the same reaction conditions on the enantiomer 18 was
unsuccesful. Alternating catalysts, ligands and solvents were employed to overcome
this puzzling problem. As shown in Tabel 2.1, when using a Pd(II) catalyst and a
Tol-BINAP ligand the regioselectivity is lovered remarkably, but the yield is increased
(entry 7). Methanol was tried as a solvent since earlier studies had shown a faster
reaction herein compared to THF,240 thereby making it possible to run the reaction
at lover temperatures and possibly giving higher enantioselectivity. This did not result
in an improvement with the Rh catalyst as no product formation was observed (entry
3). The best results was obtained by using the initial reaction conditions as used for
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Scheme 2.11: Regioselective ring opening of oxabicycle 17.
17 while raising the temperature to 50 ◦C. Under these conditions the regioselectivity
for each product (43 and 44) was 19:1 using either the (R,S)-PPF(tBu)2 or (S,R)-
PPF(tBu)2 ligand (entry 9 and 10). As expected the enantiomer of 41 (compound
43) was a crystaline product and was formed using (R,S)-PPF(tBu)2 instead of (S,R)-
PPF(tBu)2. Similar findings was valid for the enantiomers 42 and 44, which were both
isolated as oils.
Table 2.1: Optimization of the regiooselective ring opening of 18.
O H
N O
O
O
OO
H
N O
O
O
O
O
OH
Ph
H
N O
O
O
O
O
OH
Ph
18
Cat., Ligand
Cs2CO3 (5M, aq.) (0.5 eq.)
solvent, temp.
(1.2 eq.)Ph
B
O
O
43 44
+
8b
# Catalyst Ligand % cat./lig Temp. Yield [%] 43:44
1a [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 5/10 rt N.R. –
2a [Ir(COD)Cl]2 (R,S)-PPF(tBu)2 5/10 50 ◦C N.R. –
3b [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 5/10 rt N.R. –
4a [Rh(COD)I]2 (R,S)-PPF(tBu)2 5/10 50 ◦C Decomp. –
5a Pd(MeCN)2Cl2 (R,S)-PPF(tBu)2 10/10 rt 84 78:22
6b Pd(MeCN)2Cl2 (R,S)-PPF(tBu)2 10/10 0 ◦C Decomp. –
7b Pd(MeCN)2Cl2 R-Tol-BINAP 10/10 rt 95 60:40
8a [Rh(COD)Cl]2 R-Tol-BINAP 5/10 rt N.R. –
9a [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 5/10 50 ◦C 69 95:5
10a [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 5/10 50 ◦C 65 5:95
a THF b MeOH
Moving to oxabicycles with an alchohol moiety instead of an ester moiety on the
oxabicyclic ring (19, 20 and 21) turned out to be more challenging (table 2.2). No re-
action was observed at room temperature independently on each sustrate and catalyst,
entry 1, 4, 10 and 14 in Table 2.2. Running the reaction at 50 ◦C yielded A in low
yield (29%) using the (R,S)-PPF(tBu)2 ligand (entry 2) and B was isolated in 33%
yield using the (S,R)-PPF(tBu)2 ligand (entry 5). Unfortunately, the results were not
reproducible, as a second reaction only resulted in isolation of starting material, which
also turned out to be the case when running the reaction at 70 ◦C (entry 3). Changing
the catalyst to [Rh(COD)OH]2 made it possible to get reproducible ring opening of
the oxabicycle 19, unfortunately, still in very low yields (entry 7 and 8). This could
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Table 2.2: Trials of stereoselective ring opening of 19, 20 and 45.
Catalyst (5 mol%) 
Ligand (10 mol%)
THF, temp.
or8a 8b
O
N
N
H
R2
HO
Bn O
R1
N
N
H
R2
Bn O
R1
OH
Ph
OH
N
N
H
R2
Bn O
R1
OHOH
Ph
+
A B19: R1 = R2 = Bn
20: R1 = Ph,  R2 = Bn
45: R1 = iPr, R2 = Cy
# Sub. Catalyst Ligand Temp. Nu. (eq.) yield [%]
1 19 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 rt 8b (1.2 eq.) N.R.
2 19 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 50 ◦C 8b (1.2 eq.) 29 (A)
3 19 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 70 ◦C 8b (1.2 eq.) N.R.
4 19 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 rt 8b (1.2 eq.) N.R.
5 19 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 50 ◦C 8b (1.2 eq.) 33 (B)
6 19 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 50 ◦C 8b (2.2 eq.) N.R.
7 19 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 50 ◦C 8a (1.2 eq.) 20 (A)
8 19 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 80 ◦C 8a (2.0 eq.) 24 (A)
9 19 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 50 ◦C 8b (1.2 eq.) Decomp.
10 20 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 rt 8b (1.2 eq.) N.R.
11 20 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 35 ◦C 8b (1.2 eq.) N.R.
12 20 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 rt 8b (1.2 eq.) N.R.
13 20 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 80 ◦C 8a (2.0 eq.) N.R.
14 45 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 rt 8b (1.2 eq.) N.R.
15 45 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 50 ◦C 8b (1.2 eq.) Decomp.
nevertheless, not be employed for ring opening of neither oxabicycle 20 nor 45, hence it
seemed impossible to use a rhodium catalyst here (entry 10–15). It was suspected that
a problem might be interaction between the boron nucleophile and the alcohol moiety
on the oxabicycle, however increasing the quantity of nucleophile to two eqvivalents
did not result in a noteworthy increase in the yield (entry 6, 8 and 13). Since alco-
hols can be used as nucleophiles in asymmetric ring opening reactions with a rhodium
catalyst,229,230 a compeeting reaction could take place. The alcohol could either react
inter- or intramolecular, as heteronucleophiles attack from the endo face and not from
the exo face like phenylboron nucleophiles. Therefore the alcohol is placed in a position
making an intramolecular ring opening possible creating a new oxabicyclic compound;
an intramolecular attack, which to my knowledge has not been reported in literature
with any rhodium catalyst.
These findings reinforced our suspicion that the alcohol moiety was problematic for
the employed reaction conditions. Therefore, the research was continued by screening of
the oxabicycles with a t-butyldimethylsilyl (TBDMS) protecting group on the alcohols
(compounds 22-29 in Figure 2.3). It became evident after a few trials that a TBDMS
protecting group was not suitable for the reaction conditions (Table 2.3). As none of
the three different rhodium catalysts tried were able to catalyze the ring opening of 25
and 27. Using [Rh(COD)Cl]2 only starting material could be detected by NMR (entry
1) whereas [Rh(COD)OH]2 and Rh(COD)2OTf also led to some decomposition of the
starting material (entry 2-4). When using [Rh(COD)OH]2 at 50 ◦C some TBDMS
deprotected oxabicycle could be detected by NMR, while none was observed at 80 ◦C.
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Table 2.3: Trials of stereoselective ring opening of 25 and 27.
O
N
N
H
Cy
TBDMSO
Bn O
O
N
N
H
Bn
OTBDMS
O
Bn
2725
or
Cy
Catalyst (5 mol%) 
Ligand (10 mol%)
THF, temp.
or8a 8b
# Sub. Catalyst Ligand Temp. Nu.(eq.) Comment
1 25 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 50 ◦C 8b (1.2) N.R.
2 25 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 50 ◦C 8b (1.2) decomp.a
3 25 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 80 ◦C 8a (2.0) decomp.
4 27 Rh(COD)2OTf (S,R)-PPF(tBu)2 50 ◦C 8b (1.2) decomp.
a TBDMS deprotection observed
As no promissing results could be achieved for oxabicycles 19, 20 and 45 deprotection
of the TBDMS-group is undesired. Another problem with the TBDMS-group is the
size as it is a bulky group, which might prevent the ring opening to take place. Hence
a new and smaller protecting group might circumvent the problem.
Modifications of the oxabicycles 19, 20 and 45 were attempted by subjecting them
to oxidizing conditions for aldehyde or acid formation. Mild oxidation conditions were
chosen as the double bond in the oxabicycle easily could be cleaved under harsh oxida-
tion conditions such as Cr(IV) or Mn(VII). Records of such, use Collins reagent (CrO3,
pyridine) on similar oxabicycles giving rise to opening of the ring at the alkene possi-
tion.247 IBX, DMP and TEMPO was tried as oxidizing agents but none was succesfull.
No conversion took place using TEMPO or IBX at rt, when the solvent was switched
from DMSO to EtOAc and elevated temperatures (80 ◦C) resulted in decomposition
in the case of IBX.
Exposing 45 to Dess-Martin periodinane at rt unfortunately resulted in decompo-
sition although oxidation of a similar oxabicycle gave the aldehyde in 90% yield under
the same reaction conditions.248 What was possible to elucidate from crude NMR could
be formation of an amine, which was formed by cleavage of the amine from the oxabi-
cyclic ring. The crude NMR spectrum is shown in Figure 2.6 along with the predicted
structure, the formation of the doublet structure for the two H-atoms of the benzyl
group coupling with the amine H has been reported for similar structures.249 All in all,
it seems that the amine chain on the oxabicycles is to bulky to perform the oxidation
under the conditions examined, and cleavage of the amine from the oxabicycle appear
to be the only observed byproduct of the reactions tried. Other mild oxidizing agents
might work but no more effort was put in this project.
Two new compounds were synthesized to overcome the problem with the hydroxy
group; one with a methoxymethyl moiety (46) and one with an acetoxymethyl moiety
(47). Oxabicycle 46 was synthesized because of the prior studies done on the desym-
metrization of 5.239 Oxabicycle 47 was synthesized to introduce an ester group. This
was done as good results were obtained for oxabicycles 17 and 18.
The synthesis of 46 was more tedious than expected as the reaction did not run
to compleetion at 0 ◦C and some decomposition took place at rt resulting in a modest
yield of 22%. All product formed was subjected to the [Rh(COD)OH]2 catalyst and
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Figure 2.6: Crude 1H-NMR spectrum from the oxidation of 45 using DMP.
the (R,S)-PPF(tBu)2 only resulting in decomposition of the starting material, none of
the starting material could be isolated (Scheme 2.12).
On the other hand, oxabicycle 47 was obtained after standard acetylation con-
ditions in 90% yield and thereafter subjected to a [Rh(COD)OH]2 or [Rh(COD)Cl]2
catalyst. Good results were obtained using both catalysts as seen in Table 2.4. Using
[Rh(COD)OH]2 the reaction did not run to completion at rt after 15 h, nevertheless,
only the starting material and 48 could be detected by NMR, and the amount of
the mixture isolated after a short column corresponded to no loss of starting mate-
rial. Heating the reaction to 65 ◦C gave a stereoselectivity of 1:9 favoring 48, but the
isolated yield of 48 was only 33% (entry 1 and 2). With a slight lowering of temper-
ature and a change of ligand to the (S,R)-PPF(tBu)2 ligand yielded a mixture of 48
MeI, NaH, THF
O
N
N
H
Ph
Bn
MeO
Bn OO
N
N
H
Ph
Bn
HO
Bn O
0 oC - rt [Rh(COD)Cl]2 (5 mol%)
(R,S)-PPF-PtBu2 (10 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, rt.
(1.2 eq.)
B
O
O
8b
20 46
Scheme 2.12: Synthesis of 46 and conditions for the attempted ring opening of 46.
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Table 2.4: Ring opening of 47.
O
N
N
H
Ph
Bn
AcO
Bn O
N
N
HPh
Bn
Bn O
OAcHO
Ph
N
N
H
Ph
Bn
Bn O
OAc
Ph
OH
Catalyst (5 mol%) 
Ligand (10 mol%)
THF, temp.
4948
+
8a or 8b
47
# Catalyst Ligand Temp. Nu.(eq.) Yield [%] 47:48:49a
1 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 65 ◦C 8a (2.0) 33 (48) 0:90:10
2 [Rh(COD)OH]2 (R,S)-PPF(tBu)2 rt 8a (2.0) 100 (47+48) 60:40:0
3 [Rh(COD)OH]2 (S,R)-PPF(tBu)2 60 ◦C 8a (2.0) 70 (48+49) 0:13:87
4 [Rh(COD)Cl]2 (S,R)-PPF(tBu)2 50 ◦C 8b (1.2) 69 (49) 0:13:87
a predicted from crude NMR
and 49 in 70% with a ratio of 1:7 favoring 49 (entry 3). Replacing the catalyst with
[Rh(COD)Cl]2 and lowering the temperature to 50 ◦C resulted in ring opening with
approximately the same regioselectivity, however it was possible to isolate 49 in 69%
yield. The regioselectivities were estimated by 1H-NMR.
Regrettably, my external stay in Toronto had come to an end just as these new
discoveries were achieved. Newertheless the project was left at a stage where few
alterations of the oxabicycles 19–29 would give access to a library of oxabicycles, which
could be exposed to the same reaction conditions as for entry 4 in Table 2.4. Of course,
first trying the conditions on one altered oxabicycle before make the changes on all
oxabicycles assuring the conditions give similar results. Also a screening of temparature
if the conditions work for the (R,S)-PPF(tBu)2, and a different oxabicycle would be of
interest to improve the regioselectivity.
While screening reaction conditions for oxabicycles 19–29 an attempt to increase
the scope of nucleophiles for the ring opening of 17 and 18 using the pyridyl nucle-
ophiles 50 and 51 was carried out. None of the reaction conditions employed led to ring
opening of the oxabicycles 17 and 18 (Table 2.5). These findings were not totally un-
Table 2.5: Trials of regioselective ring opening of 17 and 18, with pyridyl nucleophiles.
Catalyst (5 mol%), Ligand (10 mol%)
THF, temp.
N
B(OH)2
N
B O
O
or50 51
OH
NO
O
O
O O
17 18
or
O H
N O
O
O
OO
# Sub. Catalyst Ligand Temp. Nu.(eq.) Comment
1a 17 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 50 ◦C 51 (1.3) N.R.
2a 18 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 40 ◦C 51 (1.3) N.R.
3 18 [Rh(COD)Cl]2 (R,S)-PPF(tBu)2 40 ◦C 50 (1.3) N.R.
4 18 [Rh(COD)OH]2 (S,R)-PPF(tBu)2 80 ◦C 50 (2.0) N.R.
5 17 Pd(MeCN)2Cl2 (R,S)-PPF(tBu)2 50 ◦C 51 (1.2) Decomp.b
a Cs2CO3 (5M) in H2O(0.5 eq.) added b retro Diels-Alder pruduct observed
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expected as Lautens and co-workers also had difficulties using a rhodium catalyst when
employing heteronucleophiles.240 What can be concluded from these results, which is of
new knowledge, is the fact that changing to a pyridylboronic acid ethyleneglycol ester
did not result in the opening of the oxabicycles. Using a palladium catalyst however
did not result in the desired oxabicycle, only decomposition of the starting material
took place and the retro Diels-Alder adduct was the only product identified. Thus
changing to heteroatom containing nucleophiles would be a time consuming project as
it would require screening of new catalysts, hense no more work was done on this part.
2.3 Summary and Outlook of Chapter 2
In an attempt to create a library of potential Bcl-XL antagonists a range of enan-
tiopure oxabicyles (17–29 in Figure 2.3) were desired attempted for a regioselective
ring opening. Enatiopure oxabicycles 17 and 18 were subjected to asymmetric ring
opening reactions using a rhodium catalyst and a josiphos ligand yielding two sets of
enantiomers in excellent regioselectivity and good yield.
Applying similar conditions to perform the ring opening of the oxabicycles with an
alcohol moiety was not successful. Changing to different rhodium catalysts did not
result in a satisfactory result, as the reactions were low yielding and not reproducible
in all cases. Two plausible explanations for the lack of reactivity is either coordina-
tion of the hydroxy groups with the boron forming a new 6-membered cycle with the
ring opened product, which is only possible for one of the two diastereomers. The
other explanation for the lack of reactivity is that the alcohol might be a competing
nucleophile.
Ring opening of oxabicycles with a TBDMS-protecting group on the alcohol moiety
did not solve the problem with the reactivity. The general trend for these reactions
was a mixture of starting material and decomposition of the starting material, and
for one reaction deprotection of the TBDMS-group was observed, thus generating the
undesired alcohol in situ.
These findings made it obvious that a different group than an alcohol was necessary,
hence attempts were made to prepare three new oxabicycles, one with a methoxymethyl
moiety 46, one with a acetoxymethyl moiety 47 and one with a methylester moiety
(unsuccessful synthesis). One trial of the ring opening on 46 only led to decomposition.
Whereas asymmetric ring opening of 47 employing similar reaction conditions as for
the ring opening of 18 yielded one regioisomer in good yield and regioselectivity. Whilst
the other regioisomer was isolated in modest yield and good regioselectivity employing
a [Rh(COD)OH]2 catalyst.
Ring opening of 17 and 18 was attempted using a pyridylboronic acid nucleophile
but none of the desired product could be isolated.
It was not possible to create a general asymmetric ring opening method for the
enantiopure oxabicycles 17–29, but for further studies it would be of interest to exam-
ine the reaction conditions found to work on 47 on other oxabicycles with the same
acetoxymethyl moiety. If this was possible it would lead to a library of potential Bcl-
XL antagonists containing acetyl-groups, which could be hydrolysed into the alcohol
leading to an even bigger library.
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2.4 Experimental
General Experimental Conditions. Unless otherwise noted, reactions were car-
ried out under argon atmosphere, in 2-5 mL vials or single-necked, round bottom flasks,
with magnetic stirring. Air- or water-sensitive liquids and solutions were transferred via
syringe. Organic solutions were concentrated by rotary evaporation at 23–40 ◦C under
53 mbar (house vacuum). Analytical thin layer chromatography (TLC) was performed
with aluminum sheets pre-coated with silica gel 60F (Merck 5554). Visualization was
done under a 254 nm UV light source and generally by immersion in a ceriumammoni-
umsulfate solution (1% cerium(IV)sulphate and 2.5% hexaammonium molybdate in a
10% sulfuric acid solution). Purification of reaction products was done by flash column
chromatography on silica gel (SilicycleTM Ultra-Pure 230-400 mesh).
Reagents. Solvents were purchased from Sigma-Aldrich, Inc. Tetrahydrofuran and
toluene were purified by distillation under N2 from Na/benzophenone prior to use.
Rhodium(I)catalysts, Pd(MeCN)2Cl2 and Tol-BINAP were purchased from Strem Chem-
icals Inc. and used as received. Josiphos ligands ((S,R)-PPF(tBu)2 and (R,S)-PPF(tBu)2)
were generously provided by Solvias Inc. Compound 8b was synthesized according to
the procedure described in Meiland et. al.250
Instrumentation. Proton nuclear magnetic resonance spectra (1H-NMR) and carbon
nuclear magnetic resonance spectra (13C-NMR) were recorded with a Varian Mercury
400 (400 MHz/100 MHz) NMR spectrometer equipped with a Nalorac4N-400 probe,
or a Bruker AvanceIII (400 MHz/100 MHz) NMR spectrometer equipped with BBOF
probe using the residual solvent as the internal standard. Recorded chemical shifts
are reported in parts per million (δ = scale) downfield from tetramethylsilane, and
and all coupling constants (J) are expressed in Hz. High resolution mass spectras
(HRMS) were obtained from Joel AccuTOF Direct Analysis in Real Time Time-of-
Flight (DART). Melting points were obtained using Fisher-Johns melting point appa-
ratus and are uncorrected. High performance liquid chromatography (HPLC) analyses
were carried out on a HP 1100 Series modular system from Agilent Zorbax, using a
gradient from H2O/MeCN 9:1 to pure MeCN in 15 min (flow 0.8 mL/min) with a Zor-
bax SB-C18 column (4.6 mm × 50 mm, 3.5 µm). The crystal structure was obtained
using Computer-controlled Nonius Kappa-CCD system, Oxford Cryostream variable
temperature apparatus. Compounds with clubs (♣) are new.
4-Pyridylboronic acid ethyleneglycol ester (51)250
N
B(OH)2
HO
OH+
N
B
Toluene
150 oC
O
O
50 51
Ethyleneglycol (25 µL, 4.5 mmol) was added to a suspension of 4-pyridylboronic acid
(50 mg, 0.41 mmol) in toluene (4.5 mL) and the reaction mixture stirred overnight
at 150 ◦C with a Dean-Stark apparatus. The precipitate was filtered off and washed
with toluene, which resulted in a light rosa solid product (44.9 mg, 74%). 1H-NMR
(400 MHz, D2O): δ = 8.45 (d, J = 4.6 Hz, 2H), 8.06 (d, J = 4.6 Hz, 2H), 3.68 (s, 4H)
13C-NMR (100 MHz, D2O): δ = 138.1, 129.1, 62.5.
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Exo-cis-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (10)251
O
CO2Me
O
O
O
O
H2SO4
MeOH CO2Me
52 10
Compound 10 (2.0 g, 12 mmol) was dissolved in a solution of H2SO4 (1 mol eq.)
in MeOH (20 mL) and stirred overnight. After evaporation of a few mL MeOH, a
precipitate was observed and the reaction mixture was left to crystallize. The white
crystals were washed thoroughly with MeOH and dried under vacuum (1.9 g, 73%).
M.p. 116–117 ◦C. M.p. lit. 119 ◦C.251 1H-NMR (400 MHz, CDCl3): δ = 6.44 (t, J =
1.0 Hz, 2H), 5.25 (t, J = 1.0 Hz, 2H), 3.70 (s, 6H), 2.81 (s, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 172.0, 136.7, 80.5, 52.4, 47.1.252
R-2-(N -Benzyl-N ((1R,2S,3R,4S)-3-(hydroxymethyl)-7-
oxabicyclo[2.2.1]hept-5-ene-2-yl)amino)-N -(cyclohexyl)-3-metyltetraamide
(45) ♣
O
N
N
H
Cy
TBDMSO
Bn O O
N
N
H
Cy
HO
Bn O
TBAF
THF, 0 oC
25 45
TBAF (1 M in THF, 0.15 mL, 0.15 mmol) was added to a solution of 25 (52.7 mg, 0.10
mmol) in THF (1.35 mL) at 0 ◦C. The reaction was stirred for 1 h (TLC showed full
conversion of S.M.), solvent evaporated and the product was purified by flash column
chromatography (SiO2, EtOAc/Hexanes 1:2), which resulted in a clear glassy oil (40.4
mg, 98%). 1H-NMR (400 MHz, CDCl3): δ = 7.40–7.14 (m, 5H), 6.36 (qd, J = 5.8, 1.5
Hz, 2H), 5.87 (d,J = 7.9 Hz, 1H), 4.92 (d, J = 4.5 Hz, 1H), 4.80 (d, J = 1.4 Hz, 1H),
4.48 (d,J = 15.7 Hz, 1H), 3.90–3.71 (m, 1H), 3.65 (d, J = 15.7 Hz, 1H), 3.48 (dd, J =
10.8, 7.1 Hz, 1H), 3.22 (dd, J = 10.9, 7.5 Hz, 2H), 2.89 (d, J = 3.2 Hz, 1H), 2.74 (d,
J = 10.3 Hz, 1H), 2.38 (dd, J = 7.0, 3.5 Hz, 1H), 2.21–2.07 (m, 1H), 1.97 (dd,J = 12.1,
3.5 Hz, 1H), 1.85 (dd, J = 12.5, 3.6 Hz, 1H), 1.78–1.50 (m, 3H), 1.47–1.26 (m, 2H),
1.26–0.97 (m, 6H), 0.83 (d, J = 6.5 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ = 172.5,
140.6, 136.0, 135.6, 128.5, 128.1, 126.8, 84.8, 79.6, 68.7, 65.5, 62.3, 52.1, 47.9, 43.5,
33.3, 33.1, 27.9, 25.6, 25.0, 24.9, 20.6, 19.9. MS (DART, m/z): calcd. (C25H37N2O3+)
413.2799, found 413.2805.
R-2-(N -Benzyl)-N -((1R,2S,3R,4S)-3-(hydroxymethyl)-7-
oxabicyclo[2.2.1]hept-5-ene-2-yl)amino)-N -benzyl-3-metyltetraamide (53)
♣
O
N
N
H
Bn
TBDMSO
Bn O O
N
N
H
Bn
HO
Bn O
TBAF
THF, 0 oC
22 53
TBAF (1 M in THF, 0.45 mL, 0.45 mmol) was added to a solution of 22 (188 mg,
0.307 mmol) in THF (2.5 mL) at 0 ◦C. The reaction mixture was stirred for 15 min
(TLC showed full conversion of S.M.), solvent evaporated and the product was purified
by flash column chromatography (SiO2, EtOAc/Hexanes 2:3), which resulted in a clear
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glassy oil (129 mg, 84%). 1H-NMR (400 MHz, CDCl3): δ = 7.46–7.11 (m, 10H), 6.37
(s, 1H), 6.33 (dd, J = 5.9, 1.8 Hz, 1H), 6.28 (dd, J = 5.9, 1.4 Hz, 1H), 4.77 (s, 1H),
4.69–4.52 (m, 2H), 4.45 (d, J = 15.6 Hz, 1H), 4.27 (dd, J = 14.3, 5.1 Hz, 1H), 3.60 (d,
J = 15.6 Hz, 1H), 3.42 (dd, J = 11.0, 6.7 Hz, 1H), 3.03 (s, 1H), 2.87 (d, J = 10.1 Hz,
1H), 2.77 (d, J = 3.3 Hz, 1H), 2.27–2.14 (m, 1H), 2.14–2.04 (m, 1H), 1.91 (s, 1H), 1.12
(d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H). 13C-NMR (100 MHz, CDCl3): δ = 173.2,
140.3, 138.6, 136.0, 135.5, 128.9, 128.8, 128.5, 128.2, 127.8, 126.8, 84.3, 79.6, 68.1, 65.5,
62.2, 52.1, 43.7, 43.5, 27.9, 20.7, 20.0.
R-2-(N -Benzyl)-N -((1R,2S,3R,4S)-3-(acetoxymethyl)-7-
oxabicyclo[2.2.1]hept-5-ene-2-yl)amino)-N -benzyl-2-phenylethanamide
(47) ♣
AcCl, pyridine
O
N
N
H
Ph
Bn
AcO
Bn OO
N
N
H
Ph
Bn
HO
Bn O
CH2Cl2
20 47
Acetylchloride (60 µL, 0.84 mmol) was added dropwise to a cold solution (0 ◦C) of
20 (50 mg, 0.110 mmol) and pyridine (50 µL) in CH2Cl2 (2 mL). The icebath was
removed and the mixture stirred at rt for 3 h, solvent evaporated and the product was
purified by flash column chromatography (SiO2, EtOAc/Hexanes 1:3) which resulted
in a clear glassy oil (49.0 mg, 90%). 1H-NMR (400 MHz, CDCl3): δ = 7.83 (t, J =
5.8 Hz, 1H), 7.50–7.13 (m, 15H), 6.26 (dd, J = 5.8, 1.4 Hz, 1H), 6.12 (dd, J = 5.8, 1.8
Hz, 1H), 4.79 (d, J = 4.3 Hz, 1H), 4.62–4.49 (m, 2H), 4.41 (dd, J = 14.6, 5.4 Hz, 1H),
4.26 (d, J = 14.6 Hz, 1H), 4.08 (dd, J = 11.4, 4.6 Hz, 1H), 3.70–3.45 (m, 3H), 2.74 (d,
J = 4.6 Hz, 1H), 2.35 (m, 1H), 2.03 (s, 3H). 13C-NMR (100 MHz, CDCl3): δ = 171.4,
170.8, 139.0, 138.5, 137.1, 135.4, 134.6, 130.5, 128.9, 128.9, 128.8, 128.6, 128.3, 127.9,
127.6, 127.5, 79.8, 78.9, 66.8, 66.1, 64.1, 50.6, 43.5, 42.8, 21.0.
R-2-(N -Benzyl)-N -((1R,2S,3R,4S)-3-(methoxymethyl)-7-
oxabicyclo[2.2.1]hept-5-ene-2-yl)amino)-N -benzyl-2-phenylethanamide
(46) ♣
MeI, NaH
THF
O
N
N
H
Ph
Bn
MeO
Bn O
O
N
N
H
Ph
Bn
HO
Bn O
20 46
NaH (6.0 mg, 60% suspension in oil, 0.15 mmol) was weighed into an oven dried flask
and covered by dry THF (0.5 mL). Compound 20 (50 mg, 0.11 mmol) in THF (0.5
mL) was added dropwise by syringe at 0 ◦C and the mixture was stirred for 1 h
whereupon MeI (0.0075 mL, 0.12 mmol) was added. The mixture was stirred for an
additional hour and TLC revealed a lot of starting material left. Additional NaH (6.0
mg, 60% suspension in oil, 0.15 mmol) was added and the mixture stirred for 15 min,
where MeI (0.010 mL, 0.16 mmol) was added. Additional MeI (0.010 mL, 0.16 mmol)
was added after stirring for 1 h and the mixture was left to stir overnight at rt. No
starting material observed, product purified by flash column chromatography (SiO2,
EtOAc/Hexanes 1:4) resulting in a clear oil (11.5 mg, 22%). 1H-NMR (400 MHz,
CDCl3): δ = 8.45–8.17 (m, 1H), 7.59–7.03 (m, 15H), 6.15 (dd, J = 5.8, 1.4 Hz, 1H),
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6.08 (dd, J = 5.8, 1.8 Hz, 1H), 4.88–4.64 (m, 2H), 4.54 (s, 1H), 4.39–4.15 (m, 2H), 3.56
(d, J = 14.8 Hz, 1H), 3.38 (s, 1H), 3.29 (dd, J = 9.0, 5.7 Hz, 1H), 3.16 (s, 3H), 3.08 (t,
J = 9.0 Hz, 1H), 2.90 (d,J = 4.2 Hz, 1H), 2.40 (td, J = 9.6, 4.5 Hz, 1H). 13C-NMR (100
MHz, CDCl3): δ = 171.7, 139.3, 139.0, 137.3, 136.2, 134.2, 130.5, 128.9, 128.8, 128.7,
128.7, 128.2, 127.5, 127.4, 127.3, 80.3, 78.8, 75.6, 67.4, 65.0, 59.3, 50.6, 43.2, 42.8.
Ring opening of
exo-cis-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (11 + 12)
+
11 12
O
CO2Me
OH
CO2Me
CO2Me
CO2Me
OH
CO2Me
CO2Me
[Rh(COD)Cl]2 (2.5 mol %) 
R,S-PPF-P(tBu)2 (5 mol %) 
Cs2CO3 (5M) in H2O (0.5 eq) 
THF, rt.
(1.2 eq.)
B
O
O
8b
10 4:1
70%
A 5 mL flask was charged with [Rh(COD)Cl]2 (2.9 mg, 0.0059 mmol), R,S-PPF(tBu)2
(6.4 mg, 0.012 mmol) and 10 (50 mg, 0.236 mmol). The flask was flushed with argon
for 15 min whereupon phenylboronic acid ethyleneglycol ester (42 mg, 0.283 mmol)
as a THF solution (2 mL) was added by syringe. This was followed by Cs2CO3 (5
M) in H2O (24 µL) and the reaction mixture was stirred at rt overnight. The solvent
was evaporated and the product was purified by flash column (SiO2, EtOAc/Hexanes
1:4) resulting in a mixture of two diasteriomers with a 1:4 ratio between minor and
major product (49 mg, 71%). Compound 11: 1H-NMR (400 MHz, CDCl3): 7.44–7.17
(m, 5H), 6.05 (ddd, J = 10.1, 4.8, 2.8 Hz, 1H), 5.90 (ddd, J = 10.1, 3.3, 2.0 Hz, 1H),
4.61–4.51 (m, 1H), 3.75 (s, 3H), 3.72–3.67 (m, 4H), 3.61 (td, J = 5.1, 2.8 Hz, 1H), 3.51
(d, J = 5.6 Hz, 1H), 3.13 (dd, J = 6.4, 1.9 Hz, 1H). Compound 12: 1H-NMR (400
MHz, CDCl3): 7.44–7.17 (m, 5H), 5.97 (dt, J = 10.2, 2.6 Hz, 1H), 5.83–5.73 (m, 1H),
4.50–4.43 (m, 1H), 3.92–3.82 (m, 1H), 3.77 (s, 3H), 3.72 (s, 3H), 3.30 (d, J = 10.8 Hz,
1H), 1.55 (dd, J = 3.0, 1.2 Hz, 1H).
Regioselective ring opening of enantiopure oxabicycles
(1S,4S,5S,6R)-Methyl 5-hydroxy-6-((((4-
methoxy)benzyloxy)carbonyl)amino)-4-phenyl-cyclohex-2-enecarboxylate
(41) ♣
OH
NO
O
O
O O
17
[Rh(COD)Cl]2 (3 mol%)
(S,R)-PPF-PtBu2 (6 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, rt.
+
(1.2 eq.)
B
O
O
20>141 42
H
NO
O
O
O
OH
O
H
NO
O
O
O
O
OH
8b
A 3 mL flask was charged with [Rh(COD)Cl]2 (2.2 mg, 0.0045 mmol), (S,R)-PPF(tBu)2
(4.9 mg, 0.009 mmol), oxabicycle 17 (50 mg, 0.150 mmol) and flushed with argon for
30 min. Compound 8b (27 mg, 0.18 mmol) dissolved in THF (1.5 mL) was added
by syringe, followed by Cs2CO3 (5 M) in H2O (15 µL). The mixture was stirred
at rt overnight whereupon TLC showed full conversion of starting material. Crude
HPLC showed 3% of minor exo-diastereomeric product 42. Purification by flash column
chromatography (SiO2, EtOAc/Hexanes 3:7) resulted in a white crystalline product (38
100Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
2.4. Experimental
mg, 61%). Structure verified by x-ray. Mp: 134–135 ◦C. 1H-NMR (400 MHz, CDCl3):
δ = 7.37 (t, J = 7.3 Hz, 2H), 7.33–7.26 (m, 3H), 7.21 (d, J = 7.2 Hz, 2H), 6.88 (d,
J = 8.5 Hz, 2H), 5.86 (d, J = 10.2 Hz, 1H), 5.79 (d, J = 10.2 Hz, 1H), 5.25 (d,J =
8.9 Hz, 1H), 5.03 (s, 2H), 4.35 (t, J = 10.0 Hz, 1H), 4.08 (s, 1H), 3.84 (s, 1H), 3.80 (s,
3H), 3.71 (s, 3H), 3.43–3.34 (m, 1H), 1.46 (s, 1H). 13C-NMR (100 MHz, CDCl3): δ =
173.5, 159.7, 156.0, 139.6, 130.1, 129.0, 128.7, 128.7, 128.0, 127.6, 125.2, 114.0, 71.5,
66.8, 55.4, 53.0, 52.5, 47.6, 44.5. MS (DART, m/z): calcd. (C23H26NO6+) 412.1755,
found 412.1773
(1R,2S,5R,6R)-Methyl 6-hydroxy-2-((((4-
methoxy)benzyloxy)carbonyl)amino)-5-phenyl-cyclohex-2-enecarboxylate
(42) ♣
OH
NO
O
O
O O
17
[Rh(COD)Cl]2 (3 mol%)
(R,S)-PPF-PtBu2 (6 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, rt.
(1.2 eq.)
B
O
O
1:19
+
41 42
H
NO
O
O
O
OH
O
H
NO
O
O
O
O
OH
8b
A 3 mL flask was charged with [Rh(COD)Cl]2 (2.2 mg, 0.0045 mmol), (R,S)-PPF(tBu)2
(4.9 mg, 0.009 mmol), oxabicycle 17 (50 mg, 0.150 mmol) and flushed with argon for
30 min. Compound 8b (27 mg, 0.18 mmol) as a THF solution (1.5 mL) was added
by syringe followed by Cs2CO3 (5 M) in H2O (15 µL). The mixture was stirred at rt
overnight whereupon TLC showed full conversion of starting material. Crude HPLC
showed 5% of minor exo-diastereomeric product 41. Purification by flash column chro-
matography (SiO2, EtOAc/Hexanes 3:7) resulted in a clear oil (41 mg, 66%). 1H-NMR
(400 MHz, CDCl3): δ = 7.37 (t, J = 7.2 Hz, 2H), 7.33–7.27 (m, 3H), 7.25 (d, J =
9.1 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 5.92 (d, J = 9.8 Hz, 1H), 5.80 (d, J = 8.5 Hz,
1H), 5.35 (d, J = 9.1 Hz, 1H), 5.15–4.95 (m, 2H), 4.73 (s, 1H), 4.33 (m, 1H), 3.80 (s,
3H), 3.75–3.57 (m, 4H), 2.80 (t, J = 7.5 Hz, 1H), 1.68 (s, 1H). 13C-NMR (100 MHz,
CDCl3): δ = 172.4, 159.7, 155.8, 137.7, 130.1, 130.0, 128.8, 128.7, 128.6, 128.1, 127.8,
114.0, 69.2, 66.8, 55.4, 52.3, 50.0, 48.7, 45.2.
(1R,4R,5R,6S)-Methyl 5-hydroxy-6-((((4-
methoxy)benzyloxy)carbonyl)amino)-4-phenyl-cyclohex-2-enecarboxylate
(43) ♣
+
[Rh(COD)Cl]2 (5 mol%)
(R,S)-PPF-PtBu2 (10 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, 50 oC 19:1
O H
N O
O
O
OO
18
(1.2 eq.)
B
O
O
43 44
H
N O
O
O
O
OH
O
O
O
H
N
O
O
O
OH
A 2 mL flask was charged with [Rh(COD)Cl]2 (1.1 mg, 0.00225 mmol), (R,S)-PPF(tBu)2
(2.5 mg, 0.0045 mmol), oxabicycle 18 (25 mg, 0.075 mmol) and flushed with argon for
30 min. Compound 8b (13.5 mg, 0.090 mmol) dissolved in THF (1 mL) was added
by syringe followed by Cs2CO3 (5 M) in H2O (8 µL). The mixture was stirred at rt
overnight whereupon TLC showed full conversion of starting material. Crude HPLC
showed 5% of minor exo-diastereomeric product 44. Purification by flash column chro-
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matography (SiO2, EtOAc/Hexanes 3:7) resulted in a white crystalline product (21
mg, 69%). Mp: 133.5–135 ◦C. 1H-NMR (400 MHz, CDCl3): δ = 7.36 (t, J = 7.2 Hz,
2H), 7.32–7.24 (m, 3H), 7.20 (d, J = 7.2 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.85 (d, J =
10.2 Hz, 1H), 5.78 (d, J = 10.2 Hz, 1H), 5.31 (d, J = 9.3 Hz, 1H), 5.02 (s, 2H), 4.35
(t, J = 9.9 Hz, 1H), 4.07 (s, 1H), 3.83 (s, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 3.44–3.32 (m,
1H), 1.53 (s, 1H). 13C-NMR (100 MHz, CDCl3): δ = 173.5, 159.7, 156.0, 130.1, 129.1,
128.7, 128.1, 127.6, 125.2, 114.1, 71.5, 66.8, 55.5, 53.0, 52.5, 47.6, 44.6.
(1S,2R,5S,6S)-Methyl 6-hydroxy-2-((((4-
methoxy)benzyloxy)carbonyl)amino)-5-phenyl-cyclohex-2-enecarboxylate
(44) ♣
18
[Rh(COD)Cl]2 (5 mol%)
(S,R)-PPF-PtBu2 (10 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, 50 oC
(1.2 eq.)
B
O
O
O H
N O
O
O
OO
+
1:1943 44
H
N O
O
O
O
OH
O
O
O
H
N
O
O
O
OH
A 2 mL flask was charged with [Rh(COD)Cl]2 (1.1 mg, 0.00225 mmol), (S,R)-PPF(tBu)2
(2.5 mg, 0.0045 mmol), oxabicycle 18 (25 mg, 0.075 mmol) and flushed with argon for
30 min. Compound 8b (13.5 mg, 0.090 mmol) dissolved in THF (1 mL) was added
by syringe followed by Cs2CO3 (5 M) in H2O (8 µL). The mixture was stirred at rt
overnight whereupon TLC showed full conversion of starting material. Crude HPLC
showed 5% of minor exo-diastereomeric product 43. Purification by flash column chro-
matography (SiO2, EtOAc/Hexanes 3:7) resulted in a clear oil (20 mg, 65%). 1H-NMR
(400 MHz, CDCl3): δ = 7.37 (t, J = 7.2 Hz, 2H), 7.34–7.28 (m, 3H), 7.25 (d, J = 8.8
Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.93 (d, J = 10.0 Hz, 1H), 5.80 (d, J = 8.4 Hz, 1H),
5.28 (d, J = 9.0 Hz, 1H), 5.13–4.98 (m, 2H), 4.73 (s, 1H), 4.34 (dd, J = 13.2, 6.1 Hz,
1H), 3.81 (s, 3H), 3.75–3.57 (m, 4H), 2.80 (t, J = 7.4 Hz, 1H), 1.59 (s, 1H). 13C-NMR
(100 MHz, CDCl3): δ = 172.3, 159.8, 155.8, 137.8, 130.2, 130.0, 128.9, 128.7, 128.6
128.1, 127.9, 114.1, 69.2, 66.8, 55.5, 52.4, 50.0, 48.6, 45.2.
General procedure for ring opening of oxabicycles containing free alcohols,
TBDMS-protected alcohols and acetyl-protected alcohols using
[Rh(COD)Cl]2 as catalyst
A 2 mL flask charged with [Rh(COD)Cl]2 (1.0 mg, 0.0020 mmol) and Josiphos ligand
(2.2 mg, 0.0040 mmol), was flushed with argon for 5 min whereupon THF (0.5 mL)
was added and the mixture stirred for 5 min under argon atmosphere. The oxabicycle
(0.0333 mmol) and a phenylboronic acid ethyleneglycol ester (1.2 eq.) was dissolved in
THF (1 mL) and the cat./ligand THF solution was added followed by Cs2CO3 (5 M)
in H2O (0.5 eq.) The mixture was left to stir overnight at varying temperatures.
102Synthesis of human milk oligosaccharides and regioselective ring opening of oxabicycles
2.4. Experimental
(1S,2R,5S,6S)-2-(Benzyl((R)-2-(benzylamine)-2-oxo-1-phenylethyl)amino)-
6-hydroxy-5-phenyl-cyclohex-2-ene methyl acetate (49) ♣
[Rh(COD)Cl]2 (3 mol%)
(S,R)-PPF-PtBu2 (6 mol%)
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, 50 oC
(1.2 eq.)
B
O
O
8b
O
N
N
H
Ph
Bn
AcO
Bn O
N
N
HPh
Bn
Bn O
OAcHO
Ph
N
N
H
Ph
Bn
Bn O
OAc
Ph
OH
4948
+
47 1:7
Colorless oil (13 mg, 69%) (HPLC of crude showed 13 % of 48). 1H-NMR (400 MHz,
CDCl3): δ = 7.50–7.44 (m, 2H), 7.43–7.17 (m, 16H), 7.17–7.10 (m, 2H), 6.92 (s, 1H),
5.85 (ddd, J = 10.2, 4.5, 2.1 Hz, 1H), 5.79 (d, J = 10.4 Hz, 1H), 4.67 (s, 1H), 4.43–4.29
(m, 2H), 4.24 (dd, J = 11.2, 2.4 Hz, 1H), 4.15 (dd, J = 14.5, 5.4 Hz, 1H), 4.08 (d, J
= 14.5 Hz, 1H), 3.87–3.76 (m, 1H), 3.74–3.64 (m, 2H), 3.61 (dd, J = 9.7, 1.9 Hz, 1H),
2.05 (d, J = 7.4 Hz, 1H), 1.87 (s, 3H), 1.79 (tt, J = 10.2, 2.7 Hz, 1H). 13C-NMR (100
MHz, CDCl3): δ = 172.0, 171.7, 139.9, 138.1, 138.0, 137.1, 130.4, 130.2, 130.0, 128.9,
128.8, 128.8, 128.7, 128.5, 128.4, 128.1, 127.6, 127.4, 68.0, 61.1, 56.8, 53.8, 46.4, 43.6,
40.3, 21.1.
General procedure for ring opening of oxabicycles containing free alcohols,
TBDMS-protected alcohols and acetyl-protected alcohols using
[Rh(COD)OH]2 as catalyst
A 2 mL flask charged with [Rh(COD)OH]2 (0.9 mg, 0.0020 mmol) and Josiphos ligand
(2.2 mg, 0.0040 mmol), was flushed with argon for 5 min whereupon THF (0.5 mL)
was added and the mixture stirred for 5 min under argon atmosphere. The oxabicycle
(0.0333 mmol) and a phenylboronic acid ethyleneglycol ester (1.2 eq.) or phenylboronic
acid (2.0 eq.) was dissolved in THF (1 mL) and the cat./ligand THF solution was added.
The mixture was left to stir overnight at varying temperatures.
(1R,4R,5R,6S)-6-(Benzyl((R)-2-(benzylamine)-2-oxo-1-
phenylethyl)amino)-5-hydroxy-4-phenyl-cyclohex-2-ene methyl acetate
(48) ♣
O
N
N
H
Ph
Bn
AcO
Bn O
N
N
HPh
Bn
Bn O
OAcHO
Ph
N
N
H
Ph
Bn
Bn O
OAc
Ph
OH
4948
+
47
[Rh(COD)OH]2 (3 mol%)
(R,S)-PPF-PtBu2 (6 mol%)
THF, 65 oC
(2.0 eq.)
B(OH)2
8a
9:1
Colorless oil (6.3 mg, 33%) (HPLC of crude showed 10 % of 49). Only 1H-NMR
spectrum recorded. 1H-NMR (400 MHz, CDCl3): δ = 7.51–7.35 (m, 5H), 7.35–7.15
(m, 13H), 6.97 (d, J = 7.1 Hz, 2H), 6.86 (t, J = 5.6 Hz, 1H), 5.87–5.79 (m, 1H), 5.56
(dd, J = 10.1, 1.9 Hz, 1H), 4.65 (s, 1H), 4.55 (dd, J = 10.9, 3.6 Hz, 1H), 4.40–4.29 (m,
3H), 4.26 (dd, J = 10.8, 6.1 Hz, 1H), 3.74 (d, J = 14.3 Hz, 1H), 3.44 (s, 1H), 3.36 (d,
J = 10.9 Hz, 1H), 3.24 (s, 1H), 3.06–2.97 (m, 1H), 2.00 (s, 3H), 1.11 (d, J = 3.2 Hz,
1H).
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General procedure using 4-pyridylborinic acid or ester as nucleophile
Catalyst (5 mol%), Ligand (10 mol%)
THF, temp.
N
B(OH)2
N
B O
O
or50 51
OH
NO
O
O
O O
17 18
or
O H
N O
O
O
OO
A 2 mL flask charged with catalyst (5 mol%) and Josiphos ligand (10 mol%) was
flushed with argon for 5 min whereupon THF (0.5 mL) was added and the mixture
stirred for 5 min under argon atmosphere. The oxabicycle (0.0375 mmol) and 50 or 51
was dissolved in THF (1 mL) and the cat./ligand THF solution was added followed by
Cs2CO3 (5 M) in H2O (0.5 eq.) when [Rh(COD)Cl]2 and 51 were used. The mixture
was left to stir overnight at varying temperatures.
Representative procedure for the in situ exchange of chloride to iodide
ligands:232
To a flame-dried flask under argon atmosphere was added [Rh(COD)Cl]2 (2.5 mg, 0.005
mmol), (R,S)-PPF(tBu)2 (6.0 mg, 0.011 mmol) and THF (2 mL), the mixture stirred
at rt for 5 min resulting in a dark red solution. In a separate flame-dried flask was
added AgOTf (5.5 mg, 0.02 mmol). The rhodium-phosphine solution was transferred
to the flask containing AgOTf via syringe resulting in white precipitate. This mixture
was stirred at rt for 5 min prior to its transfer to a flame-dried rb flask containing
TBAI (11 mg, 0.03 mmol). After stirring for additional 5 min the red-brown solution
was ready for use.
Attempted synthesis of compound 43 and 44
+
[Rh(COD)I]2, (R,S)-PPF-P
tBu2,
Cs2CO3 (5M) in H2O (0.5 eq.)
THF, 50 oC
O H
N O
O
O
OO
18
8b (1.2 eq.)
B
O
O
43 44
H
N O
O
O
O
OH
O
O
O
H
N
O
O
O
OH
Compound 18 (12.5 mg, 0.0375 mmol) and 8b (6.7 mg, 0.045 mmol) was dissolved in
THF (0.5 mL) and stirred under argon atmosphere for 5 min whereupon the [Rh(COD)I]2-
josiphos solution (0.8 mL) was added, followed by Cs2CO3 (5 M) in H2O (0.5 eq.).
The mixture was heated to 50 ◦C and it turned brown after 10 min, the mixture was
left to stir overnight at 50 ◦C. TLC revealed S.M. and biproduct. No product could
be detected by NMR.
Attempted synthesis of compound 43 and 44
+
[Rh(COD)I]2, (R,S)-PPF-P
tBu2,
THF, 50 oC
O H
N O
O
O
OO
18
8a (1.3 eq.)
B(OH)2
43 44
H
N O
O
O
O
OH
O
O
O
H
N
O
O
O
OH
Compound 18 (12.5 mg, 0.0375 mmol) and 8a (6.0 mg, 0.049 mmol) was dissolved in
THF (0.5 mL) and stirred under argon atmosphere for 5 min whereupon [Rh(COD)I]2-
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josiphos solution (0.8 mL) was added. The mixture was heated to 50 ◦C and it turned
orange after 10 min, the mixture was left to stir overnight at 50 ◦C. TLC revealed
S.M. and biproduct. No product could be detected by NMR.
Failed attempts on oxidizing oxabicycles
Attempted synthesis of compound 54253
O
N
N
H
Ph
Bn
HO
Bn O O
N
N
H
Ph
Bn
O
Bn O
IBX, DMSO
20 54
Compound 20 (10 mg, 0.0022 mmol) was dissolved in DMSO (0.1 mL) and IBX was
added (6 mg, 0.021 mmol) at 0 ◦C. The mixture was stirred for 15 min, at which time
TLC showed no conversion of S.M. The mixture was stirred for additional 4 h at rt,
but still no reaction. Filtered through a pad of silicagel and washed with ether before
the starting material was isolated.
Attempted synthesis of compound 55
O
N
N
H
Bn
Bn
HO
Bn O O
N
N
H
Bn
Bn
O
Bn O
IBX, AcOEt
80 oC
19 55
Compound 19 (48 mg, 0.102 mmol) was dissolved in EtOAc (4 mL) and IBX (31 mg,
0.11 mmol) was added. The mixture was refluxed for 3 h, after which it had turned
brown and NMR showed no product formation, but decomposition of starting material.
Attempted synthesis of compound 56254
O
N
N
H
Cy
HO
Bn O O
N
N
H
Cy
O
Bn O
DMP
CH2Cl2
45 56
To a solution of 45 (36 mg, 0.087 mmol) in CH2Cl2 (1 mL) was added Dess-Martin
periodinane (0.056 g, 0.132 mmol). After stirring for 5 min the solution had changed
color from clear to dark brown. After 15 min a saturated solution of Na2S2O3 (1 mL)
was added, this stirred for 15 min, whereupon Et2O (2 mL) and 1M NaOH (1 mL) was
added. The organic phase was callected and washed with brine (0.5 mL), dried over
MgSO4 and concentrated under reduced pressure. Only biproduct isolated.
Attempted synthesis of compound 57255
O
N
N
H
Bn
Bn
HO
Bn O O
N
N
H
Bn
Bn
O
Bn O
OH
TEMPO, NaClO2
CH3CN
19 57
Compound 19 (56.2 mg, 0.120 mmol) was dissolved in MeCN (0.61 mL), a sodiumphos-
phate buffer (0.45 mL, pH = 6.7) and TEMPO (1.3 mg, 0.0083 mmol) was added. When
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the reaction mixture had reached 35 ◦C one fourth of a NaClO2 solution (0.027 g in
0.12 mL H2O, 0.24 mmol) was added followed by one fourth of a NaClO2 solution (3.5
µL in 0.07 mL H2O, 0.0024 mmol). This was repeated every 15 min till all NaClO2
was added. The mixture stirred for 1 h at 35 ◦C and cooled to rt, whereupon H2O
(10 mL) was added. A 10 % NaOH solution was added untill pH = 8. The reaction
was quenched by pouring it into a 0 ◦C cold solution of Na2CO3 (3.7 mg in 0.6 mL
H2O). Precipitation after 2 min blocked the stirring of the mixture, therefore the the
temperature was raised to rt and the mixture was stirred for 30 min. The mixture
was extracted with Et2O (10 mL), acidified with 10% HCl untill pH = 3 and extracted
with Et2O (3×10 mL). The combined organic phases was washed with brine (20 mL),
dried over Na2SO4 and concentrated under reduced pressure. Only starting material
was isolated.
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List of Abbreviations
Abreviation Full name Structure
Ac acetyl
APT attached proton test
aq. aqueous
Ar aromate
Arg Arginine
BINAP 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl PPh2PPh2
Bn benzyl
br broad
BSP 1-benzenesulfinyl piperidine S N
O
Bu butyl
Bz benzoyl
cat. catalyst
Chiraphos 2,3-Bis(diphenylphosphino)butane P P
CMP Cytidine monophosphate O
OHOH
O N
N
NH2
OPHO
OH
O
COD cyclooctadiene
conc. concentration
continues. . .
109
Abbreviation Full name Structure
COSY correlation spectroscopy
Cp cyclopentadienyl
CSA camphorsulfonic acid
HO3S O
Cy cyclohexyl
d dublet
DART direct analysis in real time
dba dibenzylideneacetone
O
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene N
N
DC-SIGN dentritic cell-specific ICAM3-grabbing non-integrin
dd dublet of dublets
decomp. decomposition
DIBAL-H diisobutylaluminium hydride
DIPEA N,N -diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMF dimethylformamide
DMM N -dimethylmaleoyl N
O
O
DMP Dess-Martin periodinane O
I
O
OAcAcO
OAc
DMSO dimethyl sulfoxide
DMTST dimethylthiomethylsulfonium trifluoromethane-sulfonate
SMeS
OTf
Me
Me
dppb 1,4-bis(diphenylphosphino)butane PP
dppp 1,3-bis(diphenylphosphino)propane P P
dr diastereomeric ratio
E. coli Escherichia coli
ee enantiomeric excess
eq. equivalents
Et ethyl
EtOAc ethylacetate
Fmoc fluorenylmethyloxycarbonyl
O
O
Fuc fucose
continues. . .
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Abbreviation Full name Structure
Gal galactose
Glc glucose
GlcNAc N -acetylglucosamine
Gly glycine
h hour(s)
HIV human immunodeficiency virus
HMBC heteronuclear multiple bond correlation
HMO human milk oligosaccharide
HRMS high resolution mass spectrometry
HSQC heteronuclear single quantum correlation
IBX 2-iodoxybenzoic acid O
I
O
OHO
IDCP iodonium di-sym-collidine perchlorate N I N
ClO4
IR Infrared
Josiphos (S,R)-PPF(tBu)2 or (R,S)-PPF(tBu)2
LG leaving group
LNFP Lacto-N -fucopentaose
LNnFP Lacto-N -neofucopentaose
LNnT Lacto-N -neotetraose
LNT Lacto-N -tetraose
m multiplet
M molar (mol/L)
Me methyl
MeOTf methyl trifluoromethanesulfonate
min minutes
mp. melting point
MS molecular sieves, mass spectrometry
MU 4-methylumbelliferyl
O O
NEC necrotizing enterocolitis
Neu5Ac N -acetylneuraminic acid
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NMR nuclear magnetic resonance
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py pyridine
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RRV relative reactivity value
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FeP
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H
CH3
rt room temperature
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Fe P
H
H3C
P
sat. saturated
t tert
t triplet
TBAB tetrabutylammonium bromide
TBAF tetrabutylammonium fluoride
TBAI tetrabutylammonium iodide
TBDMS tert-butyldimethylsilyl
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O
O
Cl
Cl
Cl
Cl
TEMPO 2,2,6,6-tetramethylpiperidine-1-oxyl N
O
TES triethylsilyl
TFA trifluoroacetic acid
TFAA trifluoroacetic anhydride
TfO trifluoromethansulfonate
TfOH trifluoromethanesulfonic acid
THF tetrahydrofuran
TLC thin layer chromatography
TMS trimethylsilyl
Tol tolyl
Troc trichloroethoxycarbonyl O
O
Cl
Cl
Cl
Ts Tosyl, toluenesulfonyl
TTBP 2,4,6-tri-tert-butylpyrimidine
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OHOH
O N
NH
O
OPO
OH
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PHO
OH
O
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